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Thrombocythaemia is defined as a circulating platelet count above 450x109/L in humans. The 
major cause of thrombocythaemia is reactive (secondary) thrombocythaemia which occurs 
secondary to many conditions such as infection, cancer and inflammation. However, acquired 
clonal mutations in mainly Janus Kinas 2 (JAK2), CALR and MPL cause essential 
thrombocythaemia (ET). ET is a rare disease that leads to an increased risk of cardiovascular 
thrombotic events. Current treatment of ET uses combination of low dose aspirin (to decrease 
platelet function) and cytoreductive agents (to decrease thrombopoiesis). The most 
commonly used cytoreductive agents are hydroxyurea, anagrelide and interferon-α and all 
have unwanted side effects.  
 
Cytokine receptor-like factor 3 (CRLF3) is a 2.4kb gene that is ubiquitously expressed 
throughout the haematopoietic system. Very little is known about the function of CRLF3, with 
only one peer reviewed journal article in the literature which shows that CRLF3 may negatively 
regulate the cell cycle at the G0/G1 phase. However, nothing is known about the role of CRLF3 
in platelet biology. Using a Crlf3 knockout mouse (Crlf3-/-) developed by the Wellcome Trust 
Sanger Institute we show CRLF3’s role in platelet biogenesis and how it could be used as a 
novel therapeutic target to treat ET. 
 
Crlf3-/- mice have an isolated and sustained 25-40% decrease in platelet count compared to 
wildtype (WT) controls. Platelet function is unaffected as demonstrated in a range in a range 
of in vitro assays. The thrombocytopenia is a consequence of abnormalities in hematopoietic 
cells, as shown by bone marrow transplantations. Megakaryopoiesis is upregulated in Crlf3-/- 
mice and proplatelet morphology is unaffected, suggesting the thrombocytopenia is due to 
increased platelet clearance. Indeed, splenectomised Crlf3-/- mice show normalised platelet 
counts within 7 days, showing rapid splenic removal of platelets is responsible for the 
thrombocytopenia.  Abnormal large platelet structures that resemble proplatelets shafts 
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(preplatelets) are abnormally present in the circulation of elderly Crlf3-
/- mice. Immunohistochemistry showed increased and aberrant tubulin expression in Crlf3-/- 
platelets compared to WT controls, especially in the preplatelet forms. Cold induced 
depolymerisation of microtubules was decreased in Crlf3-/- platelets, suggestive of increased 
tubulin stability, however, the ratio of detyrosinated to tyrosinated tubulin was not altered.  
 
We then crossbred Crlf3-/- mice with JAK2 V617F ET mice, to determine the effect of Crlf3 
ablation of thrombocythaemia. Crossbred mice showed restoration of platelet counts to WT 
values without grossly affecting platelet function or other blood lineages, providing the 
rational for CRLF3 as a novel therapeutic target for treatment of ET. 
 
Finally, we aimed to resolve the crustal structure of CRLF3 and discover its interactome. To 
this end, we were able to resolve the crystal structure of a C-terminal portion of the full length 
protein containing the predicted fibronectin type III domain. To shed light on the interactome 
of CRLF3, endogenous CRLF3 was tagged with a tandem affinity purification (TAP) tag using 
CRISPR/Cas9 technology in induced pluripotent stem cells (iPSCs). We have been able to 
produce megakaryocytes from these TAP-tagged iPSCs by forward programming. However, as 
yet we have not been able to generate enough MKs to have adequate material to perform 
immunoprecipitation assays. Therefore, the interactome of CRLF3 in MKs remains unknown.  
 
In conclusion, we identified a mechanism by which Crlf3 controls platelet biogenesis. Slowed 
maturation of Crlf3-/- preplatelets in the peripheral circulation potentially due to increased 
structural stability leads to rapid removal of these immature forms by the spleen and 
therefore a decrease in platelet count. The isolated effect on platelet numbers and 
normalisation of platelet count in ET mice deficient of Crlf3 provides the rational for further 






This dissertation is the result of my own work and includes nothing which is the outcome of 
work done in collaboration except as declared in the Preface and specified in the text. It is not 
substantially the same as any that I have submitted, or, is being concurrently submitted for a 
degree or diploma or other qualification at the University of Cambridge or any other University 
or similar institution except as declared in the Preface and specified in the text. I further state 
that no substantial part of my dissertation has already been submitted, or, is being 
concurrently submitted for any such degree, diploma or other qualification at the University 
of Cambridge or any other University or similar institution except as declared in the Preface 







First and foremost, I would like to thank my PhD supervisor Dr Cedric Ghevaert. I am eternally 
thankful to Cedric for taking a chance on me and employing me as a Research Assistant soon 
after finishing my undergraduate degree in 2010. The knowledge and experience I have gained 
over the last 7 years in his lab has been invaluable. Without his knowledge and unwavering 
belief in my abilities I would not be where I am today.   
 
I would like to thank all the past and present members of the Ghevaert lab; Maria, Tom, 
Amanda D, Amanda E, José, Annett, Holly, Dan, Amie, Harriet, Wardiya, Meera, Wing, Nilly, 
Catherine, Guénaëlle and Laura. Each and every one has helped me in their own way, passing 
on knowledge and experience and most importantly making life in the lab enjoyable. A special 
thank you to Holly for reading and re-reading draft versions of this thesis and for that 
undesirable task I am extremely grateful. 
 
I would also like to thank all the collaborators near and far that have contributed to the 
research in this PhD. José Guerrero for his expertise in platelet biology and performing plasma 
TPO assays. The Wellcome Trust Sanger Institute for creating the Crlf3 mutant mice and staff 
at CBS for looking after mice. Bernhard Neiswandt and the members of his group for their 
hospitality during my visit to Würzburg, especially Simon Stritt who performed various 
experiments for me and Ayesha Baig who perform in vivo proplatelet experiments. Tina 
Hamilton and Dean Pask for having the patience and time to teach me all manner of things 
mouse related and for irradiating mice and performing tail vein injections. My secondary 
supervisor Randy Read and his lab members Yahui Yan and Richard Mifsud for helping me with 
crystallisation experiments and for resolving the tertiary structure of CRLF3. Staff at the NIHR 
Cambridge BRC Cell Phenotyping Hub for cell sorting. Renet Feret, Marco Chiapello and Mike 
Deery for all things mass spectrometry related. Karen Hoffmeister and Silvia Giannini for 
western blots of platelet galactose. 
 
I would like to thank all my friends who are there for me when times are hard and help keep 
me sane. To the 8BL, thanks for being you, not changing during the last 10 years and most 
importantly, the best nights out none of us can remember. No matter what happens in life, I 





my PhD incredible down Mill Road. Also, massive thanks for picking me up at my lowest. To 
the homeboys, thanks for everything you have done for me in life. Without all of you life would 
be a lot harder. 
 
I would like to say a special thanks to Kirsty, without whom this PhD would have been much 
more of a struggle. Thank you for everything you do for me, listening to my problems, being 
my biggest supporter, standing by my side when times are hard and most importantly trying 
to understand my work. I appreciate everything you have done and all the sacrifices you have 
made to allow me to continue with an academic career.  
 
I would like to say a massive thank you to my family. Thank you to Mum and Dad for all your 
help financially and emotionally, both of which have allowed me to pursue my many academic 
endeavors. Thank you for accepting I have ‘no common sense’ and pretending to understand 
what I do at work. Thank you to Nathan and Megan for keeping me grounded, having lengthy 
‘debates’ with me about anything and failing to accept academia is a real career.  
 
Finally, I would like to dedicate this thesis to my grandparents. Nan and Grandad, you are both 
an inspiration to me. Your hard work and unrelenting love is admirable. Grandad, your words 
‘more power to your elbow’, gave me strength to complete this thesis when times were hard! 
Table of Contents 
 
iv 
Table of contents 
 
Declaration                 i 
Acknowledgements               ii 
Table of contents              iv 
Table of Figures               ix 
Table of Tables               xi 
Abbreviations               xii 
Abstract                1 
1 Introduction               3 
1.1 Overview of haematopoiesis                        4 
1.2 Megakaryocyte maturation                             6 
1.3 Transcriptional regulation of megakaryopoiesis                                8 
1.4 Thrombopoietin signalling in megakaryopoiesis                            11 
1.5 TPO free megakaryopoiesis          16 
1.6 Megakaryocyte maturation          16 
1.6.1 Endomitosis and polyploidisation         16 
1.6.2 Demarcation membrane system         19 
1.6.3 MK migration           20 
1.7 Platelets             22 
1.7.1 Platelet formation and the proplatelet theory       22 
1.7.1.1 Microtubules          25 
1.7.1.2 Actin           26 
1.7.1.3 Spectrin           28 
1.7.2 Release of preplatelets and platelet maturation in the periphery    28 
1.7.3 Morphology           30 
1.7.3.1 Granules           30 
1.7.4 Role in thrombus formation at site of vascular injury      32 
1.7.4.1 Tethering and stable adhesion        33 
1.7.4.2 Platelet activation and aggregation       33 
1.7.4.3 Clot stabilisation          37 
1.7.5 Role in thrombus formation in the absence of vascular injury     37 
1.7.6 Removal from circulation          39 




1.8 Thrombocythaemia           42 
1.8.1 Essential thrombocythaemia         42 
1.8.1.1 Genetic causes          43 
1.8.1.2 Treatment          47 
1.8.1.2.1 Cytoreductive agents        48 
1.9 Thrombocytopenia                        50 
1.9.1 Inherited causes           50 
2 Aims              54 
3 Materials and methods            56 
3.1 Generation of Crlf3 mutant mice          57 
3.2 Genotyping             57 
3.3 Mouse husbandry and regulated procedures        58 
3.4 Induction of mutant Jak2 expression          58 
3.5 Bleeding mice            59 
3.6 Full blood counts            59 
3.7 Platelet rich plasma and washed platelets        59 
3.8 In vitro culture of bone marrow derived MKs        60 
3.9 Quantitative polymerase chain reaction         60 
3.10 Western blot            61 
3.11 Quantification of MKs in bone marrow         62 
3.12 Plasma thrombopoietin           62 
3.13 Ploidy analysis            63 
3.14 In vitro proplatelet formation          63 
3.15 In vivo proplatelet formation          64 
3.16 Platelet survival            64 
3.17 Splenectomy            65 
3.18 Preplatelet quantification           65 
3.19 Bone marrow transplants           66 
3.20 Platelet surface receptor expression         66 
3.21 Platelet activation            67 
3.22 Platelet spreading            67 
3.23 In vitro thrombus formation          67 
3.24 Platelet morphology           68 
Table of Contents 
 
vi 
3.25 Electron microscopy           68 
3.26 Platelet cytoskeleton at 37oC and 4oC         69 
3.27 Cloning Crlf3 constructs into pGEX vector         70 
3.28 Protein production            70 
3.29 Protein purification           71 
3.30 Protein concentration           71 
3.31 Protein crystallisation            71 
3.32 Structural solution            72 
3.33 Maintenance and expansion of human induced pluripotent stem cells (iPSCs)    72 
3.34 Tandem Affinity Purification (TAP) tagging CRLF3 in human iPSCs by      
CRISPR/Cas9               73 
3.35 TOPO TA cloning to screen CRLF3 in iPSC lines        74 
3.36 TAP-tag expression in iPSCs by flow cytometry        75 
3.37 CRLF3 interactome in iPSCs          75 
3.38 Forward programming           77 
3.39 Localisation of CRLF3 in proplatelet forming forward programmed MKs     78 
3.40 Statistics             78 
4 Results 1 – Phenotyping of Crlf3-/- mice and biological mechanisms for  
thrombocytopenia            83 
4.1 Introduction            84 
4.1.1 Cytokine receptor-like factor 3         84 
4.1.2 Crlf3 knockout mice          86 
4.2 Chapter hypotheses and aims          88 
4.3 Chapter overview            88 
4.4 Results             88 
4.4.1 Confirmation of genotype          88 
4.4.2 Sustained and isolated thrombocytopenia       89 
4.4.3 Platelet production is unaffected         92 
4.4.4 Increased platelet clearance in Crlf3-/- mice causes thrombocytopenia      98 
4.4.5 Platelet clearance driven by haematopoietic compartment but not due      
to platelet activation/aggregation defects                 101 
4.4.6 Ineffective thrombopoiesis       105 
4.4.7 Crlf3-/- platelets have increased microtubule stability     108 




4.5 Chapter conclusions         110 
5 Results 2 – CRLF3 as a novel therapeutic target for the treatment of essential    
thrombocythaemia          113 
5.1 Introduction          114 
5.2 Chapter hypotheses and aims        115 
5.3 Chapter overview          115 
5.4 Results           116 
5.4.1 Breeding strategy         116 
5.4.2 Ablation of Crlf3 restores platelet counts in ET mice    118 
5.4.3 Platelet reactivity and MK hyperplasia not increased    120 
5.5 Chapter conclusions         125 
6 Results 3 – CRLF3 structure and function                    127 
6.1 Introduction          128 
6.1.1 Protein structure         128 
6.1.2 Protein interactome        129 
6.2 Chapter hypotheses and aims        129 
6.3 Chapter overview          129 
6.4 Results           130 
6.4.1 CRLF3 crystal structure        130 
6.4.1.1 Design of 4 CRLF3 constructs      131 
6.4.1.2 Protein production and purification     133 
6.4.1.3 Crystallisation of construct 3 and solving of 3D structure  135 
6.4.2 Adding a Tandem Affinity Purification (TAP) tag to endogenous CRLF3          
in human iPSCs         137 
6.4.2.1 CRLF3’s interactome in iPSCs      142 
6.4.2.2 Forward programming of tagged iPSCs     143 
6.5 Chapter conclusions         145 
7 Discussion and future work         146 
7.1 Ablation of Crlf3 causes isolated chronic thrombocytopenia    147 
7.2 CRLF3 as a novel therapeutic for the treatment of essential         
thrombocythaemia          149 
7.3 Structure, function and localisation of CRLF3      150 
7.4 Towards a therapeutic against CRLF3       153 
Table of Contents 
 
viii 
7.5 Final remarks          153 
8 Bibliography           155 




Table of Figures 
 
Figure 1.1 – Schematic representation of the haematopoietic tree         5 
Figure 1.2 – Schematic representation of megakaryocyte maturation        7 
Figure 1.3 – Schematic representation of platelet clearance and thrombopoietin production 
by liver cells            12 
Figure 1.4 – Schematic representation of TPO induced signalling        15 
Figure 1.5 – Schematic representation of endomitosis        17 
Figure 1.6 – Schematic representation of proplatelet formation, preplatelet release and 
platelet maturation           24 
Figure 1.7 – Schematic representation of platelet activation and thrombus formation at sites 
of vascular injury           34 
Figure 3.1 – Generation of Crlf3 mutant mice         57 
Figure 4.1 – CRLF3 expression in haematopoietic cells        85 
Figure 4.2 – Expression of CRLF3 transcripts in the haematopoietic system      86 
Figure 4.3 – Genotyping of Crlf3-/- and WT mice         89 
Figure 4.4 – Sustained thrombocytopenia in Crlf3-/- mice        91 
Figure 4.5 – Megakaryopoiesis is upregulated in Crlf3-/- mice       94 
Figure 4.6 – plasma TPO levels are unaltered in Crlf3-/-  mice       95 
Figure 4.7 – Crlf3-/- progenitors are primed to form MKs        95 
Figure 4.8 – MK polyploidisation is unaffected by ablation of Crlf3       96 
Figure 4.9 – Proplatelet fragmentation occurs faster in Crlf3-/- MKs       97 
Figure 4.10 – Platelet clearance occurs within the first 24 hours of release and facilitated 
partly by the spleen           99 
Figure 4.11 – Thrombocytopenia in Crlf3-/- mice is driven by splenic clearance    100 
Figure 4.12 – Defects in the haematopoietic compartment cause thrombocytopenia in Crlf3-/- 
mice           102 
Figure 4.13 – Platelet activation is unaffected in Crlf3-/- mice     103 
Figure 4.14 – Crlf3-/- platelets can form stable thrombi under arteriolar shear   104 
Figure 4.15 – Large preplatelets are retained in the peripheral circulation of old Crlf3-/-     
mice                        107 
Figure 4.16 – Aberrant tubulin expression and possibly increased microtubule stability in   
Crlf3-/- mice          109 
Table of Figures 
 
x 
Figure 5.1 – Breeding strategy to create ET mice with Crlf3 ablated     117 
Figure 5.2 – Ablation of Crlf3 normalises platelet counts in ET mice     119 
Figure 5.3 – MK hyperplasia is not exacerbated by ablation of Crlf3 in ET mice   122 
Figure 5.4 – Platelet activation is not grossly affected in ET x Crlf3-/- mice    123 
Figure 5.5 – Ability of ET platelets to spread and form stable thrombi is unaltered by ablation 
of Crlf3           124 
Figure 6.1 – Vector map of Crlf3 ligated into pGEX-6P-2      131 
Figure 6.2 – Design of 4 CRLF3 constructs based on homology and disorder   133 
Figure 6.3 – Purification of CRLF3 construct 3 by ion exchange chromatography   134 
Figure 6.4 – 3D structure of CRLF3 construct 3       137 
Figure 6.5 – Schematic diagram of adding a TAP-tag to CRLF3 by CRISP/Cas9   138 
Figure 6.6 – Vector map of TAP-tag donor vector        140 
Figure 6.7 – Confirmation of TAP-tag donor vector by restriction digestion    141 
Figure 6.8 – Confirmation of CRLF3-TAP in iPSCs       141 
Figure 6.9 – Confirmation of CRLF3-TAP in forward programmed MKs    144 
Figure 6.10 – High unspecific staining in proplatelet forming forward programmed MKs  144 




Table of Tables 
 
Table 1.1 – Summary of expression and function/role of key transcription factors involved in 
megkaryopoiesis            10 
Table 1.2 – Causes of thrombocythaemia and thrombocytopenia       45 
Table 3.1 – Primers used to genotype Crlf3 WT and Crlf3 mutant alleles      58 
Table 3.2 – Antibodies used for in vitro culture of bone marrow derived MKs     60 
Table 3.3 – Primers used for qPCR           61 
Table 3.4 – Primary antibodies used for western blot        62 
Table 3.5 – Secondary antibodies used for western blot        62 
Table 3.6 – Antibodies used for platelet survival         64 
Table 3.7 – Antibodies used for platelet surface receptor expression      66 
Table 3.8 – Antibodies used for platelet activation         67 
Table 3.9 – Primers used to amplify Crlf3 constructs         70 
Table 3.10 – Primers used for creation of TAP-tag donor vector       74 
Table 3.11 – Primers used for TOPO TA cloning         74 
Table 3.12 – List of all primers used           79 
Table 3.13 – List of all antibodies used          81 
Table 4.1 – Effect of Crlf3 ablation on blood lineages at different mice ages     90 
Table 5.1 – Full blood counts in crossbred female mice      120 
Table 6.1 – Conditions in which CRLF3 construct 3 produced crystals    136 
Table 6.2 – Proteins identified in TAP-tagged but not untagged iPSC immunoprecipitation 






3D three dimension 
ACD acid citrate dextrose solution 
ACTN1 actinin 1 (α-actinin) 
ADF actin depolymerising factor 
Akt protein kinase B  
AML1 acute myeloid leukemia 1 
AMR Ashwell-Morell receptor 
AP2 adaptor protein 2 
ASGPR asialoglycoprotein receptor 
AWERB Animal Welfare and Ethical Review Body 
Bad Bcl-2-associated death promoter 
BAK Bcl-2-antagonist/killer 
BAX Bcl-2-associated X 
BCA bicinchoninic acid 
BCL-2 B-cell lymphoma 2 
Bcl-xL B-cell lymphoma-extra large 
BFU-MK burst forming unit - megakaryocyte  
BMP4 Bone morphogenetic protein 4 
bp base pair 
BPD Bleeding, thrombotic and Platelet Disorders project  
BSA bovine serum albumin 
BSS Bernard-Soulier syndrome  
CALR calreticulin 
Cas9 CRISPR associated protein 9 
CBB calmodulin binding buffer 
CBFβ core-binding factor subunit beta 
CBL Casitas B-lineage Lymphoma 
CBP calmodulin binding peptide 
CDC42 Cell division control protein 42 





CFU-MK colony forming unit - megakaryocyte  
CIP4 CDC42 interacting protein 4  
c-Kit CD117 
CLP common lymphoid progenitor 
CMP common myeloid progenitor  
COX-1 cyclooxygenase 1 
CR3 compliment receptor 3  
CRISPR Clustered Regularly Interspaced Short Palindromic Repeat 
CRLF3 cytokine receptor-like factor 3 
CRP collagen related peptide 
DAD diaphanous autoregulatory domain 
DAG diglyceride 
DAPI 4',6-diamidino-2-phenylindole 
DIAPH1  diaphanous-related formin 1 
DID diaphanous inhibitory domain 
DIW deionised water  
DMEM Dulbecco’s modified Eagle medium  
DMS demarcation membrane system 
DMSO dimethyl sulfoxide 
DNA deoxyribose nucleic acid 
DOCK dedicator of cytokin 
DTT dithiothreitol  
DVT Deep vein thrombosis 
E embryonic day 
E8 Essential 8 medium 
EB erythroblast 
ECT2 epithelial cell transforming 2 
EDTA ethylenediaminetetraacetic acid 
EGTA ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
EPO erythropoietin 




ERK extracellular signal-regulated kinase 
ES embryonic stem  
ET essential thrombocythaemia 
ETS E26 transformation-specific 
ExAC Exome Aggregation Consortium 
FACS fluorescent-activated cell sorting 
F-actin filamentous actin 
FBS foetal bovine serum 
Fc fragment, crystallisable  
FGF2 fibroblast growth factor 2 
FLAG DYKDDDDK (where D=aspartic acid, Y=tyrosine, and K=lysine) 
FLI1 friend leukemia integration 1 
FLNA filamin A 
FN3 fibronectin type III 
FOG1 friend of GATA1 
G1 Gap 1 
G2 Gap 2 
GABPα GA-binding protein alpha chain 
G-actin globular actin 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
gDNA genomic DNA 
GDP guanine diphosphate 
GEF guanine exchange factor 
GEF-H1 Rho guanine nucleotide exchange factor 2 
GFP green fluorescent protein 
GlcNAc N-acetylglucosamine 
Glu-tubulin detyrosinated tubulin 
GM-CSF granulocyte-macrophage colony-stimulating factor 
GMP granulocyte-macrophage progenitor 
GP glycoprotein 
GPCR G-protein coupled receptor 
GPRP Gly-Pro-Arg-Pro 





Grb2 growth factor receptor-bound protein 2 
GSK-3β glycogen synthase kinase 3 beta 
GST Glutathione-S-transferase 
GTP guanine triphosphate 
H&E Haemotoxylin and Eosin 
HBS HEPES buffered saline 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Hg mercury  
Hgb haemoglobin 
HIF-1 hypoxia inducing factor-1 
HipSci human induced pluripotent stem cell initiative 
HMGB-1 high motility group box-1 
HPLC high-performance liquid chromatography 
HSC haematopoietic stem cell 
ID identification number 
IFN interferon 
IgG Immunoglobulin G 
IL interlukin 
IP3 inositol 1,4,5-triphosphate 
iPSC induced pluipotent stem cell 
IPTG isopropul-1-thio-β-D-galactopyranoside 
ITP idiopathic or immune thrombocytopenic purpura 
IVC inferior vena cava  
JAK2 Janus kinase 2 
JAM junctional adhesion molecule 
JH1 JAK2 tyrosine kinase domain  
JH2  JAK2 pseudokinase domain 
KO knockout 
LIF leukaemia inhibitory factor 
LNK lymphocyte adapter protein 
loxP locus of X-over P1 




LT long term 
LYN Lck/Yes novel tyrosine kinase 
Mac-1 macrophage receptor 1  
MAPK mitogen-activated protein kinase 
MCL-1 myeloid cell leukemia 1 
MCV Mean corpuscular volume 
mDia1 diaphanous-related formin 1 
MEK mitogen-induced extracellular kinase 
MEP megakaryocyte/erythrocyte progenitor 
MFI Mean fluorescence intensity 
MK megakaryocyte 
MKB megakaryoblast 
MOI multiplicity of infection 
MPF mitosis promoting factor 
MPL myeloproliferative leukemia protein 
MPN myeloproliferative neoplasms  
MPO myeloperoxidase 
MPV mean platelet volume  
mRNA messenger ribonucleic acid 
MVB multivesicular body 
MYH9 myosin, heavy chain 9 
NBEAL2 neurobeachin-like 2 
NE neutrophil elastase 
neo neomycin 
NET neutrophil extracellular trap 
NF-κΒ nuclear factor- κΒ 
NF1 neurofibromatosis type 1 
NHS-Biotin biotin N-hydroxysuccinimide ester 
NK natural killer 
NMMHC-IIA nonmuscle myosin heavy chain IIA 
NO nitric oxide  
NOX NAPDH oxidase 





OCS open canalicular system  
PAD4 peptidylarginine deiminase 4 
PAI-1 plasminogen activator inhibitor-1 
PAK2 p21-activated kinase 2 
PAR protease-activated receptor  
PBE PBS/BSA/EDTA 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PEG polyethylene glycol 
pen/strep penicillin/streptomycin 
PFA paraformaldehyde 
Pfn profilin 1 
PGE1 Prostaglandin E1 
PGI2 prostaglandin I2 
PHD propyl hydroxylase 
PHOX phagocytic oxidase 
PI3K phosphoinositol-3 kinase 
PIP4Kα PI-5-P-4 kinase α 
pIpC polyinosinic-polycytidylic acid  
PIPES piperazine-N,N-bis-2- ethanesulfonic acid 
PLC phospholipase C 
PMF primary myelofibrosis  
PRP Platelet rich plasma 
PS phosphatidylserine 
PSGL-1 P-selectin ligand 1  
PV polycythaemia vera 
PVDF polyvinylidene fluoride 
qPCR quantitative polymerase chain reaction 
RAGE receptor for advanced glycation endproducts 
Raf-1 RAF proto-oncogene serine/threonine-protein kinase 
RBC red blood cell 




RNA ribonucleic acid 
ROS reactive oxygen species 
RT room temperature 
RUNX1 Runt-related transcription factor 1 
S phase synthesis phase 
S1P Shingosine-1-phosphate  
S1pr1 Sphingosine-1-phosphate receptor 1 
SAD single anomalous diffraction 
SCF stem cell factor 
SEM scanning electron microscopy  
sgRNA single-guide RNA 
shRNA short hairpin ribonucleic acid 
SLAM signalling lymphocyte activation molecule 
SOCS supressor of cytokine signalling 
SOS Son of Sevenless 
Src Proto-oncogene tyrosine-protein kinase Src 
ST short term 
St3gal4 st3 beta-galactoside alpha-2,3-sialyltransferase 4 
STAT signal transducer and activator of transcription 
TAP tandem affinity purification 
TEM transmission electron microscopy  
TEV Tobacco etch virus 
TF Tissue factor  
TGF-β transforming growth factor beta  
TPM Tropomyosin 
TPO thrombopoietin 
TUBB1 β1-tubulin  
TxA2 Thromboxane A2 
Tyk2 TYK2 tyrosine kinase 2 
Tyr tyrosine 
Tyr-tubulin  tyrosinated tubulin 
VTN-N truncated vitronectin 





WAS Wiskott-Aldrich syndrome 
WASp Wiskott-Aldrich syndrome protein  
WAVE Wiskott-Aldrich syndrom protein family verprolin homolog 
WBC white blood cell 
WIP WASp-interacting protein  
WT wildtype 




























Thrombocythaemia is defined as a circulating platelet count above 450x109/L in humans. The 
major cause of thrombocythaemia is reactive (secondary) thrombocythaemia which occurs 
secondary to many conditions such as infection, cancer and inflammation. However, acquired 
clonal mutations in mainly Janus Kinas 2 (JAK2), CALR and MPL cause essential 
thrombocythaemia (ET). ET is a rare disease that leads to an increased risk of cardiovascular 
thrombotic events. Current treatment of ET uses combination of low dose aspirin (to decrease 
platelet function) and cytoreductive agents (to decrease thrombopoiesis). The most 
commonly used cytoreductive agents are hydroxyurea, anagrelide and interferon-α and all 
have unwanted side effects.  
 
Cytokine receptor-like factor 3 (CRLF3) is a 2.4kb gene that is ubiquitously expressed 
throughout the haematopoietic system. Very little is known about the function of CRLF3, with 
only one peer reviewed journal article in the literature which shows that CRLF3 may negatively 
regulate the cell cycle at the G0/G1 phase. However, nothing is known about the role of CRLF3 
in platelet biology. Using a Crlf3 knockout mouse (Crlf3-/-) developed by the Wellcome Trust 
Sanger Institute we show CRLF3’s role in platelet biogenesis and how it could be used as a 
novel therapeutic target to treat ET. 
 
Crlf3-/- mice have an isolated and sustained 25-40% decrease in platelet count compared to 
wildtype (WT) controls. Platelet function is unaffected as demonstrated in a range in a range 
of in vitro assays. The thrombocytopenia is a consequence of abnormalities in hematopoietic 
cells, as shown by bone marrow transplantations. Megakaryopoiesis is upregulated in Crlf3-/- 
mice and proplatelet morphology is unaffected, suggesting the thrombocytopenia is due to 
increased platelet clearance. Indeed, splenectomised Crlf3-/- mice show normalised platelet 
counts within 7 days, showing rapid splenic removal of platelets is responsible for the 
thrombocytopenia.  Abnormal large platelet structures that resemble proplatelets shafts 
(preplatelets) are abnormally present in the circulation of elderly Crlf3-
/- mice. Immunohistochemistry showed increased and aberrant tubulin expression in Crlf3-/- 
platelets compared to WT controls, especially in the preplatelet forms. Cold induced 
depolymerisation of microtubules was decreased in Crlf3-/- platelets, suggestive of increased 





We then crossbred Crlf3-/- mice with JAK2 V617F ET mice, to determine the effect of Crlf3 
ablation of thrombocythaemia. Crossbred mice showed restoration of platelet counts to WT 
values without grossly affecting platelet function or other blood lineages, providing the 
rational for CRLF3 as a novel therapeutic target for treatment of ET. 
 
Finally, we aimed to resolve the crystal structure of CRLF3 and discover its interactome. To 
this end, we were able to resolve the crystal structure of a C-terminal portion of the full length 
protein containing the predicted fibronectin type III domain. To shed light on the interactome 
of CRLF3, endogenous CRLF3 was tagged with a tandem affinity purification (TAP) tag using 
CRISPR/Cas9 technology in induced pluripotent stem cells (iPSCs). We have been able to 
produce megakaryocytes from these TAP-tagged iPSCs by forward programming. However, as 
yet we have not been able to generate enough MKs to have adequate material to perform 
immunoprecipitation assays. Therefore, the interactome of CRLF3 in MKs remains unknown.  
 
In conclusion, we identified a mechanism by which Crlf3 controls platelet biogenesis. Slowed 
maturation of Crlf3-/- preplatelets in the peripheral circulation potentially due to increased 
structural stability leads to rapid removal of these immature forms by the spleen and 
therefore a decrease in platelet count. The isolated effect on platelet numbers and 
normalisation of platelet count in ET mice deficient of Crlf3 provides the rational for further 
study on CRLF3 drug targeting as a novel therapeutic strategy for ET. 
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1.1 Overview of haematopoiesis 
 
Haematopoiesis is essential for the generation of all the mature cells of haematopoietic 
system. Defects in haematopoiesis can result in life threatening illnesses including blood 
cancer and bleeding disorders. 
 
All the cells in the blood lineage are produced by cellular differentiation of the most naïve cell 
in the haematopoietic system, the haematopoietic stem cell (HSC) (fig. 1.1). HSCs can be 
separated into two distinct populations: long term (LT) and short term (ST). Although both LT- 
and ST-HSCs are able to produce all other haematopoietic cells, only LT-HSCs are able to 
maintain long term regeneration of the tissue through their ability to self-renew (Orkin and 
Zon, 2008). HSCs are characterised by their lack of mature lineage markers, namely: CD2, CD3, 
CD14, CD16, CD19, CD24, CD56, CD66b, GlyA (termed ‘Lin-‘) (Bryder et al., 2006; Laurenti and 
Dick, 2012).  
 
Differentiation of HSCs results in a number of multipotent progenitors that can in turn 
differentiate to produce all the mature cells of the haematopoietic system. Differentiation of 
HSCs results in the common lymphoid progenitor (CLP) and the common myeloid progenitor 
(CMP). CLPs can further differentiate into mature natural killer (NK) cells, B lymphocytes and 
T lymphocytes. CMPs however differentiate into two progenitor cells, the granulocyte-
macrophage progenitor (GMP) and the megakaryocyte/erythrocyte progenitor (MEP); 
however there is evidence that the MEP can arise directly from HSCs without the need for a 
CMP intermediate (Adolfsson et al., 2005). GMPs give rise to mature neutrophils, eosinophils, 
mast cells and monocytes/macrophages. MEP differentiation results in two committed 
progenitor cells, namely erythroblasts (EBs) and megakaryoblasts (MKBs). EBs mature into 
erythrocytes and MKBs mature into megakaryocytes (MKs) which eventually give rise to 
platelets (Bryder et al., 2006; Chang et al., 2007).  




Figure 1.1 – Schematic representation of the haematopoietic tree.  LT-HSC = long term-haematopoietic stem 
cell; ST-HSC = short term-haematopoietic stem cell; CMP = common myeloid progenitor; CLP = common lymphoid 
progenitor; GMP = granulocyte-macrophage progenitor; MEP = megakaryocyte/erythrocyte progenitor; EB = 
erythroblast; MKB = megakaryoblast and MK = megakaryocyte  
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1.2 Megakaryocyte maturation 
 
As described above, MKs originate from a bipotent progenitor cell, the MEP. The 
transcriptional regulation that directs passage through the erythroid or MK lineage from the 
MEP is not fully understood. Cells that enter the MK lineage first differentiate into the highly 
proliferative burst-forming unit (BFU-MK) and then into the less proliferative colony-forming 
unit (CFU-MK). BFU-MKs are able to produce 40-500 megakaryocytes in specific in vitro 
conditions, whereas CFU-MKs produce colonies of 3-50 megakaryocytes in in vitro colony 
forming assays (Briddell et al., 1989; Long et al., 1985). Maturation of CFU-MKs gives 
promegakaryoblasts, the first MK precursor to be recognised in bone marrow. 
Promegakaryoblasts become megakaryoblasts (Stage I MKs). Megakaryoblasts are small (10-
15µm), immature 2/4N MKs and retain the ability to proliferate. They have high nuclear: 
cytoplasm ratio and lack organelles characteristic of a mature MK (i.e. α- and dense-granules). 
Stage I MKs become Stage II MKs (promegakaryocytes) when α- and dense-granules and the 
demarcation membrane system (DMS) begin to form. Stage III and IV MKs represent mature 
MKs. Mature MKs are non-proliferative, large, polyploid cells that contain a large multilobular 
nucleus. Stage III and IV MKs are separated based on three cytoplasmic regions. The marginal 
zone contains numerous micro-vesicles and is predominant at stage III but smaller at stage IV. 
The middle zone contains α- and dense-granules and DMS. The middle zone contains some 
cytoplasm in stage III but is full of cytoplasm in stage IV. Finally, the perinuclear zone contains 
organelles such as mitochondria and endoplasmic reticulum and is present at stage III but 
missing at stage IV (Ru et al., 2016) 
 
MK maturation is monitored by expression of MK and platelet specific surface glycoproteins 
such as GPIIb/IIIa (integrin αIIbβ3 or CD41/CD61; the fibrinogen receptor) and the GPIb-V-IX 
complex (GPIba, GPIbb, GPIX and GPV or CD42a, b, c and d; the von Willebrand factor (vWF) 
receptor). Although CD41 is not truly MK specific, expression is found throughout 
haematopoietic progenitors, the MK lineage and mast cells, expression increases along the 
MK lineage. Co-expression of CD41 with CD42 (GPIb) is currently thought to be specific of the 
MK lineage. Expression of CD42 and CD61 appear at the later stages of differentiation and are 
therefore used to identify mature MKs (fig. 1.2) (Chang et al., 2007). 
 
1 – Introduction 
7 
 
Proteins contained within α-granules, such as platelet factor 4 (PF4), vWF, thrombospondin 
and coagulation factor V and proteins involved in proplatelet formation (β1-tubulin) are also 
used as indicators of the later stages of MK development (Chang et al., 2007).  
 
 
Figure 1.2 – Schematic representation of megakaryocyte maturation.  MEP = megakaryocyte/erythrocyte 
progenitor; BFU-MK = burst-forming unit-megakaryocyte and CFU-MK = colony forming unit-megakaryocyte.  
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1.3 Transcriptional regulation of megakaryopoiesis 
 
Transcription factors are proteins that bind to specific regions of DNA termed motifs. Once 
bound, transcription factors are able to recruit transcriptional machinery and/or inhibitory 
proteins to the promotor region of specific genes, thus promoting or inhibiting the expression 
of those genes.  The cell and time specific combination of transcription factors provide a 
robust mechanism for the genetic regulation of a cell. Although the role and combinations of 
transcription factors in megakaryopoiesis is not fully understood, below is an overview of the 
known essential transcription factors (summarised in Table 1.1). 
 
GATA1 and FOG1 (ZFPM1) 
 
Murine studies have revealed that GATA1 is essential for proper megakaryopoiesis. 
Homozygous null mutations of Gata1 in mice causes embryonic lethality due to anaemia 
(Fujiwara et al., 1996). A haematopoietic lineage conditional knockout (KO) results in MKs with 
decreased ploidy and excessive proliferation. Induction of cyclin–D1 in these KO mice restored 
ploidy levels, however terminal differentiation was still altered (Shivdasani et al., 1997). 
Furthermore, Moreau et al (2016) showed MKs could be generated from human induced 
pluripotent stem cells (iPSCs) by transducing with recombinant GATA1, TAL1 and FLI1 (Moreau 
et al., 2016).   
 
Friend of GATA1 (FOG1; also called ZFPM1) does not bind to DNA but binds GATA1. Murine 
Fog1 KOs die of severe anaemia midway through embryonic development as per Gata1 KO 
mice. However, unlike Gata1 KOs MKs fail to develop and platelet production was absent in 
Fog1 KO mice, suggesting an independent role of FOG1 in MK development and 




In 1995 Shivdasani et al and Robb et al showed the essential role of Scl (also known as Tal1) 
in haematopoiesis. Both groups developed KO mice that showed lethality at day E9.5. 
Interestingly, these KO mice had a complete absence of haematopoiesis (Robb et al., 1995; 
Shivdasani et al., 1995). More recently, Hall et al developed a haematopoietic specific 
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conditional Scl KO mouse. This conditional KO had perturbed megakaryopoiesis and 
erythropoiesis with a loss of early progenitors. Platelet counts and haematocrit were also 




RUNX1 (also known as AML1) functions as a heterodimeric complex with its cofactor, CBFβ. It 
is essential for the emergence of HSCs during embryogenesis and therefore Runx1 KO mice 
are embryonically lethal. Deletion of Runx1 from the adult haematopoietic system using a 
conditional murine knockout showed decreased maturation of MKs. Conditional Runx1 
knockout mice have decreased platelet counts and an accumulation of immature MK 
progenitor cells within the bone marrow, similar to what was seen in the conditional Gata1 
KO mouse (Tijssen and Ghevaert, 2013).  
 
FLI1 and GABPα 
 
FLI1, GABPα and ETV6 are part of the E26 transformation-specific (ETS) family, which is one of 
the largest families of transcription factors. All ETS proteins contain a helix-loop-helix DNA 
binding (ETS) domain and many ETS factors have a role in megakaryopoiesis. FLI1 is essential 
for MK development and has been shown to negatively regulate erythropoiesis whilst 
positively regulating megakaryopoiesis. Fli1 homozygous null mice die at approximately E11.5 
due to cerebral bleeding and show dysmegakaryopoiesis that resembles that seen in patients 
with Jacobsen Syndrome (Hart et al., 2000). Jacobsen Syndrome, also known as 11q deletion 
disorder, results in decreased platelet counts amongst many other symptoms.  
 
FLI1 potentially acts in tandem with GABPα in MKs. As MKs mature, the ratio of FLI1: GAPBα 
increases, this is consistent with the observation that GABPα regulates the expression of early 




ETV6 (also called TEL) can inhibit the activity of FLI1 at the transcriptional and biological levels 
(Kwiatkowski et al., 2000). The level of TEL expression is important for maintenance of 
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megakaryopoiesis. Overexpression of TEL in cell line causes inhibition of MK genes and the 
generation of an erythroid phenotype (Sakurai et al., 2003). In contrast, GATA1-Cre mediated 
conditional deletion of Tel in the MK-erythroid lineage had no effect on red cell population 
but caused a 50% decrease in platelet count (Hock et al., 2004).   
 
TF Expression within 
haematopoietic system 
Function/Role in haematopoiesis 
GATA1 Expressed in platelets, MKs, 
EBs and eosinophils. Low 
level of expression in 
basophils. 
Recognise [5ʹ-(A/T)GATA(A/G)-3ʹ] motifs and are 
able to bind cofactors which increase DNA 




Low levels of expression in 
platelets, MKs, EBs and 
eosinophils. 
Roles in MK development and thrombopoiesis. 
Binds GATA1 allowing the formation of a 
complex with the nucleosome remodelling and 
deacetylase (NURD). The formation of the 
GATA1/FOG1/NURD complex allows efficient 
regulation of gene transcription. 
SCL 
(TAL1) 
Expression limited to 
platelets, MKs, EBs and 
basophils. Very high in 
platelet, high in MKs and 
EBs and lower in basophils.  
Essential for proper haematopoiesis. Knockout 




Low levels of expression in 
all haematopoietic cells, 
except basophils and 
platelets that have high 
expression. 
Essential for the emergence of HSCs during 
embryogenesis. In adult system required for 
proper maturation of MKs. Forms a 
heterodimeric complex CBFβ, which causes 
increased DNA binding and stability. 
FLI1 Platelets have high 
expression and all other 
haematopoietic cells have 
medium to low expression 
levels.  
Essential for MK development, by regulating the 
expression of both early and late MK genes. It 
also negatively regulates erythropoiesis whilst 
positively regulates megakaryopoiesis.  
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GABPα Lowly expressed in all 
haematopoietic cells. 
Regulates the expression of early MK genes. 
ETV6 
(TEL) 




eosinophils and platelets 
which have higher 
expression.  
Binds to and inhibits the activity of FLI1. Level of 
TEL expression is important for maintenance of 
megakaryopoiesis, with overexpression leading 
to erythroid phenotype and ablation causing 
thrombocytopenia.  
 
Table 1.1 – Summary of expression and function/role of the key transcription factors involved in 
megakaryopoiesis. TF= Transcription factor. Expression data from Chen et al (2014). Function/role of TFs 
reviewed in Tijssen et al (2016) 
 
1.4 Thrombopoietin signalling in megakaryopoiesis 
 
The main driver of megakaryopoiesis is the cytokine thrombopoietin (TPO) binding to its 
receptor c-Mpl. TPO was discovered in 1994 (Bartley et al., 1994; Lok et al., 1994; Sohma et 
al., 1994) after the discovery of its receptor c-Mpl in 1992 (Vigon et al., 1992). However, TPO 
was known to exist long before this. In 1958 Cserhati, Tanos and Kelemen first coined the term 
TPO and postulated its role in platelet production (Cserhati et al., 1958; Kelemen et al., 1958).  
 
Once recombinant TPO was made available, it was shown to be the main regulator of 
megakaryopoiesis and platelet production. Kaushansky et al showed that addition of TPO to 
whole bone marrow cells was enough to produce polyploid MK containing colonies. When 
TPO was added to cultures containing interlukin-3 (IL-3) or c-Kit, proteins known to drive MK 
proliferation, very large MK colonies were observed. At later stages of maturation, TPO was 
shown to increase MK size and ploidy (Kaushansky et al., 1994).  
 
TPO is produced mainly in the liver, but the bone marrow, kidney and smooth muscle cells 
have also been shown to express TPO mRNA (Hitchcock and Kaushansky, 2014; Kile, 2015; 
Sungaran et al., 1997). In 2015, Grozovsky et al showed that the production of TPO is in part 
determined by clearance of platelets by the spleen. As platelets age they lose sialic acid from 
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their surface exposing galatacose oligosaccharide chains. These glatacose chains are 
recognised by the Ashwell-Morell receptor (AMR) on the vascular surface of hepatocytes 
stimulating platelet removal and TPO production (fig. 1.3) (Grozovsky et al., 2015a). 
 
Figure 1.3 – Schematic representation of platelet clearance and thrombopoietin production by liver cells. 
Newly produced platelets have sialic acid coated surfaces, as they age sialic acid is lost revealing galactose. 
Galactose molecules are recognised by the Ashwell-Morell receptor (AMR) on hepatocytes and Kuppfer cells, 
which results in platelet removal (phagocytosis) and thrombopoietin (TPO) production. Increased plasma TPO 
levels stimulate megakaryopoiesis and the generation of more platelets.  
 
TPO acts by binding to the extracellular domain of c-Mpl. c-Mpl does not have intrinsic kinase 
activity, its signalling relies on the tyrosine kinase Janus kinase 2 (JAK2) which is bound to the 
cytoplasmic region of c-Mpl. Binding of TPO to c-Mpl induces dimerisation of the c-Mpl 
receptor, which brings the JAK2 proteins close enough to become activated through trans-
autophosphorylation (Geddis, 2010; Kaushansky, 2016). Following activation of JAK2, multiple 
signalling pathways become activated, including the signal transducer and activator of 
transcription (STAT) pathway via direct phosphorylation of STAT 1, 3, 5a and 5b (fig. 1.4). Once 
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phosphorylated these STAT proteins promote the transcription of genes involved in cell cycle 
such as cyclin-D1, p21 and Bcl-xL by forming dimers and translocating to the nucleus where 
they bind STAT-responsive transcriptional elements. JAK2 phosphorylation also causes the 
small GTPase Ras to become activated. JAK2 phosphorylation is known to phosphorylate c-
Mpl at tyrosine (Tyr) 625 and 630. Phosphorylation of Tyr625 allows the binding of the adaptor 
protein Shc which subsequently leads to the assembly of a complex containing Grb2 and the 
guanine nucleotide exchange factor SOS. SOS then activates Ras by facilitating the exchange 
of GDP for GTP. Activated Ras is able to initiate signalling through two important pathways, 
namely the mitogen-activated protein kinase (MAPK) and phosphoinositol-3 kinase (PI3K) 
pathways (Geddis, 2010).  
 
TPO induced MAPK signalling has been shown to be important in megakaryocyte 
differentiation from progenitor cells (Fichelson et al., 1999). Activated Ras in turn activates 
Raf-1, mitogen-induced extracellular kinase (MEK) and finally ERK (MAPK) 1/2. Once avtivated 
ERK 1/2 enter the nucleus and activate key transcription factors including Jun and Fos (Geddis, 
2010). Although the canonical activation of Ras in TPO mediated signalling relies on 
phosphorylation of c-Mpl Tyr625, MAPK activation, although significantly reduced, is still seen 
in c-Mpl mutant mice that lack Tyr625 (Luoh et al., 2000). This suggests that the MAPK 
pathway can be activated through another mechanism. One possibility is through the 
Grb2/SOS complex recruited to phosphorylated JAK2 (Brizzi et al., 1996). 
 
TPO induced PI3K signalling is essential for megakaryopoiesis as inhibition of the PI3K pathway 
in megakaryocyte progenitors results in cell cycle arrest (Geddis et al., 2001). Activated Ras 
has been shown to contribute to the activation of PI3K (Kodaki et al., 1994). Activated PI3K 
phosphorylates the serine/threonine Akt which can activate Bad, Forkhead, the transcription 
factor FOXO3a and glycogen synthase kinase 3 beta (GSK-3β) promoting survival and 
proliferation of megakaryocytic cells (Geddis, 2010).  
 
TPO signalling is tightly controlled and defects in the control mechanisms can lead to 
myeloproliferative neoplasms amongst other diseases. Two main auto-regulation 
mechanisms are known to exist: internalisation and degradation of c-Mpl and activation of 
negative regulators. TPO-stimulation results in rapid internalisation of c-Mpl caused by 
association of Adaptor protein 2 (AP2) which drives clathrin formation and endocytosis. Once 
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internalised, c-Mpl is subjected to lysosomal and proteasomal degradation, the latter via 
ubiquitination of activated c-Mpl (Hitchcock and Kaushansky, 2014).  
 
As well as degrading c-Mpl, TPO signalling leads to activation of negative regulators. Activation 
of the JAK/STAT pathway induces transcription of the suppressor of cytokine signalling (SOCS) 
family. SOCS1 and 3 bind directly to JAK2 inhibiting its activity (Croker et al., 2008; Geddis et 
al., 2002). The Src kinase family member, LYN, has been shown to negatively regulate TPO-
induced ERK1/2 signalling. Also the adaptor protein LNK regulates the TPO-induced activation 
of STAT5 and ERK1/2 (Hitchcock and Kaushansky, 2014). 
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1.5 TPO free megakaryopoiesis  
 
Ablation of either TPO or c-Mpl in mice results in a 90% decrease in platelet counts and bone 
marrow MK numbers, indicating the importance of TPO on megakaryopoiesis. The mice in 
these studies were healthy and despite having only a platelet count 10% that of wildtype 
animals’ spontaneous haemorrhage was not observed (Bunting et al., 1997; Gurney et al., 
1994). This suggests that other regulators of megakaryopoiesis exist and are sufficient to 
maintain haemostasis in the absence of TPO. A number of cytokines could be responsible for 
this residual megakaryopoiesis and platelet formation.  The most likely candidates to promote 
the residual megakaryopoiesis are Interleukin-6 (IL-6) and other IL-6 family members such as 
IL-11 and leukaemia inhibitory factor (LIF), as this family of proteins have been shown to 
stimulate megakaryopoiesis in vitro. This family of proteins are able to bind to and signal 
through gp130 proteins. Gp130 is ubiquitously expressed and binding causes activation of the 
JAK/STAT and MAPK pathways, therefore promoting megakaryopoiesis (Burstein et al., 1992; 
Sasaki et al., 1995; Zheng et al., 2008). Other candidates include IL-3 which can promote 
proliferation of CFU-MKs and cause maturation of MK nuclei; and stem cell factor (SCF) which 
can enhance the effects of IL-3 and granulocyte-macrophage colony-stimulating factor (GM-
CSF) on the formation of BFU-MK colonies (Zheng et al., 2008).  
 
1.6 Megakaryocyte maturation 
 
As briefly mentioned in section 1.1.3, when MKs mature they become polyploid and develop 
a DMS. As well as developing these defining features, MKs migrate from the osteoblastic to 
vascular niche within the bone marrow. This section will discuss each feature of MKs 
maturation in detail.  
 
1.6.1 Endomitosis and polyploidisation 
 
During maturation MKs become polyploid through a process of DNA replication without cell 
division, termed endomitosis (fig. 1.5). This process results in very large cells with a polyploid 
nucleus. The number of endomitotic cycles a MK undergoes can vary from 2-7 with ploidy as 
large as 256N. However, most MKs undergo 3 rounds of endomitosis resulting in 16N MKs. 
1 – Introduction 
17 
 
Polyploidisation of MKs results in a functional gene amplification which likely increases protein 
synthesis in-line with increased cell size to aid platelet production (Raslova et al., 2003).  
 
 
Figure 1.5 – Schematic representation of endomitosis. Diploid megakaryocytes (MKs) progress through S phase 
and enter mitosis. Anaphase initiates with separation of sister chromatids and formation of the cleavage furrow. 
However, for reasons as yet not fully understood, cytokinesis fails and the cleavage furrow regresses resulting in 
a 4N MK that re-enters G1.  
 
During the first cycle of endomitosis, diploid MK progenitors enter a short G1 phase, followed 
by a 6-7 hour S phase allowing DNA replication. Following a short G2 phase, the cell undergoes 
prophase with chromatin condensation, rupture of the nuclear envelope and formation of an 
unusual spherical mitotic spindle. Metaphase is normal with correct attachment of mitotic 
spindles to chromatids and alignment of the chromatids equidistance from the two spindle 
poles. Anaphase starts correctly with the movement of sister chromatids to their respective 
poles, formation of the midzone (a network of antiparallel microtubules that forms between 
the separating chromosomes) and initiation of cleavage furrows. However, despite significant 
ingression of the cleavage furrows, they eventually regress, leading to failure of cytokinesis. 
The 2 daughter cells then move back and reassemble into a single cell. A nuclear envelope 
then forms around both sets of sister chromatids, creating a larger single lobed nucleus (in the 
majority of cases, single cells with multiple nuclei also been noted in vitro) and doubling the 
number of copies of chromosomes. Cells then re-enter G1 and undergo the process of 
endomitosis again. Interestingly, in MKs with higher ploidy, ingression of cleavage furrows is 
less pronounced than in immature MKs (Geddis et al., 2007; Lordier et al., 2008).  
 
The biological reasons for the failure of cytokinesis in MKs is still not fully understood, 
however, it has been the focus of several laboratories. One family of proteins that have been 
implicated in endomitosis is the cyclins. Mitosis promoting factor (MPF) is formed of a complex 
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between cyclin B1 and Cdc2. MPF has a kinase activity required for the cell to enter mitosis. 
In human and mouse cell lines it has been shown that Cdc2 is inactive and cyclin B1 is absent 
during endomitosis. However, studies using in vitro megakaryocytes oppose this view (Datta 
et al., 1996; Zhang et al., 1996). E-type cyclins have also been shown to have a role in 
endomitosis. Geng et al, showed a decrease in ploidy compared to controls of in vitro cultured 
mouse MKs from cyclin E KO mice. This suggests cyclin E is required for normal endomitosis of 
mouse megakaryocytes, at least in vitro (Geng et al., 2003).  
 
Another protein that has been implicated in polyploidisation of MKs is the GTPase RhoA. 
Conditional RhoA knockout mice develop larger MKs with higher ploidy than controls (Suzuki 
et al., 2013). RhoA usually accumulates in the cleavage furrow of mitotic cells where it 
promotes the assembly and contraction of the actomyosin ring which is essential for proper 
cytokinesis. However, during endomitosis RhoA activity and F-actin are markedly decreased 
and myosin IIA is not recruited to the contractile ring causing cytokinesis to fail (Gao et al., 
2012; Lordier et al., 2008). The decreased RhoA activity during endomitosis seems to be 
attributed to a decrease in two guanine exchange factors (GEFs) needed for RhoA activation. 
The GEFs GEF-H1 and ECT2 are downregulated during MK polyploidisation. GEF-H1 
downregulation appears to be essential for the transition from immature 2N cells to 4N, 
whereas ECT2 must be downregulated beyond the 4N stage (Gao et al., 2012).  
 
Other molecules that may have an effect on MK endomitosis and polyploidisation include 
transforming growth factor beta (TGF-β) and p21-activated kinase 2 (PAK2). Recently, it was 
shown that a competitive inhibitor of TGF-β could dramatically increase the ploidy of cultured 
human cord blood derived MKs, suggesting TGF-β signalling could have an effect on 
endomitosis. However, surprisingly, only 1 TGF-β inhibitor gave this result out of a number of 
inhibitors that were tested in the study (Huang et al., 2016).  
 
Kosoff et al showed Pak2 knockout mice (Pak2-/-) have a marked increase in ploidy level and 
diameter of megakaryocytes in their bone marrow. Indeed, treatment of mice with an 
inhibitor of Pak2 increased ploidy of bone marrow MKs. Phosphorylation of cofilin was 
reduced in Pak2-/- MKs. Cofilin is active in its un-phosphorylated state and acts to sever actin 
filaments. This may partly explain the decrease in F-actin during endomitosis mentioned 
previously. Similar to this, Aurora A/B/C phosphorylation was decreased in Pak2-/-. Aurora A 
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regulates microtubule dynamics and is a negative regulator of polyploidisation (Kosoff et al., 
2015). 
 
1.6.2 Demarcation membrane system 
 
As MKs mature, they develop a network of membrane channels composed of flattened 
cisternae and tubules unique to MKs that is termed the demarcation membrane system 
(DMS). Development of the DMS starts in promegakaryocytes but it becomes most noticeable 
in mature MKs where it dominates the entire cytoplasm except from a thin layer at the cortex. 
Electron microscopy revealed that the DMS is formed from tubular invaginations of the plasma 
membrane and that the entirety of the DMS is in contact with the extracellular space (Behnke, 
1968).  
 
The DMS originates from folding of the plasma membranes that resembles cleavage furrow 
formation at defined locations, forming a perinuclear pre-DMS. Membrane is then added to 
this pre-DMS by Golgi-dervied vesicles and the transfer of lipids mediated by the endoplasmic 
reticulum, extending the pre-DMS into its mature form (Eckly et al., 2014). 
 
It was originally hypothesised that the DMS formed ‘platelet territories’ within the cytoplasm, 
however the currently hypothesis is that the DMS serves as a reservoir for proplatelet 
production. This current hypothesis is derived from the fact that proteins that affect DMS 
formation also affect proplatelet formation. CDC42 interacting protein 4 (CIP4) is an F-BAR 
protein that binds to membrane phospholipids via its BAR domain and causes membrane 
tubulation. It also interacts with the Wiskott-Aldrich syndrome protein (WASp). Cip4 knockout 
(Cip4-/-) mice have severely reduced or missing DMS in bone marrow MKs and in vitro cultured 
Cip4-/- MKs show decreased proplatelet production (Chen et al., 2013a).  
 
PI-4,5-P2 (a phospholipid) is usually confined to the plasma membrane. However, in MKs, PI-
4,5-P2 is found in the DMS and within close proximity to PI-5-P-4 kinase α (PIP4Kα). Activation 
of PI-4,5-P2 by PIP4Kα can promote actin polymerisation by activating Rho-like GTPases and 
WASp family proteins. PI-4,5-P2 signalling from these GTPases to the ARP2/3 complex (which 
promotes actin filamentation) is mediated through members of the WASp family. Loss of 
PIPK4α expression by short hairpin (sh) RNA in murine MKs led to impairment of the DMS and 
1 - Introduction 
 
20 
proplatelet formation. However, negative regulation of all WASp family proteins (WASp, N-
WASp and WAVE) showed decreased proplatelet formation but no effect on DMS formation, 
suggesting WASp proteins do not affect DMS formation (Schulze et al., 2006). Recently, a study 
using in vitro cultured human MKs showed that N-WASp but not WASp is involved in formation 
of DMS and proplatelet formation. When N-WASp expression was reduced using shRNA DMS 
development was affected causing dilation of the DMS and proplatelet formation was 
decrease. Interestingly, N-WASp is expressed at much lower levels than WASp in MKs, but 
expression increases as MKs mature (Palazzo et al., 2016). 
 
Despite N-WASp and CIP4 being involved with CDC42 (WASp family proteins are effectors of 
CDC42), CDC42 itself is dispensable for proper DMS formation. Despite a dominant negative 
form of CDC42 displaying decreased proplatelet formation, no effect on the DMS was 
observed (Palazzo et al., 2016).  
 
Mutations in GPIb-V-IX the vWF receptor complex result in Bernard-Soulier syndrome (BSS), a 
rare bleeding disorder characterised by macrothrombocytopenia. MKs from patients with BSS 
and from GPIbα knockout mice show impaired DMS development (Dutting et al., 2017; Poujol 
et al., 2002).  
 
1.6.3 MK migration 
 
Haematopoiesis starts in the osteoblastic niche of the bone marrow. Most LT-HSCs found in 
close contact to osteoblasts and osteoclasts, which secrete many factors required for HSC 
maintenance. The main extracellular matrix component of the osteoblastic niche is fibrillar 
collagen type I. In vitro studies have shown that collagen type I significantly inhibits proplatelet 
formation, therefore preventing the early release of proplatelets (and platelets) into the 
osteoblastic niche by MKs. MKs, like platelets, express two main collagen receptors GPVI and 
integrin α2β1. Collagen type I induced proplatelet inhibition mainly depends on its interaction 
with integrin α2β1 (Sabri et al., 2004). 
 
In contrast, the extracellular matrix of the vascular niche, which surrounds the bone marrow 
arterioles, capillaries and venous sinusoids, is replete with vWF, fibrinogen and fibronectin 
(Machlus and Italiano, 2013). All three of these extracellular matrix proteins are important in 
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the productions of platelets. Fibrinogen has been shown to promote proplatelet formation 
(the precursor to platelet production, see section 1.7.1) in vitro. Fibrinogen induced 
proplatelet formation is mediated via signalling through the major fibrinogen receptor on 
MKs, αIIbβ3. This is known as blocking the fibrinogen receptor on MKs with αIIbβ3 antagonists 
prevented proplatelet formation (Larson and Watson, 2006). Interestingly, αIIbβ3 is expressed 
on MKs early during their development, however it only becomes functionally active as MKs 
mature; thus preventing premature proplatelet release (Eto et al., 2002).  
 
As mentioned in section 1.6.2 mutations in GPIb-V-IX result in BSS. MKs from BSS patients 
show impaired proplatelet formation in vivo (Balduini et al., 2011), linking binding of vWF to 
MKs in the control of platelet size and numbers. Finally, fibronectin is important in MK 
development, promoting both differentiation and proliferation, as well as proplatelet 
formation. Proplatelet formation in MKs is enhanced by the binding of fibronectin to very late 
antigen 4 and 5 (VLA-4 and VLA-5) on MKs and subsequent activation of the MAPK pathway 
(Matsunaga et al., 2012). 
 
The migration of MKs from the osteoblastic niche to the vascular niche is mainly driven by the 
cytokine stromal derived growth factor 1α (SDF-1α (or CXCL12)). Unlike other blood vessels, 
bone marrow residing sinusoids are devoid of pericytes but are instead surrounded by 
specialised CXCl12-abudant reticular (CAR) cells. CAR cells secrete SDF-1α therefore creating 
a gradient of SDF-1α between the osteoblastic and vascular niches (Psaila et al., 2012; 
Sugiyama et al., 2006). Binding of SDF-1α by its receptor on MKs, CXCR4, is responsible for the 
migration of MKs towards sinusoids (Avecilla et al., 2004). When MKs are on a fibronectin 
matrix, as is abundant in the vascular niche, directional movement towards the SDF-1α 
gradient is dependent on Src family kinases (SFKs), Syk kinase and phospholipase C γ2 (PLCγ2) 
signalling downstream of the fibronectin receptor integrin αIIbβ3. Mazharian et al, showed that 
in vitro cultured MKs were unable to migrate towards an SDF-1α gradient when treated with 
either SFKs or Syk inhibitors or an αIIbβ3 antagonist. This is because SFKs and Syk inhibitors 
prevented MKs from spreading, a prerequisite for cell motility, on fibronectin surfaces 
(Mazharian et al., 2010). The initial movement out of the osteoblastic niche, where fibronectin 
is not present, and into the vascular niche may be mediate through another pathway. In 2013, 
Abbonante et al, described a novel collagen receptor expressed by human MKs, discoidin 
domain receptor 1 (DDR1). They showed that binding of DDR1 to collagen type 1 facilitated 
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MK migration as migration was severely decreased when a DDR1 blocking molecule was added 
to MKs. Similarly to MK motility on fibronectin, DDR1 induced migration involves Syk 
signalling. Binding of DDR1 to fibrillar collagen causes phosphorylation and increased enzyme 
activity of the SH2 domain-containing phosphatase SHP1, which in turn dephosphorylates Syk 




Platelets are small (2-4µm) anucleated discoid cells that are derived from MKs mainly in the 
bone marrow but also in the spleen and lungs. Recent data suggests that as much as 50% of 
platelet formation occurs in the lungs of mice (Lefrancais et al., 2017); although, this has yet 
to be confirmed experimentally. The first description of platelets in scientific literature was by 
William Osler in 1873. Osler described platelet as single disc like cells in the blood that are able 
to aggregate. However, he was unsure if these disc like cells were normal blood components 
or from an exogenous source (Osler, 1873). In 1882, Giulio Bizzozero was the first to attribute 
platelets in haemostasis. He noted that platelets adhered to vascular lesions and to each other 
to form a thrombus (Mazzarello et al., 2001; Norris and Neale, 1882).   
 
Since the discovery of platelets, they have attracted much scientific interest due to the 
involvement in a multitude of physiological processes. Not only do they participate in normal 
haemostasis and wound healing, they have been shown to have roles in tumour metastasis 
(Leblanc and Peyruchaud, 2016), inflammation (Semple et al., 2011), bacterial infection 
(Deppermann and Kubes, 2016) and tissue repair and regeneration (Gawaz and Vogel, 2013). 
 
1.7.1 Platelet formation and the proplatelet theory 
 
The mechanism by which platelets are generated have been of scientific interest since the 
early 20th century. Wright was the first to indicate that platelets derive from MKs in 1906, but 
it was not until 1955 that there was indisputable evidence of this link between platelets and 
MKs (Humphrey, 1955; Wright, 1906).   
 
Originally it was believed platelets were generated by fragmentation of MK cytoplasm along 
DMS fracture lines between ‘platelet territories’. The majority of evidence now dismisses this 
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in support of the proplatelet theory of platelet biogenesis in which long cytoplasmic 
protrusions extend from MKs into the bone marrow sinusoids. This theory is supported by the 
fact that: in vitro proplatelet formation produces platelets that are functionally and 
structurally similar to blood platelets (Choi et al., 1995); many species of mammals have been 
shown to produce proplatelets (Choi et al., 1995; Handagama et al., 1987; Junt et al., 2007); 
and mutations that cause a decrease/loss of proplatelet formation also result in a decreased 
platelet count (Chen et al., 2013a; Palazzo et al., 2016). However, in 2015 Nishimura et al 
presented evidence that rapid rupture of MKs may be responsible for the generation of 
platelets during times of acute platelet need. This MK rupture is believed to be driven by 
interleukin-1α (IL-1α) rather than by TPO as in steady state platelet biogenesis (Nishimura et 
al., 2015). 
 
The proplatelet theory, established by Becker and De Bruyn, postulates that MKs produce 
pseudopod like cytoplasmic extensions in the bone marrow that extend into the sinusoids and 
later fragment to produce single platelets (fig. 1.6) (Becker and De Bruyn, 1976). The 
cytoplasmic extensions, which are believed to be an intermediate structure in the transition 
from MKs to platelets, have a ‘beads-on-a-string’ structure with numerous platelet sized 
swelling tethered together by thin cytoplasmic bridges. Before proplatelet formation occurs, 
the DMS polarises to one pole of the MK. Proplatelet formation starts with the erosion of MK 
cytoplasm at the pole where the DMS has polarised and the formation of thick extensions 
from this pole. These thick protrusions extend over 4-10 hours into thin 2-4µm tubes which 
bend, branch and develop platelet sized swellings to give the stereotypical proplatelet shape. 
Proplatelet formation uses almost all of the MKs cytoplasm and intracellular component and 
once completed the MK is left as a naked nuclei (Italiano et al., 1999). 
 
Directional control of proplatelets into the lumen of bone marrow sinusoids has recently been 
attributed to crosstalk between GPIbα/CDC42 and RhoA signalling in MKs. Mutation of the 
ectodomain of Gp1bα or deletion of CDC42 in mouse MKs located MKs further from bone 
marrow sinusoids. This suggests activation of CDC42 downstream of GP1bα signalling acts as 
a positive regulator to locate MKs to the sinusoids. In stark contrast, ablation of RhoA led to 
an increase of MKs in the lumen of sinusoids, suggesting RhoA signalling acts as a negative 
regulator of MK guidance to the sinusoids. Once located at the vascular interface of sinusoids, 
polarisation of the DMS is needed for MKs to produce proplatelets. DMS polarisation is 
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associated with CDC42 activation. Mice with mutated Gp1bα had decreased CDC42 activation, 
showing the importance of CDC42 activation via GP1bα for DMS polarisation. RhoA knockout 
mice had increased CDC42 activity at the polarised DMS, suggesting RhoA controls DMS 
polarisation by limiting CDC42 activity (Dutting et al., 2017). 
 
Shingosine 1 phosphate (S1P) and its receptor on MKs (S1pr1) have also been shown to act as 
regulators of directional proplatelet formation and release. S1P circulates in the blood and 
because of the location of MKs at the vascular interface of bone marrow sinusoids, MKs are 
subjected to a gradient of S1P. This S1P gradient is thought to guide proplatelet formation into 
the sinusoid lumen. Mice lacking S1P show abnormal formation and shedding of proplatelets 
in the extravascular space of the bone marrow (Zhang et al., 2012). S1pr1 is a G-protein 
coupled receptor (GPCR; see section 1.7.4.2 for details), but the exact signalling pathway 
involved in the directional control of proplatelet formation by S1P-S1pr1 is not known. In other 
cell types, activation of S1P-S1pr1 leads to signalling via different pathways which in turn 
causes a range of different downstream effects. For example, activation of the P13K-Akt 
signalling pathway leads to increased survival of lymphocytes, whereas activation of Ras-
ERK1/2 signalling pathway causes immune cell proliferation (Mazharian and Senis, 2016).  
 
 
Figure 1.6 – Schematic representation of proplatelet formation, preplatelet release and platelet maturation. 
 
 





Proplatelet formation is driven mainly by MK cytoskeletal proteins. The main cytoskeletal 
proteins involved in this process are microtubules, actin and spectrin. Microtubules serve to 
power proplatelet elongation and allow transport of organelles and granules along 
proplatelets. Microtubules are hollow tubes, 24nm in diameter, composed of polymerised αβ 
tubulin dimers. β-tubulin has GTPase activity and addition of tubulin heterodimers activates 
the GTPase, locking the β-tubulins in a GDP bound state. Microtubules are polar molecules 
due to the orientation of the heterodimers. The end of a microtubule that terminates with an 
α-tubulin protein (minus end) is much more stable than the plus end, which terminates in a β-
tubulin protein. Therefore, microtubule elongation and retraction happens mainly at the plus 
end. To help prevent depolymerisation, the β-tubulins at the end of the microtubules form a 
GTP cap (Parker et al, 2014). It has been shown that β1-tubulin is especially important for 
proper thrombopoiesis. β1-tubulin expression is restricted to platelets and mature MKs and 
ablation of β1-tubulin in the mouse leads to thrombocytopenia due to defective proplatelet 
formation (Schwer et al., 2001). 
 
In immature MKs, microtubules extend from the cell centre to the cortex in a starburst like 
pattern. During the initial stages of proplatelet formation when thick pseudopodia are 
forming, cortex and membrane associated microtubules merge into thick bundles positioned 
just the plasma membrane of these pseudopodia. Elongation of the pseudopodia into 
proplatelets, at a rate of 1µm/min (in vitro, but up to 30µm/min in vivo), is driven by 
continuous polymerisation of thick bundles of microtubules at a rate of ~10µm/min. As the 
proplatelet extends it narrows and the bundles of microtubules thin out, with thick bundles 
seen near the cell body of the MK and bundles of approximately seven microtubules at the 
proplatelet tip. At the proplatelet tips, microtubules coil 8-12 times to form a tear drop shaped 
loop and then proceed to re-enter the shaft of the proplatelet. This microtubule coil, which is 
a defining feature of mature platelets, is only seen in the bulbs at the end of proplatelet tips 
suggesting that only these bulbs will form mature platelets (Italiano et al., 1999; Patel et al., 
2005). 
 
The fact that microtubule assembly rates are approximately 10 times faster than proplatelet 
elongation rates in vitro suggests that these processes are not tightly linked. Indeed, 
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proplatelet elongation is still observed when microtubule assembly is chemically blocked 
(Patel et al., 2005). Proplatelet elongation has been attributed to microtubule sliding control 
by dynein. Dynein is a minus end microtubule motor protein that concentrates along 
microtubules in proplatelets. Inhibition of dynein in proplatelet forming MKs prevented 
elongation of the proplatelet shafts (Bender et al., 2015). These experiments reveal that 
dynein-mediated microtubule sliding actually provides the power for proplatelet elongation.  
 
A second function served by microtubules in proplatelets is to facilitate the transport of 
organelles, granules and membrane from the MK body to the nascent platelets at the 
proplatelet tips. Organelles are able to travel bi-directionally along proplatelet shafts until 
they are captured in the proplatelet tips. This movement of organelles is not affected by 
inhibitors of actin filament, suggesting it is a microtubule based mechanism. Richardson et al 
have postulated a twofold microtubule based mechanism of organelle transport in 
proplatelets. Firstly, organelles and granules translocate bidirectionally along microtubules 
likely facilitated by kinesin. Kinesin is a microtubule motor protein that walks along 
microtubule filaments towards the plus end, powered by the hydrolysis of ATP. The 
bidirectional movement is permitted due to the mixed polarity of microtubules in proplatelets. 
Secondly, indirectly moving in a ‘piggy back’ fashion as microtubules slide bidirectionally to 




Actin is a 42 kDa protein that exists in two forms: a monomeric form, known as globular (G-) 
actin, and a polymerised form called filamentous (F-) actin. Although actin is dispensable for 
proplatelet formation, it is vital for proplatelet bending and bifurcation. As nascent platelets 
are believed to arise from the proplatelet tips, amplification of these tips is important process 
of proplatelet formation. Proplatelet tip amplification is caused by proplatelet shafts being 
bent into sharp kinks that then bend back on themselves, forming a loop in the microtubule 
bundle. This new microtubule loop then elongates forming a new proplatelet shaft branching 
from the original proplatelet. The branching process of proplatelet tip amplification has been 
shown to be driven by actin. MKs exposed to actin depolymerising agents are able to produce 
proplatelets but they are devoid of branching and contain few swellings (Italiano et al., 1999). 
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How actin causes this branching process in proplatelets is still unclear, however several actin 
binding proteins have been suggested to play a role.  
 
One possibility is that non-muscle myosin II powers this branching process. Mutations in 
MYH9, the gene encoding non-muscle myosin heavy chain-A, results in MYH9-related diseases 
including May-Hegglin anomaly and the Sebastin, Fechtner, and Epstein syndromes. These 
four autosomal dominant diseases result in macrothrombocytopenia and can be distinguished 
from each other by the combination of associated clinical and laboratory signs. Fechtner 
syndrome is associated with Döhle-like leukocyte inclusions as well as sensorineural deafness, 
cataracts, and nephritis. Epstein syndrome is similar to Fetchner syndrome and is associated 
with sensorineural deafness and nephritis, but patients do nto present cataracts or Döhle-like 
leukocyte inclusions. Both May-Hegglin anomaly and Seastin syndrome are associated with 
Döhle-like leukocyte inclusions and lack sensorineural deafness, cataracts, and nephritis. 
These diseases are distinguished by ultrastructure analysis of the leukocyte inclusions. 
Leukocyte inclusions of May-Hegglin anomaly are composed of cytoplasm surrounding parallel 
microfilaments with clustered ribosomes, in Sebastian syndrome the inclusions are composed 
of highly dispersed microfilaments with few ribosomes (Ma and Key, 2009; Rodriguez et al., 
2013).  MYH9-related diseases are characterised by macrothrombocytopenia. Analysis of 
proplatelet formation in MKs cultured from patients with MYH9-related diseases showed 
decreased proplatelet formation, which could be rescued with a myosin II inhibitor (Chen et 
al., 2013b). However, cultured murine MKs from mice with Myh9 deleted were able to branch 
and bifurcate (Eckly et al., 2009).  
 
 Other actin binding proteins involved in the proplatelet forming process include: filamin A, 
cofilin-1 and profilin1. Filamin A cross links actin filaments, anchors membrane receptors and 
promotes high angle branching of actin filaments. Mice with conditional deletion of Filamin A 
in the MK and platelet have severe macrothrombocytopenia but proplatelets were able to 
branch normally (Begonja et al., 2011). 
 
Cofilin-1 is a F-actin severing protein, along with actin depolymerising factor (ADF) and cofilin-
2, and promotes the disassembly of actin filaments. Conditional cofilin-1 knockout of the MK 
and platelet lineage in mice results in a 60-80% decrease in platelet count associated with 
increased platelet size. Surprisingly, ADF knockout mice have normal platelet counts. ADF and 
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cofilin-1 deletion virtually abolishes platelet formation with platelet counts below 5% that of 
controls (Bender et al., 2010). Profilin1 binds to monomeric G-actin accelerating the 
nucleotide-exchange from ADP to ATP and consequently promoting actin filament elongation. 
Ablation of Profilin1 in the MK and platelet lineage of mice results in microthrombocytopenia 
and premature release of platelets into the extravascular space of the bone marrow. This 
phenotype recapitulated those seen in Wiskott-Aldrich syndrome in which the WASp protein 
is mutated (Bender et al., 2014). These results suggest cytoskeletal dynamics and actin 




Spectrin is a cytoskeletal protein that lines the intracellular side of the plasma membrane and 
is important for membrane integrity. α- and β-spectrin monomers associate laterally to form 
a heterodimer. Dimers then associate head to head to form a tetramer. Association of 
tetramers in an end to end fashion with actin filaments creates triangular pores. Platelets 
contain approximately 2,000 spectrin molecules that form a network that coats the 
cytoplasmic surface of the open canalicular system (OCS) and the plasma membrane.  
 
Electron microscopy of proplatelet forming MKs shows proplatelets contain a spectrin based 
cytoskeleton similar to that of platelets. Cultured murine MKs expressing a spectrin-tetramer 
disrupting peptide showed severely impaired proplatelet formation. Also, addition of this 
disrupting peptide to proplatelet forming MKs disrupted proplatelet morphology, causing 
massive swelling (Patel-Hett et al., 2011). These results show the importance of spectrin in 
proplatelet formation and preservation of proplatelet structure.  
 
1.7.2 Release of preplatelets and platelet maturation in the periphery 
 
Intravital microscopy in mice has allowed proplatelet formation and platelet release to be 
visualised in vivo. Surprisingly, proplatelet fragments released into the circulation are much 
larger than mature platelets (Junt et al., 2007; Zhang et al., 2012). The shedding of these large 
proplatelet fragments from proplatelet shafts is reliant on S1pr1 signalling as S1pr1 knockout 
mice rarely shed proplatelets fragments in vivo (Zhang et al., 2012).  
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The released proplatelet fragments generally resemble proplatelet shafts with a bead-on-a-
string morphology. Fission of these large proplatelet fragments results in smaller fragments 
termed preplatelets. The fission occurs by thinning and eventually snapping of the 
connections between bulbous swellings at a constriction site resembling a cleavage furrow. 
Once the fission has taken place the fragmented ends retract toward their daughter cells. 
Preplatelets are giant platelets (3-10µm diameter discoid cells) that have a cortical 
microtubule band and contain platelet organelles. Preplatelets are thought to be 
intermediates between proplatelets fragments and mature platelets and can reversibly 
change between resembling barbells and giant platelets by forces generated by twisting of 
microtubules. By injection of pre-labelled in vitro cultured proplatelet fragments/preplatelets 
into mice it was shown that preplatelet fission results in the formation of mature platelets 
(Thon et al., 2012a; Thon et al., 2010). This generation of mature platelets from proplatelet 
fragments and preplatelets is accelerated by shear stress in vitro (Thon et al., 2010). This 
compliments the observation that proplatelet fragments/preplatelets are more concentrated 
in pre-pulmonary vessels compared to post-pulmonary vessels in rats (Handagama et al., 
1987). Myosin IIA has also been implicated in the fission of preplatelet to mature platelets. 
Phosphorylation of myosin IIA leads to inactivation and has been shown to decrease during 
thrombopoiesis with threefold more phosphorylation in MKs than platelets. 
Dephosphorylation of myosin IIA causes assembly of myosin filaments that interact with actin 
filaments and contributes to membrane integrity and cell division. Shear induced activation of 
myosin IIA is important for the fission of preplatelets into platelets as pharmacological 
inhibition of myosin IIA with blebstatin in platelets results in decreased fission of proplatelets 
(Spinler et al., 2015).  
 
Although preplatelets are present in the blood of healthy humans (Behnke and Forer, 1998), 
they are rarely recorded. This is possibly due to blood smears generally being performed on 
EDTA treated blood. EDTA treatment can cause platelet sphering and condensation of 
platelets, preventing preplatelets from being seen on blood smears (the same is true for 
heparin treatment.). However, when human blood is treated with sodium citrate, preplatelets 
are readily observed on blood smears (Thon et al., 2012a). Nevertheless, the effects of 
different anticoagulants on murine preplatelets have not been tested, so cannot be assumed. 
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The ability of mature platelets to create progeny has also recently been shown (Schwertz et 
al., 2010). The process in which this occurs is remarkably similar to the formation of 
proplatelets and fission of preplatelets into mature platelets. The molecular mechanisms 
behind the formation of cytoskeletal projections and production of progeny is unknown, 
however one possibility is that platelets maintain a preplatelet like phenotype allowing them 




As mentioned in section 1.7.1.1, resting platelets contain a marginal microtubule coil, which 
is a defining feature of platelets. The coil is comprised of multiple microtubules with mixed 
polarity that form a band that circulates the periphery 8-12 times (Patel-Hett et al., 2008). The 
coil is responsible for maintaining the discoid shape of resting platelets. Depolymerisation of 
microtubules with pharmaceutical agents or by chilling platelets at 4oC causes loss of the 
stereotypical discoid shape. The plasma membrane and OCS are also supported by an actin-
spectrin based scaffold. The OCS is a tubular network of invaginations of the plasma 
membrane that acts as a reservoir of membrane for platelet spreading upon activation and 
facilitates in the uptake and release of granule proteins (White and Clawson, 1980). Platelets 
contain approximately 2,000 spectrin molecules that attach to the 2-5,000 actin filaments in 
a triangular lattice fashion to create a cytoskeletal scaffold. Actin filaments are also crosslinked 
by proteins such as filamin and α-actinin to create a rigid network. 
 
The resting platelet can be divided into three distinct zones. 1) The peripheral zone which is 
responsible for platelet adhesion and aggregation. This zone comprises a glycoprotein coat, 
the platelet membrane containing receptors for agonists and the cytoskeleton. 2) The sol-gel 
zone which is responsible for contraction and support of microtubules and contains the 
tubules of the OCS. 3) The organelle zone which contains all the platelet organelles such as α- 
and dense granules, lysosomes and mitochondria (Cimmino and Golino, 2013). 
 
1.7.3.1 Granules  
 
A significant proportion of the total platelet volume is filled by secretory granules. Platelets 
contain four main types of secretory granules, α- and dense granules, lysosomes and the  
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α-Granules are the most abundant platelet granule with roughly 50-80 per platelet, ranging in 
size from 200-500nm and totalling approximately 10% of the platelet volume. Genesis of α-
granules begins in MKs but continues in platelets. In MKs, small vesicles that contain newly 
synthesised proteins, such as vWF, bud off from the trans-Golgi network and travel to 
multivesicular bodies (MVBs). Other α-granule proteins, for example fibrinogen, can be 
delivered to MVBs after endocytosis by the plasma membrane. MVBs are endosomal 
structures that serve as an intermediate stage of granule production and sort endocytosed 
and newly synthesised vesicles. Immature α-granules are then transported along proplatelets 
where they become trapped in the terminal tips. Maturation of α-granules continues in the 
peripheral circulation by endocytosis of platelet plasma membrane in a clathrin dependant 
manner (Blair and Flaumenhaft, 2009; Heijnen et al., 1998). 
 
α-Granules contain over 300 proteins involved in a multitude of processes. Many of the 
proteins are involved in haemostasis and coagulation (for example, vWF and fibrinogen). α-
Granules also contain several membrane receptors including GPIIb/IIIa and P-Selectin and 
small vesicles known as exosomes (Blair and Flaumenhaft, 2009).  
 
Mutations in the scaffolding protein NBEAL2 result in gray platelet syndrome (GPS), a rare 
bleeding disorder. GPS patients have macrothrombocytopenia with platelets appearing grey 
due to their lack of α-granules. Nbeal2 knockout mice which have a GPS phenotype show 
protection against cancer metastasis, revealing the importance of α-granules in cancer 




Dense granules are the second major secretory granule in platelets (3 to 8 per platelets) and 
are so named because of their dark appearance in electron microscopy. Dense granules are 
formed in a similar fashion to α-granules with MVBs as an intermediate. However, platelet 
storage pool diseases affecting dense granules, such as Hermansky-Pudlak syndrome, show 
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normal α-granule formation but defective dense granules, suggesting formation of the two 
granules are distinct (Blair and Flaumenhaft, 2009; Heijnen and van der Sluijs, 2015; 
Youssefian and Cramer, 2000). 
 
Dense granules contain a variety of proteins involved in haemostasis including serotonin, ADP, 
ATP, calcium, magnesium as well as membrane proteins such as GPIb and P-Selectin (Israels 
et al., 1992; Youssefian and Cramer, 2000). 
 
Lysosomes   
 
Platelet lysosomes have a role in digestion of phagocytic and cytosolic components and as 
such contain degrading enzymes such as proteases, hydrolases and glycosidases. The may also 
have roles in extracellular functions such as degradation of extracellular matrix and facilitating 




T-granules are a novel secretory granule found in platelets that were first described in 2012 
(Thon et al., 2012b). They have a tubular morphology and contain protein disulphide 
isomerase (PDI). PDI has been shown to be released from activated platelets and is critical for 
proper thrombus formation in mice (Cho et al., 2008).  
 
1.7.4 Role in thrombus formation at sites of vascular injury 
 
The primary role of platelets is to maintain haemostasis by forming platelet plugs at sites of 
vascular injury. Circulating platelets are maintained in a resting state mainly by the actions of 
endothelial cells that line the blood vessels. Endothelial cells act as a physical barrier between 
platelets and the activating subendothelial extracellular matrix and also secrete platelet 
inhibiting factors such as nitric oxide (NO), prostaglandin I2 (PGI2) and ectonucleotidase CD39 
(Furie and Furie, 2008; Rumbaut and Thiagarajan, 2010). 
 
The formation of the platelet clot at sites of exposed endothelial extracelluar matrix requires 
a series of coordinated sequential events. Firstly, platelets must adhered to sites of vascular 
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injury (tethering and stable adhesion). Adherence of platelets leads to platelet activation 
which causes the release of numerous soluble factors that recruit and activate addition 
platelets (platelet activation and aggregation). Finally, the platelet aggregate undergoes a final 
stabilisation step to form an effective thrombus that stops blood loss (clot stabilisation) (fig. 
1.7). This process of thrombus formation must be tightly controlled, as uncontrolled 
thrombosis can cause vessel blockade and tissue ischaemia that can lead to major events such 
as myocardial infarction and stroke. 
 
1.7.4.1 Tethering and stable adhesion 
 
Vessel injury leads to exposure of platelets to the subendothelial matrix. Platelets adhere to 
either exposed fibrilar collagen or von Willebrand factor (vWF) multimers (that have bound to 
the exposed collagen via their A3 (and possibly A1) domain (Cruz et al., 1995)) depending on 
shear rates. At low venous shear rates (<200 s-1) platelets bind to collagen, however at arterial 
(>500 s-1) and arteriolar shear rates (1,000 – 1,800 s-1) platelets bind to vWF (Fogelson and 
Neeves, 2015; Furie and Furie, 2008). 
 
Collagen/GPVI or integrin α2β1 adhesion 
 
Stable adhesion of platelets to the exposed matrix is brought about by binding to fibrillar 
collagen. At low shear rates, platelets are able to bind directly to collagen, but at high shear 
tethering of platelets to vWF decreases platelet speed allowing platelet/collagen interactions. 
The main collagen receptors expressed by platelets are GPVI and integrin α2β1 (GPIa/IIa). 
Stable platelet adhesion is achieved via synergistic binding of both receptors to collagen 
(Rivera et al., 2009). This is evident by the fact that murine GPVI or α2β1 knockouts have partial 
defect in thrombi formation whereas ablation of both GPVI and α2β1 causes complete 
inhibition of thrombus formation (Sarratt et al., 2005).  
 
1.7.4.2 Platelet activation and aggregation 
 
Stable adhesion of platelets to exposed fibrillar collagen leads to activation of platelets and 
the release of a multitude of factors that in turn recruit further platelets causing aggregation. 
 




Figure 1.7 – Schematic representation of platelet activation and thrombus formation at sites of vascular injury. 
Platelets are maintained in their resting state by endothelial cells. Upon exposure of the extracellular matrix, 
platelets tether to von Willebrand Factor (vWF) and adhere to collagen fibres. Stable adhesion of platelets causes 
activation and platelet degranulation. Tissue factor (TF) produces fibrin, which creates a mesh forming a stable 
thrombi.  





Platelet activation is characterised by platelet shape change and degranulation and is 
dependent on increased intracellular concentrations of calcium ions (Ca2+). Platelet GPVI 
receptors are bound to the Src kinases Fyn and Lyn via their cytoplasmic tail. GPVI is also 
constitutively associated with a Fc receptor (FcR) γ-chain dimer that has an immunoreceptor 
tyrosine-based activation motif (ITAM). When GPVI binds to collagen in the exposed 
extracellular matrix, the Src kinases phosphorylate the ITAM sequence and initiates activation 
of a downstream signalling cascade. Important to the signalling is the formation of the 
‘signalosome’ which is composed of multiple adapter and effector proteins. The signalosome 
activates phospholipase Cγ (PLCγ) which liberates the second messengers 1, 2 diacylglycerol 
(DAG) and inositol 1,4,5 triphosphate (IP3). DAG and IP3 increase intracellular Ca
2+ by 
mediating calcium influx via the plasma membrane and liberating intracellular stores, 
respectively, thus resulting in platelet activation. Increased Ca2+ and liberation of DAG also 
activates protein kinase C (PKC) family proteins. Activation of PKC proteins has been shown to 
be critical for platelet degranulation, as broad range PKC inhibitors have been shown to ablate 
platelet granule secretion. In contrast, PKC proteins appear to have differential effects on 
platelet spreading.  Some isoforms (PKCband q) positively regulate platelet spreading on 
fibrinogen, whereas other isoforms (PKCd) seem to negatively regulate filopodia formation 
(Harper and Poole, 2010). Binding of collagen to integrin α2β1 triggers a similar signalling 
cascade to GPVI/collagen binding and results in platelet activation. 
 
During platelet activation, platelets undergo shape change in which their morphology changes 
from discoid to spiny spheres. Shape change is mediated by extensive reorganisation of the 
cytoskeleton. Platelets also undergo degranulation, where contents of the α- and dense-
granules are released into the lumen of the OCS and then into the exterior. Thromboxane A2 
(TxA2), a potent platelet activator, is also released by the plasma membrane. Increased 
cytosolic Ca2+ leads to the liberation of arachidonic acid from membrane phospholipids. 
Arachidonic acid is converted to TxA2 by enzymes including cyclooxygenase 1 (COX-1). Finally, 
platelet activation induces conformational changes and therefore activation of many 
membrane integrin receptors, such as integrin αIIbβ3. 
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Many factors released by the platelet granules upon activation are platelet activators 
themselves (ADP, TxA2, thrombin and adrenaline for example) and many of these act by 
binding to GPCRs. Binding of agonists to GPCRs leads to downstream activation of PLCβ which 
in turn releases DAG and IP3 as per PLCγ. This local increase of platelet agonists leads 
recruitment of further platelets to the area of vascular injury (Rivera et al., 2009; Rumbaut 
and Thiagarajan, 2010). 
 
Activated platelets are able to bind to neutrophils via interactions of P-selectin on activated 
platelets and P-selectin glycoprotein ligand-1 (PSGL-1) on neutrophils (Sreeramkumar et al., 
2014). Once bound to platelets, neutrophils become activated by interactions of the 
transmembrane receptor RAGE (receptor for advanced glycation endproducts) on neutrophils 
with high motility group box-1 (HMGB-1) protein that is exposed on the membrane of 
activated platelets (Maugeri et al., 2014). Activation of neutrophils by RAGE/HMGB-1 
interactions results in NETosis, the process of neutrophil extracellular trap (NET) formation. 
NETosis begins with the production of reactive oxygen species (ROS) by phagocytic oxidase 
(PHOX), which liberates the proteases neutrophil elastase (NE) from azurophilic granule 
membranes, potentially by ROS interactions with the protease myeloperoxidase (MPO). Once 
liberated, NE bind actin filaments in the cytoplasm and promotes F-actin degradation, allowing 
NE to enter the nucleus (Metzler et al., 2014). MPO also migrates to the nucleus after NE, 
where the two proteases facilitate chromatin decondensation. Chromatin decondensation is 
further enhanced by peptidylarginine deiminase 4 (PAD4), which catalyses the conversion of 
arginine residues to citrulline. After chromatin has fully decondensed, neutrophils rupture, 
releasing  NETs which consist of extracellular chromatin fibres surrounding a backbone of 
histones decorated with granular and cytoplasmic proteins (Brinkmann and Zychlinsky, 2012). 
NETs themselves are able to bind and activate platelets, mediated by histones (Brinkmann et 
al., 2004), thus propagating platelet activation during thrombus formation.  
 
Platelets can also become activated in a collagen independent manner. Tissue factor (TF) 
released at sites of vascular injury forms a complex with blood coagulation enzyme factor VIIa 
that circulates in the blood. This interaction initiates a cascade of coagulation factors that 
results in the formation of thrombin. Thrombin activates platelets by binding to the GPCRs 
protease-activated receptor (PAR) 1 and 4 (Furie and Furie, 2008). 
  





Integrin αIIbβ3 is a fibrinogen and vWF receptor located on the plasma membrane of platelets. 
In resting platelets it is maintained in a low affinity state, upon platelet activation the integrin 
undergoes a conformational change into a high affinity state. Activated αIIbβ3 can bind soluble 
plasma fibrinogen and the fibrinogen acts as a bridge between two αIIbβ3 receptors on 
adjacent platelets. These fibrinogen bridges cause the aggregation of platelets. vWF can also 
substitute for fibrinogen as the bridging molecule under high shear.  
 
Although fibrinogen/vWF bridging via αIIbβ3 is the most studied method of platelet 
aggregation, other molecules have been implicated. These include junctional adhesion 
molecules (JAMs), signalling lymphocyte activation molecule (SLAM) proteins and CD40 ligand 
(CD40L aka CD154). (Rivera et al., 2009; Rumbaut and Thiagarajan, 2010). 
 
1.7.4.3 Clot stabilisation 
 
The formation of a fibrin mesh within the thrombus is the last critical event in the production 
of a stable thrombus. Fibrin is produced by cleavage of fibrinogen by thrombin. As discussed 
in section 1.7.4.2, thrombin is produced by TF. As well as TF derived from vessel damage, TF 
is present in monocyte derived microparticles. These monocyte microparticles are captured 
by in the thrombus by interaction between P-selectin on activated platelets and PSGL-1 on the 
microparticles or trapped by NETs (Rivera et al., 2009).  
 
The conversion of TF to thrombin is accelerated roughly 150,000-fold by the presence of 
plasma membrane phosphatidylserine (PS). PS is located of the cytoplasmic surface of the 
plasma membrane in resting platelets. However, vesicles produced by activated platelets 
contain PS on the plasma facing side of the membrane. This exposed PS allows efficient 
production of thrombin and formation of a fibrin mesh (Lentz, 2003).  
 
1.7.5 Role in thrombus formation in the absence of vascular injury 
 
In 1856 Rudolf Virchow proposed a triad of factors that contribute to venous thrombosis. He 
postulated that changes in vessels walls, changes in blood coagulability or blood stasis could 
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cause thrombosis. Given that the venous thrombi are rarely the result of vascular injury 
(Sevitt, 1974), initiation of thrombosis in veins is mainly controlled by blood stasis or changes 
in blood coagulation factors.  
 
Many autopsy (Sevitt, 1974; Teviotdale and Gwynne, 1967) and phlebography (Browse and 
Thomas, 1974; Cotton and Clark, 1965) studies have concluded that lower limb venous valve 
sinuses are the major site of thrombus formation in the absence of vascular injury. This 
conclusion is supported by the correlation between the number of valves an individual has 
and the frequency of deep vein thrombosis (DVT) (Liu et al., 1986). Valve sinuses are areas in 
which blood undergoes prolonged periods of stasis. McLachlin et al showed that contrast 
media used in venography studies remained for an average of 27 minutes, but up to 60 
minutes in the valve sinuses of lower limbs and that the stasis time was highly correlated with 
age (McLachlin et al., 1960). The prolonged blood stasis in lower limb valve sinuses is 
correlated with hypoxia in these regions. It was shown that at the bottom of canine limb valve 
sinuses, the region where venous thrombosis usually occurs, blood undergoes localised serve 
hypoxia when exposed to static flow for 2 hours. Early thrombus formation was also noted in 
the most hypoxic regions, implicating hypoxia with initiation of venous thrombosis (Hamer et 
al., 1981).   
 
Intermittent hypoxia, as occurs at lower limb valve sinuses, results in activation of endothelial 
cells and leukocytes. Hypoxia is sensed by mitochondria or NADPH oxidase (NOX) leading to 
production of ROS. ROS accumulation leads to degranulation of Weibel-Palade bodies in 
endothelial cells and exposure of P- and E-selectin and vWF on their plamsa membrane. ROS 
also activates two important transcription factors, namely hypoxia inducing factor -1 (HIF-1) 
and early growth response -1 (Egr-1), via inhibition of HIF prolyl hydroxylase (PHD) or 
activation of nuclear factor-κΒ (NF- κΒ). Activation of HIF-1 and Erg-1 alters the transcriptional 
activity of endothelial cells, which leads to a prothrombotic state (decreased production of 
NO, increased production of plasminogen activator inhibitor-1 (PAI-1), which inhibits 
fibrinolysis, and potentially exposure of TF on the plasma membrane) (Bovill and van der Vliet, 
2011).  
 
Activated endothelium is able to capture platelets via vWF interactions (see 1.7.4.1) and 
leukocytes (mainly neutrophils and monocytes (von Bruhl et al., 2012)) and TF positive 
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leukocyte and platelet derived microparticles via interactions of P-selection with PSGL-1 
(Mackman, 2012). Captured leukocytes become activated by hypoxia in a similar fashion to 
endothelial cells as above, leading to exposure of TF on their plasma membrane and release 
of TF positive microparticles (Bovill and van der Vliet, 2011). Leukocyte capture by P-selectin 
and localised exposure of TF are both critical for venous thrombosis. This is demonstrated by 
the fact both mice lacking P-selectin and mice with very low levels of TF are protected against 
thrombus formation in a model of DVT (von Bruhl et al., 2012). NETosis has also been shown 
to be critical for proper venous thrombosis propagation. Treatment of mice with DNase1 or 
heparin (which has a high affinity for histones) reduced NET formation and significantly 
reduced thrombus growth in a model of DVT (von Bruhl et al., 2012).  
 
As discussed in sections 1.7.4.2 and 1.7.4.3 TF causes the generation of thrombin which 
convert fibrinogen to fibrin. Venous thrombi are composed of a fibrin mesh trapping a 
multitude of blood cells. Unlike thrombi at sites of vascular injury, venous thrombi are called 
red clots due to their high level of red cell content.  
 
Although platelets do not appear to be critical for the generation of venous thrombi, there is 
growing evidence suggesting they contribute. For example, thrombocytosis has been shown 
to be a risk factor for venous thromboembolism in cancer patients (Jensvoll et al., 2014) and 
mice depleted of platelets had significantly reduced thrombi in a model of DVT (von Bruhl et 
al., 2012). Also, platelets appear to be important for the recruitment of leukocytes to venous 
thrombi and for the formation of NETs. Platelets are able to interact with leukocytes via 
numerous receptor interactions, the most common being platelet P-selectin with leukocyte 
PSGL-1 and platelet GPIbα with leukocyte αMβ2 integrin (Li et al., 2015). Both leukocyte 
numbers and NET formation were significantly reduced in a model of DVT which used mice 
lacking the external domain of GPIbα (von Bruhl et al., 2012).   
 
1.7.6 Removal from circulation 
 
After being released by MKs into the peripheral circulation platelets circulate for 8 to 10 days 
(in humans, 4 to 5 in mice) before being removed (Leeksma and Cohen, 1955; Machlus and 
Italiano, 2013). Platelet clearance mainly occurs in the spleen and liver and is controlled by 
several mechanisms. 




One such mechanism involves signals induced by aging (senescence) of platelets. Senescent 
platelets lose sialic acid from plasma membrane associated receptors, exposing underlying β-
galactose. This loss of sialic acid is probably due to upregulation of the sialidases, Neu1 and 
Neu3. Exposed galactose residues are recognised by Ashwell-Morrell receptors (AMRs), 
located on liver macrophages (Kupffer cells) and hepatocytes, which leads to platelet 
clearance (fig. 1.3). The AMR is a transmembrane heteroligomeric glycoprotein receptor 
composed of two ASGPR1 molecules and one ASGPR2 molecule. Studies using knockout mice 
revealed the importance of desialyation and the AMR in platelet clearance. St3gal4 knockout 
mice, which lack the enzyme responsible for sialyation of β-galactose, have thrombocytopenia 
due to increased hepatic platelet clearance, whereas Asgr2 knockout mice have increased 
platelet counts and half-life. Cross-breeding of these mice normalised platelet counts, proving 
that the AMR was responsible for recognising desialyated platelets (Grozovsky et al., 2015a; 
Grozovsky et al., 2015b; Sorensen et al., 2009).  
 
Kupffer cells are also able to clear platelets via interin αMβ2 (also called CD11b, macrophage 
receptor 1 (Mac-1) and compliment receptor 3 (CR3)). Desialyated platelets can undergo de-
galactosylation, removing the galactose residues that cap GPIbα subunits of the vWF receptor 
and exposing N-acetylglucosamine (GlcNAc). Exposed GlcNAc on GPIbα subunits are 
recognised by the αM subunit of integrin αMβ2 leading to phagocytosis and platelet 
clearance. De-galactosylation of platelets is rapidly increased when platelets are cooled below 
room temperature and cooled platelets are rapidly removed from the circulation upon 
transfusion. Thus, platelet transplant units are stored at room temperature and as such have 
a short shelf life due to the potential of bacterial contamination (Grozovsky et al., 2015b; 
Grozovsky et al., 2010). 
 
Platelet lifespan has been attributed to the interplay between members of the BCL-2 family, 
which are regulators of the intrinsic apoptotic pathway. Deletion of the pro-survival protein 
BCL-XL in mice dramatically accelerates platelet clearance, whereas ablation of the pro-
apoptotic proteins BAK and BAX increased platelet half-life (Mason et al., 2007). However, 
other pro-survival proteins, namely BCL-2 and MCL-1, are dispensable for platelet survival as 
deletion in mice had no effect on platelet clearance (Debrincat et al., 2015). In nucleated cells, 
BCL-2 pro-survival proteins interact with BAK/BAX inhibiting their pro-apoptotic actions. In 
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response to pro-apoptotic signals, BH3-only pro-death proteins (e.g. BAD, BIM and BID) 
become activated and disrupt the interaction between BCL-2 pro-survival proteins and 
BAK/BAX, allowing BAK/BAX to become activated and initiate apoptosis (McArthur et al., 
2018). Whether this canonical apoptotic pathway exists in platelets is yet to be fully 
elucidated. BAD knockout mice have increased platelet counts due to a mild but significant 
increase in platelet lifespan, but BIM knockout mice have no alteration in platelet count (Kelly 
et al., 2010). Also, whether this modest increase in platelet count and lifespan in BAD knockout 
mice is due to BAD actively signalling to BAK and/or BAK or due to decreased inhibition of BCL-
XL is unknown. Therefore, if BH3-only pro-death proteins are involved in the apoptotic 
pathway of platelets, the exact BH3-only pro-death proteins and combination in which they 
function are unknown. BAK/BAX-mediated apoptosis leads to the classical hallmarks of 
apoptosis in cells, i.e. mitochondrial damage, caspase activation, cytoplasmic condensation 
and PS exposure. Once platelets are apoptotic, it is presumed they are cleared by phagocytes 
of the mononuclear phagocyte system in both the liver and spleen (Grozovsky et al., 2015b). 
One may expect that desialyation of platelets triggers the intrinsic apoptosis pathway as both 
mechanisms lead to platelet clearance, however a clear link between platelet desialyation, 
platelet ageing and the triggering of platelet apoptosis remains unknown.  
 
Platelets can also be cleared in an antibody dependant manner by macrophages primarily, but 
not exclusively, in the spleen. Immunoglobulin G (IgG) autoantibodies produced by the white 
pulp of the spleen bind to circulating platelets. The antibodies are mainly directed against the 
two most numerous membrane glycoproteins, namely integrin αIIbβ3 and the GPIbα subunit 
of the GPIb-V-IX complex. The slow movement of IgG bound platelets through splenic 
sinusoids allows association between the IgG Fc region and Fcγ receptors of macrophages. 
This binding initiates phagocytosis and destruction of platelets by the macrophages 
(Grozovsky et al., 2015b; Grozovsky et al., 2010). 
 
The spleen acts as a filter for misshaped or irregular blood cells. This is evident as 
splenectomised patients are easily identified by their blood films which show red blood cells 
with membrane abnormalities (codocytes/target cells) and red blood cells containing 
remnants of nuclear material (Howell-Jolly bodies). The exact mechanism by which the spleen 
removes abnormal red blood cells is not known. Whether the spleen plays a role in 
thrombocytopenia seen in genetic disorders that cause the formation of abnormally shaped 
1 - Introduction 
 
42 
platelets is also unknown. However, the early removal of platelets by the spleen has been 
implicated in twinfilin 2a knockout mice. These mice have thrombocytopenia due to the early 
removal of hyper-reactive platelets. Although the exact mechanism by which the spleen 
removes these hyper-active platelets has not been resolved, it is independent of 
macrophages. This is evident as macrophage depletion using clodronate liposomes had no 
effect on platelet counts, whereas splenectomy restored platelet counts to normal levels 




Thrombocythaemia, also known as thrombocytosis, is defined as a circulating platelet count 
of above 450x109/L in humans (see Table 1.2). The major cause of thrombocythaemia is 
reactive (secondary) thrombocythaemia which occurs secondary to many conditions such as 
infection, cancer and inflammation. Reactive thrombocythaemia is driven by elevated levels 
of cytokines that drives thrombopoiesis, for example TPO, IL-6 and IL-11 (Schafer, 2004).  
 
1.8.1 Essential Thrombocythaemia 
 
Thrombocythaemia due to acquired clonal mutations of HSCs is termed essential (primary) 
thrombocythaemia (ET). ET is a member of a family of diseases called Philadelphia 
chromosome negative myeloproliferative neoplasms (MPNs) along with polycythaemia vera 
(PV) and primary myelofibrosis (PMF). Diagnosis criteria of ET set by the World Health 
Organisation is one of exclusion. As well as sustained thrombocythaemia and increased bone 
marrow megakaryocytes, ET diagnosis is confirmed on exclusion of other MPNs, myeloid 
neoplasms or iron deficiency as the cause of the thrombocythaemia (Cervantes, 2011). 
 
ET is a rare disease with a prevalence of around 30 per 100,000 people and an incidence rate 
of ≈2 per 100,000. The median age of diagnosis is 65 to 70 years but the age of onset is very 
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1.8.1.1 Genetic causes 
 
The work of many groups have identified acquired mutations that lead to an ET phenotype. 
The major mutations seen in ET affect the tyrosine kinase Janus Kinase 2, the endoplasmic 
reticulum chaperone, Calreticulin, and the TPO receptor gene MPL. Other genetic mutations 
have been elucidated, for example loss of function mutations of LNK which negatively 
regulates TPO/erythropoietin (EPO) signalling and mutations of CBL. Despite this work, 
approximately 10% of patients have ET of unknown cause (McPherson et al., 2017). 
 
Janus Kinase 2 
 
In 2005, four groups identified a mutation in exon 14 of JAK2 that causes a substitution of 
valine for phenylalanine at amino acid 617 (JAK2 V617F), which is present in approximately 
50% of ET and PMF cases and 90% of PV cases (Baxter et al., 2005; James et al., 2005; Kralovics 
et al., 2005; Levine et al., 2005). Allele burden is thought to determine how one mutation leads 
to multiple phenotypes, with lower burdens leading to ET. Most patients with PV are 
homozygous for JAK2 V617F whereas homozygosity is rare in ET patients (Scott et al., 2006). 
These results are paralleled by mouse models, where high mutant JAK2 levels caused a PV 
phenotype but lower mutant transgene levels resulted in an ET phenotype (Li et al., 2010; 
Tiedt et al., 2008).   
  
JAK2 has two kinase domains, a canonical tyrosine kinase domain (JH1) paired in tandem with 
a pseudokinase domain (JH2). Under normal physiology, the JH2 interacts with and inhibits 
the JH1 domain in the absence of ligand binding. The JAK2 V617F mutation is located in the 
JH2 domain and prevents inhibition of JH1 by JH2. Therefore, JAK2 V617F causes continuous 
activation of JAK2 and downstream signalling independent of cytokine stimuli. However, in 
the heterozygous state of ET, TPO receptors are still responsive to growth factor binding and 
for full signalling binding is required (Spivak, 2017). Growth factor binding to JAK2 V617F 
bound receptors leads to increased and prolonged signalling. This upregulation of JAK2 
signalling results in increased megakaryopoiesis seen by increased bone marrow MKs, 
increased proplatelet formation and thrombocythaemia. Beyond an increase of platelet 
numbers the JAK2 V617F mutation causes platelets to hyper-reactive to a range of agonists 
(Hobbs et al., 2013).  





Mutations in CALR, the gene that encodes calreticulin, are the second most common in MPNs. 
CALR has roles in glycoprotein folding and calcium homeostasis. Exome sequencing revealed 
that approximately 70% of ET patients with non-mutated JAK2 carry CALR exon 9 mutations. 
CALR exon 9 mutations result in frameshifts producing CALR protein with a novel C-terminus 
with positive instead of negative charge (Klampfl et al., 2013; Nangalia et al., 2013). Mutated 
CALR is able to bind c-Mpl via c-Mpl’s extracellular domain and chaperone it to the plasma 
membrane. Binding of mutant CALR to c-Mpl is presumed to causes structural changes in c-
Mpl leading to activation of JAK2 and constitutive downstream signalling (Araki et al., 2016). 
CALR positive ET patients have a lower risk of thrombosis and increased overall survival 




Approximately 15% of JAK2 V617F negative ET patients have mutations in the MPL gene, 
mainly in exon 10 (primarily W515L/K). These mutations lead to constitutive activation of the 
JAK/STAT pathway seen by constitutive phosphorylation of JAK2, STAT3 and STAT5 in mutated 






count Disease Cause/mutated gene 
150-400 
x109/L None, normal platelet range N/A 
>450x109/L 
Essential thrombocythaemia JAK2 (≈50%), CALR (≈7-8%), MPL (≈35%), ≈10% unknown (McPherson et al., 2017). 
Reactive thrombocythaemia  
Secondary to many conditions such as infection, cancer and 
inflammation, driven by elevated levels of thrombopoietic 





Thromobocytopenia associated with 
sitosterolaemia 
ABCG5 (Berge et al., 2000) 
ABCG8 (Berge et al., 2000) 
ACTN1 related thrombocytopenia ACTN1 (Murphy et al., 2016) 
Thrombotic thrombocytopenic purpura 
(TTP), Upshaw-Schulman syndrome ADAMTS13 (Levy et al., 2001) 
ANKRD26-related thrombocytopenia ANKRD26 (Noris et al., 2011) 
CYCS-related thrombocytopenia CYCS (Morison et al., 2008) 
DIAPH1 related macrothrombocytopenia DIAPH1 (Stritt et al., 2016) 
Thrombocytopenia 5 (THC5) ETV6 (Zhang et al., 2015) 
Paris Trousseau type thrombocytopenia/Jacobsen 
(11q23 del) FLI1 (Tunnacliffe et al., 1999) 
FLNA-related thrombocytopenia FLNA (Nurden et al., 2011) 
Novel thrombocytopenia FYB (Levin et al., 2015) 
GATA1 related disease  GATA1 (Nichols et al., 2000) 
Bernard-Soulier Syndrome (BSS)  
GP1BA (Ware et al., 1990) 
GP1BB (Budarf et al., 1995) 
GP9 (Wright et al., 1993) 














Amegakaryocytic thrombocytopenia with radio-
ulnar synostosis HOXA11 (Thompson and Nguyen, 2000) 
Glanzmann's thrombasthenia 
ITGA2B (Burk et al., 1991) 
ITGB3 (Loftus et al., 1990) 
Thrombocytopenia with immunodeficiency MKL1 (Record et al., 2015) 
Congentical amegakaryocytic thrombocytopenia MPL (Ihara et al., 1999) 
MYH9 related disease MYH9 (Spinler et al., 2015) 
Grey Platelet Syndrome NBEAL2 (Gunay-Aygun et al., 2011) 
Bleeding disorder, platelet-type 19 PRKACG (Manchev et al., 2014) 
Thrombocytopenia with absent radii (TAR) RBM8A (Albers et al., 2012) 
Familial platelet disorder and predisposition to 
AML RUNX1 (Song et al., 1999) 
Novel thrombocytopenia SLFN14 (Fletcher et al., 2015) 
Stormorken Syndrome STIM1 (Picard et al., 2009) 
Mild novel thrombocytopenia (heterozygous) THPO (Dasouki et al., 2013) 
TPM4-related macrothrombocytopenia TPM4 (Pleines et al., 2017) 
TUBB1-related macrothrombocytopenia TUBB1 (Kunishima et al., 2009) 
Von Willebrand disease type 2B vWF (Cooney et al., 1991) 
Wiskott-Aldrich syndrome, X-linked 
thrombocytopenia (XLT) WAS (Derry et al., 1994) 
Secondary thrombocytopenia 
Secondary consequence in a number of diseases (cancers 
and infections), therapeutic treatments (chemotherapy) 
and autoimmunity. 


















The main complications of ET are arterial and venous thrombotic events. The incidence of 
these thrombotic complications in ET have been difficult to assess, however a review of the 
literature in 2005 by Elliot and Tefferi showed that arterial thrombotic events are more 
common than venous events. At presentation 10-25% of ET patients show major thrombosis 
with 80-90% of these being arterial thrombotic events. At follow up, the number of thrombotic 
events is similar to presentation statistics, but venous thrombotic events contributed to a 
greater proportion of the total thrombotic events (up to 37.5%) compared to presentation. 
The review by Elliot and Tefferi also highlighted that thrombotic events account for a 
significant proportion of deaths in ET patients, with up to 27.3% of patients ET patients dying 
from thrombotic events (in studies where multiple patients died) (Elliott and Tefferi, 2005). 
Despite this, survival rates are high in ET (80% at 15 years); and as such, the focus of 
therapeutic management in ET patients is primarily to prevent thrombotic events that cause 
significant morbidity without increasing the risk of bleeding. This is done by reducing platelet 
function and, in high risk patients, which make up the majority of ET patients as onset is usually 
above 60 years of age (see below), platelet numbers (Dombi et al., 2017). However, current 
therapies for high risk patients (section 1.8.1.2.1) are not platelet specific and therefore have 
a range of unwanted side effects. 
 
Treatment of ET is based on the individual patient needs depending on their risk of thrombosis 
and/or bleeding. The three risk factors used to categorise patients into low risk and high risk 
are: patient’s age ≥ 60 years, history of thrombosis or major bleeding and platelet count ≥ 
1500x109/L (Birgegard, 2016; Rumi and Cazzola, 2016). 
 
Low risk patients are those with none of the three risk factors and receive no therapeutic 
treatment or low dose aspirin, depending on the genetic mutation which causes ET. All JAK2 
V617F positive ET patients receive aspirin, whereas CALR positive, MPL positive and triple-
negative patients may not be administered aspirin if they do not have other cardiovascular 
risk factors such as hypertension, diabetes or tobacco use (Rumi and Cazzola, 2016). Aspirin is 
used to reduce platelet function, due to its ability to inhibit COX by acetylating its active site, 
thus decreasing the formation of TxA2 from arachidonic acid (see section 1.1.6.5.2) (Patrignani 
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et al., 1982), and has been shown to reduce the incidence of venous thrombosis without 
increasing the risk of bleeding in JAK2 V617F positive patients (Alvarez-Larran et al., 2016). 
 
High risk patients are those with 1-3 of the three risk factors. All high risk patients with a 
platelet count below 1500x109/L will receive low dose aspirin, above this aspirin treatment is 
associated with a decrease of plasma vWF multimers and excessive bleeding times (van 
Genderen et al., 1997). High risk patients may also be administered cytoreductive agents. 
 
1.8.1.2.1 Cytoreductive agents 
 
The use of cytoreductive therapy in the treatment of high risk ET patients is dependant mainly 
on the patients’ age. All patients over 60 years will be administered cytoreductive therapies 
whereas only 15 and 20% of patients are administered cytoreductive therapies if they are 
under 40 years or between 40-60 years, respectively. The requirement of cytoreductive 
therapies for patients under 60 years is based on fulfilment of 1 or both of the other two risk 
factors that group patients into high and low risk (Rumi and Cazzola, 2016).  
 





Hydroxyurea is used widely in the treatment of high risk ET patients as it effectively decreases 
platelets counts and prevents thrombotic events (Cortelazzo et al., 1995; Rumi and Cazzola, 
2016). Hydroxyurea impairs DNA synthesis through inhibition of ribonucleotide reductase, 
which catalyses the formation of single DNA nucleotides from ribonucleotides. Impairment of 
DNA synthesis in MKs impedes maturation, decreasing platelet biogenesis and therefore 
lowering platelet counts (Tefferi et al., 2000). Impaired DNA synthesis impacts on other high 
turnover tissues, in particular the whole haematopoietic compartment and therefore other 










In 1957 Isaacs and Lindenmann discovered the first cytokine and named it Interferon (IFN) 
because of its ability to interfere with viral propagation (Isaacs and Lindenmann, 1957). The 
IFN-α family comprises 14 genes that encode 13 proteins. Binding of IFN-α proteins to their 
receptors on cell membranes (type I IFN receptors), activates receptor associated JAKs (Tyk2 
and JAK1). Activation of these JAKs leads to STAT1/2 activation and translocation to the 
nucleus where they promote the transcription of IFN regulated genes (Kiladjian et al., 2008). 
 
Although the exact mechanism by which IFN-α treatment decreases platelet counts in ET 
patients is yet to be elucidate, IFN-α has been shown to reduce the colony-forming ability of 
erythroid, granulocytic and megakaryocytic progenitors. Evidence from both in vitro and in 
vivo assays suggest IFN-α targets clonal progenitors preferentially to unaffected counterparts. 
Megakaryocyte biogenesis seems particularly sensitive to IFN-α treatment. IFN-α treated 
patients have decreased bone marrow MK numbers and MKs also have decreased size (Chott 
et al., 1990; Kiladjian et al., 2008). 
 
IFN-α treatment is associated with a variety of side effects. Haematological effects include 
neutropenia, although this is rare in ET, and lymphopenia.  Other side effects of IFN-α 
treatment include flu-like symptoms, fatigue, musculoskeletal pain and mood changes such as 




Anagrelide was originally developed as an antiplatelet agent and its thrombocytopenic actions 
were observed during pre-clinical trials. It is the most platelet specific cytoreductive agent and 
has no effect on red or white blood cell lineage. It affects MK differentiation, decreasing MK 
ploidy and size but MK proliferation appears to be unaffected with normal bone marrow MK 
numbers. The platelet lowering action of anagrelide is mediated through its ability to decrease 
proplatelet formation and proplatelet complexity, possibly via phosphorylation of myosin II 
light chain (Birgegard, 2016; Espasandin et al., 2015)). Comparison of ET patients treated with 
anagrelide or hydroxyurea in combination with aspirin showed anagrelide treatment is more 
effective at reducing thrombotic events (Dombi et al., 2017). 
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The most common side effects of anagrelide treatment are tachycardia, headache, dizziness 
and diarrhoea and although common in the first weeks of treatment, they usually subside. 
Due to its tachycardic effects and worsening cardiac insufficiency in some patients, anagrelide 
treatment is used with caution in patients with a history of cardiac failure. Combination 
therapy with low dose aspirin increases the risk of haemorrhage and therefore should be used 




Thrombocytopenia is defined as a circulating platelet count below 150x109/L. 
Thrombocytopenia is generally the consequence of decreased platelet production or 
increased platelet clearance. Like thrombocythaemia, thrombocytopenia can occur secondary 
to a number of diseases (such as cancer and infections), therapeutic treatments (such as 
chemotherapy) and autoimmunity, but it can also be inherited (Table 1.2). 
 
1.9.1 Inherited causes 
 
There are currently over 30 known genes whose mutations lead to thrombocytopenia (table 





Mutations in MYH9 that encodes for non-muscle myosin heavy chain IIA (NMMHC-IIA) are 
responsible for MYH9-related disorders which encompass several autosomal-dominant 
diseases previously classified as May-Hegglin anomaly, Fechtner syndrome, Sebastian 
syndrome, or Epstein syndrome. All patients share the combination of 
macrothrombocytopenia and leukocyte inclusions (Döhle-like bodies). Despite the 
thrombocytopenia, platelet mass (thrombocrit) is unchanged, suggesting the 
thrombocytopenia is a result of terminal platelet formation in the periphery. MYH9 mutations 
result in increased platelet myosin IIA phosphorylation and therefore inactivation. Increased 




inactivation results in decreased fission of preplatelets, thus resulting in 




Wiskott-Aldrich syndrome (WAS) is caused by mutations in the WAS gene located on 
chromosome X and is characterised by severe microthrombocytopenia, immunodeficiency 
and eczema (Derry et al., 1994). WAS protein (WASp) regulates actin assembly and prevents 
actin degradation in platelets by constitutive interaction with WASp-interacting protein (WIP). 
Interestingly, WAS mutated platelets have increased microtubule content, increased 
microtubules coils in the marginal band, altered microtubule organisation and increased 
microtubule stability. Surprisingly, this phenotype is recapitulated by condition 
megakaryocytic lineage knockout of the actin binding protein profilin 1 in mice. Profilin 1 
localises to the microtubule marginal band in healthy resting platelets and re-localises to the 
cytoplasm upon microtubule disassembly, suggesting profilin 1 localisation is microtubule 
dependant. Platelets from WAS patients show mislocalisation of profilin 1, suggesting WASp 




Bernard-Soulier syndrome (BSS) is a severe bleeding disorder characterised by 
macrothrombocytopenia. BSS is caused by mutations in the GPIbα (Ware et al., 1990), GPIbβ 
(Budarf et al., 1995) or GPIX (Wright et al., 1993) subunits of the GPIb-V-IX vWF receptor 
complex. As discussed in section 1.1.5.2 mutations in the GPIb-V-IX complex cause reduced 
DMS maturation. GPIbα knockout murine MKs locate further from BM sinusoids, which may 




Mutations in TUBB1 that encodes for β1-tubulin results in macrothrombocytopenia with an 
absence or severely decreased marginal microtubule coil. Mutated β1-tubulin failed to 
incorporate into microtubules in mouse foetal liver derived MKs, which resulted in decreased 
proplatelet formation with abnormal morphology (large bleb protrusions). This lack of 
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proplatelet formation due to decrease of microtubule formation is thought to confer the 
thrombocytopenia seen in patients with TUBB1 mutations (Kunishima et al., 2009; Kunishima 




FLNA encodes the actin cross-linking protein filamin A. Mutations in FLNA results in irregular 
sized platelets that are generally larger and rounder. FLNA mutant platelets have 
heterogeneous α-granule content with some large α-granules and murine FlnA knockout 
platelets have increased microtubules in the marginal microtubule coil. FLNA mutated MKs 
have impaired proplatelet formation and murine FlnA knockout proplatelets have increased 
tip size and increased platelet shedding. Thrombocytopenia in FlnA knockout mice is 




ACTN1 encodes the rod shaped actin cross-linking protein actinin 1 (α-actinin). Currently 13 
mutations in ACTN1 have been identified and are linked with macrothrombocytopenia. ACTN1 
mutations cause disorganisation of the actin cytoskeleton in cell lines potentially due to 




Tropomyosins (TPMs) form copolymers with actin filaments and have muscle and non-muscle 
(cytoskeletal) isoforms. Nonmuscle TPMs regulate the interaction of other actin-binding and 
myosin motor proteins to the actin firmaments. TPM4 is the major tropomyosin isoform 
present in MKs and platelets. Mutations in TPM4 confer macrothrombocytopenia with the 
inclusion of large vacuoles. In human proplatelet forming MKs, TPM4 localises to proplatelets 
and co-localises with F-actin. Mutations in TPM4 cause decreased proplatelet formation in 
human and murine MKs with aberrant morphology (decreased branching and tip size). TPM4 
mutations also effects many actin-binding proteins. Expression of both filamin A and actinin 1 
are decreased in TPM4 mutated platelets, NMMHC-IIA localisation in proplatelets is 
dysregulates and phosphorylation of cofilin is decreased in MKs and platelets, suggesting 




increased actin turnover and indeed F-actin is decreased. This data suggest cytoskeletal 




DIAPH1 encodes diaphanous-related formin 1 (DIAPH1 or mDia1), which is known to stabilise 
and orientate microtubules. A heterozygous point mutation in DIAPH1 results in a premature 
stop codon at amino acid 1213 (R1213*) and causes macrothrombocytopenia and hearing 
loss. Proplatelet formation is increased in cultured MKs in which DIAPH1 had been knocked 
down by shRNA, but decreased when a constitutively active form of DIAPH1 is overexpressed, 
suggesting that activation of DIAPH1 inhibits proplatelet formation. DIAPH1 activation is 
regulated by interaction of two domains (diaphanous autoregulatory domain (DAD) and 
diaphanous inhibitory domain (DID)) that causes autoinhibition. DIAPH1 R1213* is likely to 
decrease the interaction of the DAD and DID domains and therefore decrease autoinhibition 
of DIAPH1. This is reflected by the fact that proplatelet formation is decreased in in vitro 
cultured MKs from patients harbouring the R1213* mutation. DIAPH1 also effects microtubule 
stability. DIAPH1 R1213* platelets have increased microtubules in the marginal coil compared 
to control and their microtubules do not disassemble at 4oC. Increase tubulin stability is 
associated with increased detyrosinated (Glu) tubulin: tyrosinated (Tyr) tubulin ratio and 
DIAPH1 R1213* platelets show higher Glu-tubulin: Tyr-tubulin (Pan et al., 2014; Stritt et al., 
2016). 











As described in section 1.8.1.1, ET is caused by mutations in mainly JAK2, MPL and CALR and 
results in a chronic increase of platelet numbers. Treatment of ET patients at high risk of 
thrombotic and/or bleeding events relies on cytoreductive therapies that have unwanted 
haematological side effects (Cervantes, 2011). An ideal therapy would normalise platelet 
numbers whilst having minimal side effects, especially those relating to the haematopoietic 
system.  
 
This thesis is split into 3 sections, with the overall aim of showing that a cytokine receptor-like 
factor 3 (CRLF3) could be a novel therapeutic target for the treatment of thrombocythaemia 
(including cases of reactive thrombocythaemia). This thesis focusses specifically on the 
platelet lowering effect of CRLF3 in ET as murine models of ET were freely available and have 
been extensively studied. We will use a Crlf3 knockout mouse (Crlf3-/-) developed by the 
Wellcome Trust Sanger Institute that have an isolated platelet phenotype (see section 4.1.2 
for more details). In the first section of the thesis we have two main aims: firstly, to determine 
whether ablation of Crlf3 results in an isolated and sustained thrombocytopenic phenotype 
and secondly, to determine the biological mechanisms underlying the observed 
thrombocytopenia.  
 
In the second section of the thesis we cross the Crlf3-/- mice with a JAK2 V617F knock-in mouse 
that has a phenotype similar to that of JAK2 V617F positive ET patients (see section 5.1 for 
more details). The main aim of this section is to determine whether CRLF3 could be a potential 
novel therapeutic target for the treatment of ET. 
 
In the final section of this thesis we look at the structure and function of CRLF3. Firstly, we aim 
to resolve the 3D structure of CRLF3 by X-ray crystallography. We then go on to tag 
endogenous CRLF3 in human induced pluripotent stem cells (iPSCs). We forward programme 
these tagged iPSCs into MKs and the final aim of the thesis is to determine the interactome of 
CRLF3 in these MKs, which should help uncover the function of CRLF3 in MKs.  











3.1 Generation of Crlf3 mutant mice 
 
Generation of Crlf3 mutant mice was performed by the Wellcome Trust Sanger Institute 
(WTSI) as part of an international consortium (www.knockountmouse.org) as previously 
reported (Ryder et al., 2013; Skarnes et al., 2011; White et al., 2013). Briefly, a mutant 
Crlf3tm1a(KOMP)Wtsi allele was created by insertion of a lacZ-neo cassette upstream of Crlf3 exon 
2 and loxP sites upstream and downstream of exon 2 into ES cells using standard cloning 
techniques (fig. 3.1A). The ES clone EPD0033_3_C11 was selected on the basis of neomycin 
resistance and β-galactosidase expression, confirming Crlf3tm1a(KOMP)Wtsi allele expression. Mice 
were generated according to standard techniques and after germline transmission of the 
Crlf3tm1a(KOMP)Wtsi allele, exon 2 of Crlf3 was excised by cre-mediated recombination by crossing 
with HprtTg(CMV-cre)Brd mice, producing the mutant Crlf3tm1b(KOMP)Wtsi allele (fig. 3.1B). After 
confirmation of allele conversion, mice carrying the Crlf3tm1b(KOMP)Wtsi allele were backcrossed 
to eliminate the cre transgene, generating Crlf3+/- mice.  
 
Figure 3.1 Generation of Crlf3 mutant mice. A) Production of the mutant Crlf3tm1a(KOMP)Wtsi allele by insertion of 
a lacZ-neo cassette upstream of Crlf3 exon 2 and loxP sites upstream and downstream of exon 2 in ES cells by 





For Crlf3-/- and WT mice, genotyping of mice was performed by PCR of genomic (g) DNA with 
specific primers (table 3.1 and 3.12). gDNA was produced from mouse ear notches using 
PureLink Genomic DNA Mini Kit (Invitrogen). PCR products were resolved by electrophoresis 
on a 1.5% agarose TBE (100mM Tris base, 100mM boric acid, 2mM EDTA) gel supplemented 
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with 5µl/ml DNA SafeView (NBS Biologicals Ltd). Crlf3 mutant (Crlf3tm1b(KOMP)Wtsi) alleles 
produced bands of 159bp and wildtype alleles produced bands of 281bp.  
 
For crossbred mice used in chapter 4, genotyping was performed as above for Crlf3 mutant 
and Crlf3 WT alleles. For Jak2 WT, Jak2 mutant and Mx1Cre alleles, genotyping was performed 
as per Crlf3 alleles using primers described in Li et al. (2010).  
 




Table 3.1 – Primers used to genotype Crlf3 WT and Crlf3 mutant alleles  
 
3.3 Mouse husbandry and regulated procedures 
 
Mice were housed in pathogen free conditions at Central Biomedical Services (University of 
Cambridge, Cambridge, UK) and cared for by staff. This research has been regulated under the 
Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 following ethical 
review by the University of Cambridge Animal Welfare and Ethical Review Body (AWERB). 
Experiments were performed under Project Licence 70/8406 (formerly 80/2376) by trained, 
Personal Licence (PIL) holders. Experiments carried out at the University of Würzburg 
(Würzburg, Germany) in collaboration with the group of Professor Bernhard Nieswandt were 
approved by the district government of Lower Franconia (Bezirksregierung Unterfranken). 
Power analysis was performed using a Type I error rate (a) of 5% and 80% power based on 
the results of preliminary experiments. These analyses determined few mice (3-6 per 
genotype per experiment) would be required to detect significant outcomes. 
 
3.4 Induction of mutant Jak2 expression 
 
Two to three day-old mice were injected subcutaneously with sterile polyinosinic-polycytidylic 
acid (pIpC; Sigma-Aldrich) to induce Cre recombinase expression. All mice were injected with 
50µL pIpC (3mg/mL in PBS, 150µg/dose) every other day for a total of 4 injections.   
 
 




3.5 Bleeding mice 
 
Mice were bled via the tail vein or the inferior vena cava (IVC), unless otherwise stated. For 
tail vein bleeds, mice were heated at 38-40oC for 10-15 minutes in a heat box. The tail vein of 
heated mice was punctured with a sterile scalpel blade and up to 200µL blood was collected 
in EDTA coated Microvette® tubes (Sarstedt). For IVC bleeds, mice were killed by exposure to 
increasing volumes of carbon dioxide. Once death had been confirmed, up to 1ml blood was 
withdrawn from the IVC using a 25G needle and 1ml syringe into 100µl 0.5M EDTA, 1,000U/ml 
heparin or acid citrate dextrose (ACD; 111mM glucose, 71mM citric acid, 116mM sodium 
citrate) to prevent coagulation.  
 
3.6 Full blood counts 
 
Full blood counts were recorded using a Scil Vet ABC animal blood analyser (Woodley), using 
blood collected into EDTA. 
 
3.7 Platelet rich plasma and washed platelets 
 
Platelet rich plasma (PRP) was made by diluting whole blood with 1.5 volumes Tyrode’s buffer 
(134mM sodium chloride, 2.9mM potassium chloride, 0.34mM sodium phosphate dibasic, 
12mM sodium bicarbonate, 20mM HEPES, 1mM magnesium chloride, 5mM glucose, pH 7.3) 
and centrifuging at 100g for 10 minutes. The top yellowish layer (PRP) was collected, being 
careful to avoid the white buffer coat. 
 
Washed platelets were prepared by adding 50ng/ml Prostaglandin E1 (PGE1; Caymen Chemical 
Company) and 0.5U/ml apyrase (Sigma-Aldrich) to PRP and centrifuging at 1,000g for 10 
minutes. The platelet pellet was resuspended in Tyrode’s buffer supplemented with 50ng/ml 
PGE1 and 0.5U/ml apyrase and centrifuged at 1,000g for 10 minutes. Washed platelets were 
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3.8 In vitro culture of bone marrow derived MKs 
 
Tibia and femurs were removed from culled mice and stored on ice. Bone marrow was 
removed by flushing tibia and femurs with Dulbecco’s modified Eagle medium (DMEM; PAA 
laboratories) supplemented with 10% BSA (Biosera), 2mM L-glutamate (PAA Laboratories) and 
100U/ml penicillin/streptomycin (pen/strep; PAA Laboratories) and pelleted at 200g for 5 
minutes. Red cells were lysed by incubation with ACK (150mM ammonium chloride, 1mM 
potassium bicarbonate, 0.1mM EDTA, pH 7.3) and cells pelleted again. Pelleted cells were 
incubated with antibodies against mouse CD11b, Ly6G, CD45R and CD16/CD32 (table 3.2 and 
3.13) for 30min at 4oC and leukocytes removed with magnetic beads against rat IgG 
(Invitrogen). Remaining cells enriched in blood progenitors were again pelleted, washed in 
supplemented DMEM and finally cultured in CellGRO SCGM (Cellgenix) supplemented with 
100U/ml pen/strep and 50ng/mL (unless stated) recombinant murine TPO (PepreoTech) for 
4-5 days at 37oC under 5% CO2 in a humidified incubator.  
 
MKs were purified by pelleting cells at 120g and resuspending in 4ml PBS (PAA Laboratories). 
Resuspended cells were layered on to an 8ml 1.5/3% BSA gradient and resolved at 1g for 45 
mins. The bottom 2ml MK fraction was collected, washed with PBS and pelleted at 120g for 5 
minutes. MKs were resuspended as needed.  
 
Antibody Clone Manufacturer 
Biotin Rat anti-mouse CD11b  M1/70 eBioscience 
Rat anti-mouse Ly-6G (Gr-1)  RB6-8C5 eBioscience 
Rat anti-mouse CD16/CD32 2.4G2 BD Pharmigen 
Biotin Rat anti-mouse CD45R/B220 RA3-6B2 BD Pharmigen 
Table 3.2 – Antibodies used for in vitro culture of bone marrow derived MKs 
 
3.9 Quantitative polymerase chain reaction 
 
RNA was extracted from purified in vitro cultured MKs (section 3.8) using RNeasy plus mini Kit 
(Qiagen). Complementary (c) DNA was made using SuperScipt III First Strand Kit (Invitrogen) 
starting from 100ng total RNA and using oligo-dT as reverse transcription primers. 
Quantitative polymerase chain reaction (qPCR) of the murine genes Crlf3 and Gapdh was 
carried out using specific primers that had previously been tested for optimal efficiency (table 




3.3 and 3.12), Brilliant II SYBR green chemistry (Agilent Technologies) and Mx3000P Real-Time 
PCR system (Stratagene). The analysis of gene expression was performed by the Δ Ct method, 
where: 
ΔCt = Ct target gene (Crlf3) – Ct housekeeping gene (Gapdh) 
Relative gene expression was expressed as 2-ΔCt. 
 





Table 3.3 – Primers used for qPCR  
 
3.10 Western blot 
 
Purified in vitro cultured MKs (section 3.8) or washed platelets (section 3.7) were lysed in RIPA 
buffer (150mM sodium chloride, 60mM Tris pH 8.0, 0.6% w/v sodium deoxycholate, 0.1% w/v 
sodium dodecyl sulfate, 1% v/v NP-40). Samples were diluted 1:1 with 2x Laemmli sample 
buffer (125mM Tris pH 6.8, 20% v/v glycerol, 4% w/v sodium dodecyl sulfate, 10% v/v β-
mercaptoethanol, 0.002% w/v bromophenol blue) and incubated at 95oC to denature 
proteins. Proteins were resolved on 4-12% Bis-Tris NuPAGE gradient gels (Invitrogen), 
transferred to PVDF membrane (Millipore) that had been soaked in 100% methanol for 5 
minutes then washed in ultrapure water using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-
Rad) for 1 hour at 90mA. Membranes were then blocked for >2 hours in 5% non-fat milk 
(Sigma-Aldrich) in TBS-T (20mM Tris, 137mM sodium chloride, 0.1% Tween-20, pH 7.6) or 
Odyssey Blocking Buffer (LI-COR). Post block membranes were immunoblotted with primary 
antibodies (table 3.4 and 3.13) overnight at 4oC, then washed with TBS-T or Odyssey Blocking 
Buffer and then incubated with the appropriate secondary antibodies (table 3.5 and 3.13) TBS-
T or Odyssey Blocking Buffer supplemented with 0.1% Tween-20 in for 1 hour at RT in the 
dark. Membranes were then washed with TBS-T or Odyssey Blocking Buffer supplemented 
with 0.1% Tween-20, before proteins were detected by enhanced chemiluminescence (HRP 
conjugated) or imaged with Odyssey Fc OFC-1095 version 1.0.36 imaging system (LI-COR; 
IRDye® 680RD and IRDye® 800CW conjugated). Expression was quantified using Image Studio 
Lite (https://www.licor.com/bio/products/software/image_studio_lite).  
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Antibody Clone Manufacturer 
anti-β-actin produced in mouse AC-15 Sigma-Aldrich 
Rabbit anti-human CRLF3 polyclonal Atlas antibodies 
Rabbit anti-human GAPDH 14C10 Cell Signalling Technology 
anti-Detyrosinated tubulin produced in rabbit polyclonal Millipore 
anti- tyrosine tubulin produced in mouse TUB-1 A2 Sigma-Aldrich 
Biotinylated Ricinus Communis Agglutinin I (RCA-I) n/a Vector Laboratories 
Rabbit anti-human Integrin beta 1 polyclonal Abcam 
Table 3.4 – Primary antibodies used for western blot 
 
Antibody Manufacturer 
HRP Sheep anti-mouse IgG GE Healthcare 
HRP donkey anti-rabbit IgG GE Healthcare 
Streptavidin HRP Cell Signalling Technology 
IRDye 800CW Donkey anti-rabbit IgG LI-COR 
IRDye 800CW Goat anti-mouse IgG LI-COR 
IRDye 680LT Goat anti-rabbit IgG LI-COR 
IRDye 680LT Donkey anti-mouse IgG LI-COR 
Table 3.5 – Secondary antibodies used for western blot 
 
3.11 Quantification of MKs in bone marrow 
 
Tibia and humeri were removed and fixed in 10% neutral buffered formalin solution (Sigma-
Aldrich) and processed by the Department of Pathology, University of Cambridge, Cambridge, 
UK or the Histopathology Team, WT-MRC Stem Cell Institute, University of Cambridge, 
Cambridge, UK as described elsewhere (Guerrero et al., 2014). Briefly, fixed tissue was 
embedded in paraffin and sections cut, deparaffinised and rehydrated. Sections were then 
stained with Haematoxylin and Eosin stain. After staining, images were acquired using an 
Axiovert 40 CFL microscope and AxioVision 40 version 4.8.2.0 software (both Zeiss) and MKs 
blindly quantified manually by myself or José Guerrero (University of Cambridge, Cambridge, 
UK). 
 
3.12 Plasma thrombopoietin  
 
Plasma thrombopoietin (TPO) assays were performed by José Guerrero (University of 
Cambridge, Cambridge, UK). Plasma was collected by centrifugation of whole blood 




withdrawn from the IVC at 6,000rpm. Plasma TPO concentrations were determined by 
following the manufacturer’s instructions of a commercially available ELISA kit (Mouse 
Thrombopoietin Quatikine ELISA Kit; R&D systems). 
 
3.13 Ploidy analysis 
 
Purified MKs (section 3.8) were fixed in 70% ethanol at -20oC for >24h after BSA gradients. 
Fixed MKs were washed in PBE (0.3% BSA, 0.5mM EDTA in PBS) and then stained with 
fluorescently labelled antibodies against CD41 (FITC Rat anti-mouse CD41, clone MWReg30; 
BD Pharmigen) for 15 mins in the dark. MKs were again washed in PBE and resuspended in 
ploidy stain buffer (PBE supplemented with 32.5µg/mL propidium iodide, 0.025mg/mL RNase 
A and 0.1% v/v Tween (all Sigma-Aldrich)) and incubated at 37oC for 30 mins in the dark. Ploidy 
of CD41+ events were analysed by flow cytometry using a CyAN flow cytometer and Kaluza 
Analysis version 1.5a software (both Beckman Coulter). 
 
3.14 In vitro proplatelet formation 
 
Purified MKs (section 3.8) were resuspended in culture medium supplemented with 100U/mL 
heparin sodium (Wockhardt UK Ltd) and seeded onto glass coverslips coated with 20ng/ml 
fibrinogen (Enzyme Research). Cells were incubated at 37oC under 5% CO2 for either 3 or 5 
hours. Attached MKs were fixed with 10% neutral buffered formalin solution and washed in 
PBS. Fixed MKs were stained for and imaged by confocal microscopy using the 20x objective 
as per section 3.24 with primary antibodies against CD41 (Rat anti-mouse CD41, clone 
MWReg30; BioLegend), appropriate fluorescent secondary antibodies (Alexa Flour 488 Goat 
anti-rat IgG; Invitrogen), a fluorescently labelled F-actin probe (Alexa Flour 555 Phalloidin; 
Invitrogen) and the nuclear stain DAPI (Sigma-Aldrich). Proplatelet forming MKs were counted 
against the total number of MKs to calculate the percentage of proplatelet forming MKs using 
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3.15 In vivo proplatelet formation  
 
In vivo proplatelet formation experiments were performed by Ayesha Baig (University of 
Würzburg, Würzburg, Germany). Briefly, mice were anaesthetised with triple narcotics 
((Midazolam [5 μg/g body weight] (Pfizer), Medetomidine [0.5 μg/g body weight] (Roche), 
Fentanyl [0.05 μg/g body weight] (Janssen-Cilag))) and a 1cm incision was made along the 
midline to expose the frontoparietal skull while carefully avoiding damage to the bone tissue. 
The mouse was placed on a customized metal stage equipped with a stereotactic holder to 
immobilize its head. Bone marrow vasculature was visualized by injection of 
tetramethylrhodamine dextran (Molecular Probes) and rat anti-CD105 alexa fluor 594 (clone 
MJ17/18; Biolegend) (table 3.12). Platelets and MKs were antibody-stained (Alexa Flour 488 
Rat anti-mouse GPIX, clone Xia.B4; Emfret Analytics) (table 3.12). Images were acquired every 
5 minutes with a fluorescence microscope equipped with a 20x water objective with a 
numerical aperture of 0.95 and a TriM Scope II multiphoton system (LaVision BioTec), 
controlled by ImSpector Pro-V380 software (LaVision BioTec). Emission was detected with 
HQ535/50-nm and ET605/70-nm filters. A tuneable broad-band Ti:Sa laser (Chameleon, 
Coherent) was used at 760nm to capture Alexa F488 and rhodamine dextran fluorescence. 
ImageJ software (NIH) was used to generate movies. 
 
3.16 Platelet survival 
 
Mice were injected with 1mg biotin N-hydroxysuccinimide ester (NHS-Biotin; Sigma-Aldrich) 
dissolved in 250µL 20% dimethyl sulfoxide (DMSO; Sigma-Aldrich) in PBS into the tail vein 
(injections performed by Dean Pask). Injected and uninjected control mice were bled from the 
tail vein 24, 48, 72, 96 and 168 hours post injection into EDTA-coated Microvette® tubes 
(Sarstedt). Cells were washed and incubated with fluorescently labelled antibodies against 
CD41, Ter-119 and streptavidin (table 3.6 and 3.13). The percentage of biotinylated platelets 
at each time point was determined by flow cytometry as the percentage of CD41+/Ter-119- 
events that were streptavidin positive. 
 
Antibody Clone Manufacturer 
FITC Rat anti-mouse CD41 MWReg30 BD Pharmigen 
APC Streptavidin n/a BD Pharmigen 




PE Rat anti-mouse TER-119 TER-119 BD Pharmigen 




Splenectomies were performed by Simon Stritt (University of Würzburg, Würzburg, Germany). 
Briefly, the surgical site on anesthetized mice (triple narcotics (as per section 3.15)) was 
sterilely prepared and a 1cm incision was made. After the spleen was identified, blood supply 
was stopped by ligation of vascular pedicles and the spleen was removed. Mice were 
monitored for 48 hours for signs of internal bleeding and infection. After a recovery period of 
6 days, platelet counts and size were followed over time by flow cytometry. Mice were then 
bled from the retro-orbital plexus every 7 days to determine platelet and preplatelet counts. 
Platelet counts were determined on a FACSCalibur (BD Biosciences) using fluorescently 
labelled antibodies against GPV (FITC Rat anti-mouse GPV, clone DOM2; Emfret Analytics) and 
GPIIbIIIa (PE Rat anti-mouse GPIIb/IIIa, Leo.F2; Emfret Analytic). 
 
3.18 Preplatelet quantification  
 
Method was adapted from (Thon et al., 2012a). Briefly, whole blood was diluted 1:20 in 
Tyrode’s buffer (section 3.7) supplemented with 2U/ml heparin. Diluted blood was incubated 
with antibodies against GPV and GPIIb/IIIa (section 3.17). Preplatelets were determined by 
flow cytometry using a FACSCalibur and CellQuest™ software (BD Biosciences) as 
GPV+/GPIIbIIIa+ events that have larger forward /sideward scatter characteristics than normal 
platelets. To exclude the possibility preplatelets could be platelet microaggregates, 
heparinised diluted blood was incubated with antibodies against activated GPIIbIIIa (PE rat 
anti-mouse GPIIb/IIIa, clone JON/A; Emfret Analytics) and CD62P (FITC rat anti-mouse CD62P, 
clone Wug.E9; Emfret Analytics) and assessed by flow cytometry as above. 
 
3.19 Bone Marrow Transplants 
 
Donor mice were culled and tibia collected. Bone marrow cells were flushed into 2% foetal 
bovine serum (FBS; Gibco) in PBS and made into a single cell solution by repeated passes 
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through a 25 gauge needle then passing through a 70µm cell strainer (BD Falcon). Recipient 
mice were sub lethally irradiated with a split dose of 4.75Gy and injected with 5x106 donor 
cells in 200µL 2% FBS/PBS via the tail vein (irradiation and tail vein injections performed by 
Dean Pask, University of Cambridge, Cambridge, UK). Irradiated mice were treated with oral 
antibiotics for 7 days (Bayrtil (2.5% enrofloxacin); Bayer). Mice were bled from the tail vein 
and full blood counts performed. 
 
3 months post-transplant, mice were culled by cervical dislocation, tibia and femurs removed 
and MKs cultured as per section 3.8. Chimerism was determined by western blot of purified 
MKs with primary antibodies against CRLF3 and GAPDH (table 3.4 and 3.13) and appropriate 
secondary antibodies (table 3.5 and 3.13) following the method described in section 3.10. 
 
3.20 Platelet surface receptor expression 
 
ACD (section 3.5) anticoagulated whole blood was diluted 1:10 with HBS (150mM sodium 
chloride, 5mM potassium chloride, 1mM magnesium sulphate, 10mM HEPES, pH 7.4) and 
incubated with antibodies against CD41, CD61, CD42a, CD42d, CD49b, GPVI, FITC IgG or PE IgG 
(table 3.7 and 3.13) individually for 20 minutes. Blood was then further diluted 1:10,000 in 
0.2% formyl saline (0.2% formalydehyde (Sigma-Aldrich), 0.85% sodium chloride) to fix 
platelets. Mean fluorescence intensity (MFI) was assessed by flow cytometry using a Gallios 
flow cytometer (Beckman Coulter) and Kaluza Analysis version 1.5a software. Staining of the 
antibodies was confirmed to be specific by gating against the appropriately labelled IgG 
isotype control. 
 
Antibody Clone Manufacturer  
PE Mouse anti-human CD42a ALMA.16 BD Pharmigen 
FITC Rat anti-mouse CD49b Sam.G4 Emfret Analytics 
FITC Rat anti-mouse GPVI JAQ1 Emfret Analytics 
FITC hamster anti-mouse CD61 2C9.G3 eBioscience 
PE hamster anti-mouse CD42d 1C2 eBioscience 
PE Rat anti-mouse IgG1, κ Isotype Control n/a BD Pharmigen 
FITC Rat anti-mouse IgG1, κ Isotype Control n/a BD Pharmigen 
Table 3.7 – Antibodies used for platelet surface receptor expression 
 




3.21 Platelet activation  
 
ACD (section 3.5) anticoagulated whole blood was diluted 1:10 with HBS (section 3.20) and 
incubated with fluorescently labelled antibodies against P-Selectin, fibrinogen and CD41 (table 
3.8 and 3.13) and either no agonist, EDTA, thrombin, Gly-Pro-Arg-Pro (GPRP), ADP (all Sigma-
Aldrich) or collagen related peptide (CRP; Department of Biochemistry, University of 
Cambridge) for 20 minutes. Blood was then further diluted 1:10,000 in 0.2% formyl saline 
(section 3.20) to fix platelets. P-Selectin surface expression on and fibrinogen binding to CD41+ 
events was assessed by flow cytometry using a Gallios flow cytometer and Kaluza Analysis 
version 1.5a software.  
 
Antibody Clone Manufacturer 
APC Rat anti-mouse CD41  MWReg30 eBioscience 
PE Rat anti-mouse P-selectin (CD62P) Wug.E9 Emfret analytics 
FITC Rabbit anti-human Fibrinogen polyclonal DakoCytomation 
Table 3.8 – Antibodies used for platelet activation 
 
3.22 Platelet spreading 
 
Washed platelets were resuspended in Tyrode’s buffer (section 3.7) at a concentration of 
1x105/µl and allowed to rest at 30oC for >30 minutes. 2mM Ca2+ and 0.01U/ml thrombin 
(Sigma-Aldrich) was added to the rested platelets, which were then immediately placed on a 
glass coverslip coated with 100ng/ml fibrinogen (Enzyme Research) and incubated at 37oC for 
45 minutes. Attached platelets were fixed to the coverslip using 10% neutral buffered formalin 
solution. Fixed platelets were stained for and imaged by confocal microscopy as per section 
3.24 with a fluorescently labelled F-actin probe (Alexa Flour 555 Phalloidin; Invitrogen). 
Average platelet area was determined by thresholding of F-actin expression using ImageJ 
software.  
 
3.23 In vitro Thrombus formation  
 
Channels of a Vena8 Fluoro+ Biochip (Cellix) were pre coated with HORM Collagen (Takeda) 
and subsequently blocked with Tyrode’s buffer (section 3.7) supplemented with 2mM Ca2+ 
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and 0.1% w/v bovine serum albumin (BSA; Sigma-Aldrich). Tyrode’s buffer supplemented with 
2mM Ca2+ was then flowed through the channel at 400µl/min to linearize the HORM collagen. 
Whole blood anticoagulated in heparin was then flowed at 40µl/min (1,000s-1) for 3 minutes. 
The channel was washed with Tyrode’s buffer supplemented with 2mM Ca2+ to remove 
unbound blood cells. Five images per channel were taken using an EVOS fl microscope and an 
AMG camera. The area of each thrombus was measured using ImageJ software.  
 
3.24 Platelet morphology  
 
Blood smears were created by pushing 5µL whole blood across a microscope slide and leaving 
to air dry overnight. Blood smears were then stained with Rapid Romanowsky staining kit (TCS 
biosciences) following the manufacturer’s instructions.  
 
To assess platelet morphology by confocal microscopy, blood smears were washed with 
50mM ammonium chloride to remove red cells, then remaining cells were permeabilised with 
PBS containing 0.1% w/v saponin and 0.2% w/v gelatin (both Sigma-Aldrich). Samples were 
incubated with primary antibodies against CD41 (Rat anti-mouse CD41, clone MWReg30; 
BioLegend) and von Willebrand Factor (vWF) (Rabbit anti-human von Willebrand Factor; 
DakoCytomation) in saponin-gelatin-PBS for 1 hour at room temperature. Samples were 
washed with saponin-gelatin-PBS before incubating with appropriate secondary antibodies 
(Alexa Flour 488 Goat anti-rat IgG or Alexa Flour 555 Goat anti-rabbit IgG; both Invitrogen) in 
saponin-gelatin-PBS for 1 hour at room temperature in the dark. Samples were again washed 
in saponin-gelatin-PBS before glass coverslips were mounted using hydromount (National 
Diagnostics) and images were acquired using a Leica Sp5 inverted confocal microscope with 
the 63x immersion-oil objective and the Leica LAS 2.1 software. 
 
3.25 Electron microscopy  
 
For transmission electron microscopy (TEM), washed platelets were resuspended in 0.85% 
sodium chloride (Sigma-Aldrich), diluted 1:1 with 0.4% glutaraldehyde in 0.1M sodium 
cacodylate pH 7.4 (gift from Cambridge Advanced Imaging Centre, University of Cambridge, 
Cambridge, UK) and incubated at room temperature for 2 hours. Platelets were then pelleted 
at 1,000g, resuspended in fixation buffer (2% glutaraldehyde, 2% formaldehyde, 0.05M 




sodium cacodylate, pH 7.4; gift from Cambridge Advanced Imaging Centre) and incubated at 
4oC for 4-6 hours. Fixed platelets were then processed by Jeremy Skepper (Cambridge 
Advanced Imaging Centre). Briefly, platelets were incubated serially in buffers containing 1% 
osmium tetroxide and 1.5% potassium ferricyanide, 1% thiocarbohydrazide, 2% osmium 
tetroxide and finally 2% uranyl acetate. Samples were then dehydrated in an ascending series 
of ethanol solutions from 50% to 100%, followed by treatment with dry acetonitrile and 
infiltration with Quetol epoxy resin. Sections were cut at 60nm using a diamond knife with a 
Leica UCT ultramicrotome. Sections were viewed using an FEI Tecnai G2 TEM and images 
captured with an AMT XR60B camera using Deben software.  
 
For scanning electron microscopy (SEM), washed platelets were resuspended in 0.85% sodium 
chloride, diluted 1:1 with 0.4% glutaraldehyde in 0.1M sodium cacodylate pH 7.4 and 
incubated at room temperature for 2 hours. Platelets were then pelleted at 1,000g, 
resuspended in fixation buffer (as above) and stored at 4oC until processed. Fixed platelets 
were then processed by Jeremy Skepper (Cambridge Advanced Imaging Centre). Briefly, 
platelets were rinsed in deionised water (DIW) and incubated in 1%  osmium ferricyanide for 
4 days, rinsed again in DIW and incubated in 2% uranyl acetate in 0.05M Maleate buffer (pH 
5.5) for 4 days at 4oC. Platelets were resuspended in DIW and attached to poly-L-lysine coated 
glass cover-slips for 30 minutes in a humid chamber so no air drying occurred. After 
unattached platelets were removed, samples were quench frozen in melting propane cooled 
in liquid nitrogen, then dried overnight in a Quorum K775 freeze dryer. The dry cover-slips 
were attached to 13mm Cambridge SEM stubs with colloidal silver DAG sputter coated with 
10 nm of iridium and viewed in an FEI Verios 460L using a secondary electron detector and 
images were recorded as tiff files. 
 
3.26 Platelet cytoskeleton at 37oC and 4oC 
 
Experiments were performed by Simon Stritt (University of Würzburg, Würzburg, Germany). 
Briefly, PRP was prepared and adjusted to 3x105 platelets/µL with Tyrode’s buffer (section 
3.7). PRP was incubated at 37oC or 4oC for 3 hours then attached to poly-L-lysine (Sigma-
Aldrich) coated coverslips and fixed with PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM 
EGTA, 2 mM magnesium chloride, pH 6.9) supplemented with 4% paraformaldehyde (PFA) 
and 1% IGEPAL CA-630 (both Sigma-Aldrich), stained with fluorescent antibodies against α-
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tubulin (Mouse anti-α-tubulin-Alexa 488, clone B-5-1-2; Invitrogen) and a fluorescently 
labelled F-actin probe (phalloidin-Atto647N; Attotec) and mounted with Fluoroshield 
(Sigma-Aldrich). Samples were visualised using a Leica TCS SP5 confocal microscope 
controlled by LAS AF software (Leica Microsystems).  
 
3.27 Cloning Crlf3 constructs into pGEX vector 
 
Crlf3 constructs (see section 6.4.1.1 and fig. 6.2 for details) were amplified from murine in 
vitro cultured MK cDNA by PCR using specific primers that include the BamHI or NotI 
restriction sites (table 3.9 and 3.12) and Platinum High Fidelity Taq Polymerase (Invitrogen) 
following manufacturer’s instructions. PCR products were resolved on a 1.5% agarose TAE 
(40mM Tris, 20mM acetic acid, 1mM EDTA) gel and specific bands extracted and purified using 
QIAquick Gel Extraction Kit and QIAquick PCR Purification Kit (both QIAGEN). Purified PCR 
products were digested for 1 hour at 37oC with NotI and BamHI (both New England Biolabs). 
Vector pGEX-6P-2 (GE Healthcare) was also digested with NotI and BamHI then resolved on a 
1.5% agarose TAE gel, the resulting open plasmid vector extracted and cleaned as above. The 
Crlf3 PCR fragments were subsequently ligated into the open pGEX-6P-2 vector using T4 Ligase 
(New England Biolabs) following manufacturer’s instructions (see fig. 6.1 for vector map). 
pGEX vectors containing Crlf3 constructs were transformed into BL21-CodonPlus™-(DE3)-RP 
competent E.coli cells (Stratagene) following manufacturer’s instructions.  
 







Table 3.9 – Primers used to amplify Crlf3 constructs 
 
3.28 Protein production  
 
Protein from Crlf3 constructs were produced as per Harper and Speicher Harper and Speicher 
(2008). Briefly, transformed BL21 cells were grown in 2xTY media at 37oC until OD600 reached 




≈0.8. 1mM isopropul-1-thio-β-D-galactopyranoside (IPTG; Sigma-Aldrich) was added and cells 
were incubated at 30oC for ≥5h. Pelleted cells were lysed in PBS supplemented with 1mg/mL 
lysozyme (Sigma-Aldrich), 10mM magnesium chloride, 10U/mL DNase I (Sigma-Aldrich) and 
1x Protease Inhibitor Cocktail (c0mplete Tablets EDTA-free; Roche). Lysed cells were spun at 
10,000rpm, 40min, 4oC and supernatant containing protein stored at -80oC until needed. 
 
3.29 Protein purification  
 
Glutathione-S-transferase (GST) was removed from CRLF3 constructs by affinity 
chromatography using GSTrap FF 5mL columns and PreScission Protease (both GE Healthcare), 
following manufacturer’s instructions. Remaining free GST was removed by ion exchange 
chromatography using HiTrap Q FF columns (GE Healthcare) following manufacturer’s 
instructions. 
 
3.30 Protein concentration  
 
Protein was concentrated under centrifugation using VivaSpin 2 columns with 10kDa cut off 
(Sartorius Stedim Biotech) following manufacturer’s instructions. Protein concentration was 
determined by Nanodrop or bicinchoninic acid (BCA) assay using Pierce® BCA Protein Assay 
Kit (both Thermo Scientific) following manufacturer’s instructions.   
 
3.31 Protein crystallisation 
 
Crystallisation was screened by the vapour diffusion method in 96-well sitting drop plates set 
up with a Nanodrop Screenmaker 96+8 (Innovadyne Technologies), using drops containing 
200nL protein and 200nL screening solution equilibrated with 70µL screening solution. Screen 
plates Structure Screen 1 and 2, PACT Premier, Stura Footprint Screen, MacroSol and JCSG-
Plus (all Molecular Dimensions), Wizard 1, 2, 3 and 4 and Cryo I and II (all Emerald BioSystems) 
and  PEG/Ion Screen and PEG/Ion 2 Screen (both Hampton Research) were used. Screen plates 
were kept at 20oC and imaged using a Rock Imager crystal screening system (Formulatrix). 
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3.32 Structural solution 
 
Structural solution was performed by Randy Read, Yahui Yan and Richard Mifsud (University 
of Cambridge, Cambridge, UK). Briefly, crystals from a range of conditions were picked for X-
ray diffraction and stored in 25% ethylene glycol (Hampton Research) as a cryopreservative. 
A number of crystals underwent heavy atom soaking before cryopreservation, which was 
optimised by soaking crystals with serial dilutions of the mercury heavy atom derivative 
thimerosal (Sigma-Aldrich) for various times. Diffraction data were recorded at Diamond Light 
Source beamline I04 (Didcot, UK). Diffraction data were indexed, integrated, and scaled using 
Mosflm (Leslie and Powell, 2007) and Aimless (Evans, 2011) via the xia2 automated data 
processing pipeline (Winter, 2010). The structure of CRLF3 construct 3 was determined by Hg-
SAD using AutoSol-wizard (Terwilliger et al., 2009) of the PHENIX suite (Adams et al., 2010) 
Further refinement was then performed using Phenix.refine (Adams et al., 2010) and by 
manual building in Coot (Emsley et al., 2010). Molecular graphics were prepared using PyMOL 
version 1.5.0.4 (https://www.pymol.org/). 
 
3.33 Maintenance and expansion of human induced pluripotent stem cells 
(iPSCs) 
 
Qolg iPSCs (HipSci line HPSI1113i-qolg_3 (http://www.hipsci.org)) were maintained as 
colonies on truncated vitronectin (VTN-N; Thermofisher Scientific) coated tissue culture 
plastic plates (Corning) in Essential 8 medium (E8; Gibco) unless stated. iPSCs were fed daily 
with fresh E8 after removal of old medium. Near confluent cultures were split to new VTN-N 
coated plates by dissociation of colonies into small clumps with 0.5mM EDTA in PBS and 
manual scraping After 24 hours, medium was removed and replaced with E8 and cells then 
fed daily as above. When iPSCs were needed in single cell solution for differentiation or 
electroporation experiments, colonies were dissociated with TrypLE (Life technologies), 
pelleted at 300g before resuspending in E8 medium supplemented with 10µM Y-27632 
(Sigma-Aldrich) to prevent apoptosis. 
 
 




3.34 Tandem Affinity Purification (TAP) tagging CRLF3 in human iPSCs by 
CRISPR/Cas9 
 
CRISPR ID 1146192702 was picked from www.sanger.ac.uk/htgt/wge (Hodgkins et al., 2015), 
due to its close proximity to CRLF3’s stop codon and having few predicted off target sites. 
Single-guide RNA (sgRNA) expression constructs were generated using the plasmid-based 
procedure as described by Ran et al. (2013). Briefly, sgRNA oligos were synthesised and cloned 
into the pSpCas9(BB)-2A-GFP plasmid (Adgene). This was used to transform Mix & GO E.Coli 
cells (Zymo Research), which were plated on LB agar plates supplemented with ampicillin and 
grown overnight at 37oC. Ampicillin resistant colonies were expanded in 2xTY media liquid 
cultures overnight at 37oC with shaking and sgRNA/Cas9-GFP plasmid DNA was prepared from 
liquid cultures using QIAprep® Spin Miniprep Kit (QIAGEN).  
 
For the donor vector (see section 6.4.2 and fig. 6.6 for details), 1Kb gDNA homology arms 
upstream and downstream of CRLF3’s stop codon and the TAP-tag were amplified by PCR 
using specific primers (table 3.10 and 3.12) and Platinum Taq DNA HiFi Polymerase 
(ThermoFisher Scientific) from iPSC gDNA and a plasmid containing the TAP-tag (gift from 
David Adams, Wellcome Trust Sanger Institue, Hinxton, UK), respectively. Vector pBS KS 
(Addgene) was linearized by PCR with specific primers (table 3.10 and 3.12) and Platinum Taq 
DNA HiFi Polymerase. Homology arms and the TAP-tag were then cloned into pBS KS by Gibson 
assembly using a commercial kit (Gibson Assembly Cloning Kit; New England Biosciences). 
Donor vector DNA was then transformed into XL-10 Gold ultra-competent E.coli (Straragene) 
following manufacturer’s instructions. Transformed E. coli were plated on LB agar plates 
supplemented with ampicillin and grown overnight at 37oC. Ampicillin resistant colonies were 
expanded in 2xTY media liquid cultures overnight at 37oC with shaking and TAP-tag donor 
vector DNA was prepared from liquid cultures using QIAprep® Spin Miniprep Kit. 
 
sgRNA/Cas9-GFP plasmid and TAP-tag donor vector DNA were introduced into Qolg iPSC’s in 
a single cell solution by nucleofection using Amaxa Human Stem Cell Nucleofector Kit 2 and 
an Amaxa Nucleofector II (both Lonza), following manufacturer’s instructions. 48 hours after 
nucleofection, cells were sorted based on GFP expression by flow assisted cell sorting (cell 
sorting performed by staff of the NIHR Cambridge BRC Cell Phenotyping Hub, University of 
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Cambridge, Cambridge, UK). GFP positive iPSCs were seeded individually to laminin 
(Biolamina) coated 96 well tissue culture plates and maintained in E8 medium supplemented 
with 100U/ml pen/strep for 5 days then E8 medium until needed.  
 















Table 3.10 – Primers used for creation of TAP-tag donor vector 
 
3.35 TOPO TA cloning to screen CRLF3 in iPSC lines 
 
CRLF3 was amplified from cDNA from iPSC lines BobC and Qolg (cDNA gifted by Amanda Evans, 
University of Cambridge, Cambridge UK) by PCR using specific primers (table 3.11 and 3.12) 
and Platinum Taq DNA HiFi Polymerase. PCR products were resolved by electrophoresis on 
0.8% agarose TBE (section 3.2) gels and specific bands cut out. DNA was extracted from gel 
using QIAquick gel extraction kit (Qiagen). CRLF3 fragments were cloned into TOPO vector and 
subsequently transformed into One Shot TOP 10 competent E. coli using TOPO TA cloning kit 
(ThermoFisher Scientific), following manufacturer’s instructions. Transformed E. coli were 
plated on LB agar plates supplemented with ampicillin and grown overnight at 37oC. Ampicillin 
resistant colonies were expanded in 2xTY media liquid cultures overnight at 37oC with shaking 
and TOPO vector DNA containing the inserted CRLF3 was prepared from liquid cultures using 
QIAprep® Spin Miniprep Kit.  
 
Primer Sequence (5'>3') 
CRLF3_TOPO_F GGAACCCGCGCTAGGTTTCG 
CRLF3_TOPO_R CATCTAAAACACTAACACTTTCCATCCAGGA 
Table 3.11 – Primers used for TOPO TA cloning 
 




3.36 TAP-tag expression in iPSCs by flow cytometry 
 
To screen for genetically modified iPSC clones, untagged and TAP-tagged iPSCs were detached 
from cultured plates with TrypLE and pelleted (section 3.33). Cells were then fixed and 
permeabilised using a commercial kit (FIX & PERM™ Cell Permeabilization Kit; Life 
Technologies) following manufacturer’s instructions and then incubated with fluorescently 
labelled antibodies against the TAP-tag (FITC anti-FLAG M2 produced in mouse, clone M2; 
Sigma-Aldrich) or an IgG control (FITC mouse IgG1 к isotype control; BD Pharmigen) . Stained 
samples were washed once in PBE (section 3.13) then resuspended in PBE and analysed by 
flow cytometry using a Gallios flow cytometer and Kaluza Analysis version 1.5a software. 
 
3.37 CRLF3 interactome in iPSCs 
 
9x106 iPSCs were dissociated to a single cell solution, washed 3 times in PBS then snap frozen 
and stored at -80oC until needed. Frozen pellets were then lysed in lysis buffer (10mM Tris 
hydrochloride, 150mM sodium chloride, 0.1% NP-40), centrifuged at 13,000rpm for 15 
minutes and lysates collected. Proteins interacting with TAP-tagged CRLF3 were then collected 
by incubating the lysates with magnetic beads (Dynal protein G; Invitrogen) coated with anti-
FLAG antibody (anti-FLAG M2 produced in mouse, clone M2; Sigma-Aldrich) before collecting 
the beads. Beads where then washed 3 times in lysis buffer and then twice in TEV buffer 
(10mM Tris hydrochloride, 150mM sodium chloride, 0.1% NP-40, 0.5mM EDTA, 1mM 
Dithiothreitol) to remove unbound proteins. Bead bound proteins were then dissociated by 
incubation with 100U AcTEV protease (Invitrogen) in TEV buffer before collection of the 
eluates. The eluates were then diluted in calmodulin binding buffer (CBB; 10mM Tris-HCl, 
150mM sodium chloride, 1mM magnesium acetate, 1mM Imidazole, 2mM calcium chloride, 
10mM β-mercaptoethanol, 0.1% NP-40) before interacting proteins were further purified by 
incubation of the diluted eluates with calmodulin binding peptide (CBP) affinity resin (Agilent), 
pelleting and removal of the supernatant. CBP resin was then washed 3 times with CBB before 
incubation in calmodulin elution buffer (10mM Tris-HCl, 150mM sodium chloride, 0.02% NP-
40, 1mM magnesium acetate, 1mM Imidazole, 20mM EGTA, 10mM β-mercaptoethanol) to 
dissociate bound proteins, which were collected in the eluates after pelleting of the CBP resin. 
The eluates were then snap frozen and stored at -80oC until mass spectrometry was 
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performed. Mass spectrometry and LC-MS/MS analysis was performed by Renata Feret, 
Marco Chiapello and Mike Deery (Cambridge Centre for Proteomics, University of Cambridge, 
Cambridge, UK). Briefly, samples were mixed with SDS loading buffer and run on 12% SDS 
PAGE gel in order to remove MS incompatible detergents. Samples were only run till a dye 
front was about 2cm below the well.  Gel was stained with coomassie blue colloidal stain and 
each lane cut into 4 equal pieces.  Each piece was finely chopped and transferred to 0.5ml 
Eppendorf tube and was treated as individual MS sample.  The gel pieces were distained by 
washing with 50% acetonitrile, 50% ammonium bicarbonate followed by wash with HPLC 
water. Distained samples were then treated with 100% acetonitrile, air dried and reduced with 
10mM DTT in 100mM ammonium bicarbonate for 1 hour at 37OC.  The DTT solution was 
removed and replaced with 55mM iodoacetamide in 100mM ammonium bicarbonate and 
incubated for 45 minutes at RT in darkness.  Samples were then washed with 50% ammonium 
bicarbonate, 50% acetonitrile followed by addition of 100% acetonitrile.  Acetonitrile was 
removed and samples dried again, before resuspending in a 1:200 solution of trypsin in 50mM 




Post-trypsin digestion, the supernatant was pipetted into a sample vial and loaded onto an 
autosampler for automated LC-MS/MS analysis. 
 
All LC-MS/MS experiments were performed using a Dionex Ultimate 3000 RSLC nanoUPLC 
system and a Q Exactive Orbitrap mass spectrometer (both Thermo Fisher Scientific). 
Separation of peptides was performed by reverse-phase chromatography at a flow rate of 
300nL/min and a Thermo Scientific reverse-phase nano Easy-spray column (Thermo Scientific 
PepMap C18, 2µm particle size, 100Å pore size, 75nm i.d. x 50cm length). Peptides were 
loaded onto a pre-column (Thermo Scientific PepMap 100 C18, 5µm particle size, 100Å pore 
size, 300nm i.d. x 5mm length) from the Ultimate 3000 autosampler with 0.1% formic acid for 
3 minutes at a flow rate of 10nL/min. After this period, the column valve was switched to allow 
elution of peptides from the pre-column onto the analytical column. Solvent A was water + 
0.1% formic acid and solvent B was 80% acetonitrile, 20% water + 0.1% formic acid. The linear 
gradient employed was 2-40% B in 30 minutes. 
 




The LC eluent was sprayed into the mass spectrometer by means of an Easy-Spray source 
(ThermoFisher Scientific). All m/z values of eluting ions were measured in an Orbitrap mass 
analyzer, set at a resolution of 70000 and was scanned between m/z 380-1500. Data 
dependent scans (Top 20) were employed to automatically isolate and generate fragment ions 
by higher energy collisional dissociation (HCD, NCE:25%) in the HCD collision cell and 
measurement of the resulting fragment ions was performed in the Orbitrap analyser, set at a 
resolution of 17500.  Singly charged ions and ions with unassigned charge states were 
excluded from being selected for MS/MS and a dynamic exclusion window of 20 seconds was 
employed. 
 
Post-run, the data was processed using Protein Discoverer (version 2.1., Thermo Scientific).  
Briefly, all MS/MS data were converted to mgf files and the files were then submitted to the 
Mascot search algorithm (Matrix Science) and searched against the UniProt human database 
(UniProt_Human201701 201701, 70956 sequences; 23911858 residues) and a common 
contaminant sequences (115 sequences, 38274  residues).  Variable modifications of oxidation 
(M), deamidation (NQ) and carbamidomethyl were applied. The peptide and fragment mass 
tolerances were set to 5ppm and 0.1 Da, respectively. A significance threshold value of p<0.05 
and a peptide cut-off score of 20 were also applied. 
  
3.38 Forward programming  
 
Forward programming of iPSCs to MKs was carried out following the method of Moreau et al. 
(2016). Briefly, near confluent (50-80%) untagged and TAP-tagged iPSC cultures were 
dissociated to single cells and seeded onto vitronectin coated 6 well tissue culture plates at 
125,000 cells per well. After 24 hours, cells were washed once with PBS then transduced with 
GATA1, FLI1 and TAL1 lentiviral vectors (MOI 20, Vectalys) suspended in transduction medium 
(AE6 media (DMEM/F12 (Gibco), 0.05% sodium bicarbonate (Gibco), 64mg/L L-Ascorbic acid 
(Sigma), 20mg/L Insulin, 11mg/L Transferrin, 13.4μg/L Selenium (all ThermoFisher Scientific)) 
supplemented with 20ng/ml FGF2, 10ng/ml BMP4 (both Bio-Techne) and 10µg/ml protamine 
sulphate (Sigma-Aldrich)). 24 hours after transduction, the medium was removed, cells were 
washed with PBS and mesoderm media was added (AE6 media supplemented with 20ng/ml 
FGF2 and 10ng/ml BMP4). 24 hours later, mesoderm medium was removed, cells were 
washed in PBS and MK medium (CellGRO SCGM (CellGenix) supplemented with 20ng/ml TPO 
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(Bio-Techne) and 50ng/ml SCF (Gibco)) was added. 9 days after transduction, cells were split 
using TrypLE and further maintained as suspension cultures in MK medium up to 25 days post 
transduction.  
 
3.39 Localisation of CRLF3 in proplatelet forming forward programmed MKs 
 
Forward programmed MKs were pelleted and resuspended in RPMI (Gibco). 1.5x105 MKs were 
seeded onto glass coverslips coated with 100ng/ml fibrinogen (Enzyme Research) and 
incubated at 37oC under 5% CO2 for 24-48 hours until proplatelets were observed. MKs 
attached to the coverslips were fixed with 10% neutral buffered formalin and washed in PBS. 
Fixed MKs were stained for and imaged by confocal microscopy as per section 3.24 with 
primary antibodies against the TAP-tag (anti-FLAG M2 produced in mouse, clone M2; Sigma-
Aldrich) and appropriate secondary antibodies (Alexa Flour 488 Goat anti-mouse IgG; 




Statistical significance between 2 experimental groups was analysed using an unpaired 2-
tailed Student’s t test with correction for multiple comparisons using the Holm-Sidak method 
where appropriate or a two-way analysis of variance (ANOVA) using Tukey’s or Sidak’s 
correction for multiple comparisons (as stated). When more than 2 experimental groups were 
compared, data were analysed using a one- or two-way ANOVA using Tukey’s correction for 
multiple comparisons (Prism 7; GraphPad Software). P values less than 0.05 were considered 














Primer Sequence (5'>3') 
Section referred 
to in 
Crlf3_F TGGATACATTGATTAGCTTGACAGA 3.2 and 4.4.1 
Crlf3_R AGGGGATGAGAGGGTCTTCAG 3.2 and 4.4.1 
Cassette_R TCGTGGTATCGTTATGCGCC 3.2 and 4.4.1 
Crlf3_F_qPCR GGGTGTTCTCTACTCCAGCG 3.9 
Crlf3_R_qPCR GCCATTCTGCCTTTCTGCAC 3.9 
Gapdh_F_qPCR CCCTTAAGAGGGATGCTGCC 3.9 
Gapdh_R_qPCR TACGGCCAAATCCGTTCACA 3.9 
CRLF3_1_BamHI
_F ATACTGGGATCCATGAAGGGCGATGGAGCCG 3.27 and 6.4.1 
CRLF3_17_BamH
I_F AAAAGGATCCGCCCGCGAGAACGTGGAG 3.27 and 6.4.1 
CRLF3_34_BamH
I_F AAAAGGATCCCGGGAGGCGCAGAGGCA 3.27 and 6.4.1 
CRLF3_174_Bam
HI_F AAAAGGATCCCATGGAACAGTAGCTTCCCGC 3.27 and 6.4.1 
CRLF3_173_NotI
_R CCCCGCGGCCGCTCACTTAAAAATGTGGTCTTTCACTATGT 3.27 and 6.4.1 
CRLF3_442_NotI
_R GCGGCCGCTTACTAAAATACC 3.27 and 6.4.1 
M13_F GTAAAACGACGGCCAG 6.4.2 

















Vector_F TTTCATATGTATGTAATATGATCAAGCTTATCGATACCGTCGAC 3.34 
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Vector_R CCCAGCCAACACCACAAAATGGGATCCACTAGTTCTAGAGCGG 3.34 
TAP_tag_F GATGGAAAGTGTTAGTGTTTGGAAGCATGGAGAAGAGGCG 3.34 
TAP_tag_R CAGCTACGTTAGACCCTGAACTTGTCGTCATCGTCTTTGTAGTCA 3.34 
iPSC_DV_Seq_T
AP_F GGAAGCATGGAGAAGAGGC 6.4.2 
iPSC_DV_Seq_3'
HA_R CATATTACATACATATGAAATGGCTAACACTG 6.4.2 
CRLF3_TOPO_F GGAACCCGCGCTAGGTTTCG 3.35 and 6.4.2 
CRLF3_TOPO_R CATCTAAAACACTAACACTTTCCATCCAGGA 3.35 and 6.4.2 
 Table 3.12 – List of all primers used  
  




Antibody Clone Manufacturer Section 
used in 
Dilution/   
concentration 
Biotin Rat anti-mouse 
CD11b  
M1/70 eBioscience 3.8 1:250 
Rat anti-mouse Ly-6G (Gr-1)  RB6-8C5 eBioscience 3.8 1:250 
Rat anti-mouse CD16/CD32 2.4G2 BD Pharmigen 3.8 1:250 
Biotin Rat anti-mouse 
CD45R/B220 
RA3-6B2 BD Pharmigen 3.8 1:250 
anti-β-actin produced in 
mouse 
AC-15 Sigma-Aldrich 3.10 1:1,000 
Rabbit anti-human CRLF3 polyclonal Atlas antibodies 3.10 1:1,000 
Rabbit anti-human GAPDH 14C10 Cell Signalling 
Technology 
3.10 1:1,000 
HRP Sheep anti-mouse IgG n/a GE Healthcare 3.10 1:10,000 
HRP donkey anti-rabbit IgG n/a GE Healthcare 3.10 1:10,000 
anti-Detyrosinated tubulin 
produced in rabbit 
polyclonal Millipore 3.10 1:1,000 
anti- tyrosine tubulin 
produced in mouse 
TUB-1 A2 Sigma-Aldrich 3.10 1:1,000 
Biotinylad Ricinus 





Rabbit anti-human Integrin 
beta 1 
polyclonal Abcam 3.10 1:1,000 
Streptavidin HRP n/a Cell Signalling 
Technology 
3.10 1:10,000 
IRDye 800CW Donkey anti-
rabbit IgG 
n/a LI-COR 3.10 1:15,000 
IRDye 800CW Goat anti-
mouse IgG 
n/a LI-COR 3.10 1:15,000 
IRDye 680LT Goat anti-
rabbit IgG 
n/a LI-COR 3.10 1:15,000 
IRDye 680LT Donkey anti-
mouse IgG 
n/a LI-COR 3.10 1:15,000 




Rat anti-mouse CD41 MWReg30 BioLegend 3.14, 
3.24 
1:200 
Alexa Flour 488 Goat anti-
rat IgG 
n/a Invitrogen 3.14, 
3.24 
1:1,000 
Alexa Fluor 594 Rat anti-
mouse CD105 
MJ7/18 BioLegend 3.15 0.4 µg/g 
Alexa Flour 488 Rat anti-
mouse GPIX 
Xia.B4 Emfret Analytics 3.15 0.6 μg/g 
APC Streptavidin n/a BD Pharmigen 3.16 1:100 
PE Rat anti-mouse TER-119 TER-119 BD Pharmigen 3.16 1:50 
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FITC Rat anti-mouse GPV DOM2 Emfret Analytics 3.17, 
3.18 
1:10 
PE Rat anti-mouse 
GPIIb/IIIa 
Leo.F2 Emfret Analytics 3.17, 
3.18 
1:10 
PE Rat anti-mouse 
GPIIb/IIIa 
JON/A Emfret Analytics 3.18 1:10 
FITC rat anti-mouse CD62P Wug.E9 Emfret Analytics 3.18 1:10 
PE Mouse anti-human 
CD42a 
ALMA.16 BD Pharmigen 3.20 1:25 
FITC Rat anti-mouse CD49b Sam.G4 Emfret Analytics 3.20 1:25 
FITC Rat anti-mouse GPVI JAQ1 Emfret Analytics 3.20 1:25 
FITC hamster anti-mouse 
CD61 
2C9.G3 eBioscience 3.20 1:25 
PE hamster anti-mouse 
CD42d 
1C2 eBioscience 3.20 1:25 
PE Rat anti-mouse IgG1, κ 
Isotype Control 
n/a BD Pharmigen 3.20 1:25 
FITC Rat anti-mouse IgG1, κ 
Isotype Control 
n/a BD Pharmigen 3.20, 
3.36 
1:25 
APC Rat anti-mouse CD41  MWReg30 eBioscience 3.21 1:25 
PE Rat anti-mouse P-
selectin (CD62P) 
Wug.E9 Emfret analytics 3.21 1:10 
FITC Rabbit anti-human 
Fibrinogen 
polyclonal DakoCytomation 3.21 1:25 
Rabbit anti-human von 
Willebrand Factor 
polyclonal DakoCytomation 3.24 1:50 
Alexa Flour 555 Goat anti-
rabbit IgG 
n/a Invitrogen 3.24 1:1,000 
Mouse anti-α-tubulin-Alexa 
488  
B-5-1-2 Invitrogen 3.26 1:150 
FITC anti-FLAG M2 
produced in mouse 
M2 Sigma-Aldrich 3.36 1:25 
anti-FLAG M2 produced in 
mouse 
M2 Sigma-Aldrich 3.37, 
3.39 
1:10, 1:200 
Alexa Flour 488 Goat anti-
mouse IgG 
n/a Invitrogen 3.39 1:1,000 
 Table 3.13 – List of all antibodies used  
 
  






Phenotyping of Crlf3-/- mice 
and biological mechanisms for 
thrombocytopenia 
  




4.1.1 Cytokine receptor-like factor 3 
 
Cytokine receptor-like factor 3 (CRLF3) also known as CYTOR4, CREME9, FRWS, P48 and P48.2 
is a 2.4kb gene locate in the neurofibromatosis type 1 (NF1) microdeletion region on the q 
arm of chromosome 17 (chromosome 11 in mice). The NF1 microdeletion region encompasses 
13 genes (CRLF3, C17orf41, C17orf42, CENTA2, RNF135, OMG, EVI2B, EVI2A, RAB11FIP4, 
C17orf79, UTP6, SUZ12 and LRRC37B) and mutations in this region cause NF1 (5-10% of cases 
are due to deletions). NF1 is a common genetic condition with an incidence rate of 1:3,000, 
which causes tumors to grow along the nervous system (neurofibromas) along with a 
multitude of other symptoms. Individuals with deletions are more likely to have facial 
dysmorphism, learning disability, congenital heart defects and high numbers of 
neurofibromas (Douglas et al., 2007). 
 
CRLF3 is ubiquitously expressed throughout the haematopoietic system (fig 4.1). CRLF3 has 
two protein coding isoforms, the longer of which contains 442 amino acids and a shorter 
transcript containing 118 amino acids. In mice the longer isoform contains 442 amino acids is 
93% homologous to the human longer isoform. The shorter isoform contains 334 amino acid 
and is missing exon 7 of longer transcript. However, expression within the haematopoietic 
system is almost exclusive to the longer transcript (fig. 4.2) (Chen et al., 2014). CRLF3 has been 
shown to be localised mainly in the cytoplasm of cell lines. This localisation of CRLF3 was 
deciphered by transfection of labelled CRLF3 into a range of human and monkey cell lines 
(Yang et al., 2009). 
 
Very little is known about the function of CRLF3. To date there has only been one published 
peer-reviewed journal article on mammalian CRLF3, which implicated CRLF3 as a potential 
negative regulator of cell cycle at the G0/G1 phase (Yang et al., 2009). Overexpression of CRLF3 
in the human cell line HEK293T caused G0/G1 arrest with fewer cells entering S phase. This 
cell cycle arrest was mediated by increased phosphorylation of STAT3 leading to upregulation 
of cyclin D1, cyclin D3 and p27. Conversely, repressing CRLF3 expression with specific small 
interfering RNA reduced the G0/G1 cell population. CRLF3’s full interactome is yet to be 
discovered, however, CRLF3 has been shown to interact with DOCK6, DOCK7 DOCK8, LRCH1, 
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LRCH2 and LRCH3 (Couzens et al., 2013). DOCK6, 7 and 8 are atypical guanine exchange factors 
for the cytoskeletal-associated guanosine triphosphate Rac. LRCH family proteins contain a 
calponin homology domain that mediates interactions with actin filaments.  
 
 
Figure 4.1 – CRLF3 expression in haematopoietic cells. CRLF3 (blue) is expressed throughout the haematopoietic 
system, whereas GP6 (green) expression is limited mainly to MKs. Thickness of line represents level of expression. 
HSC = haematopoietic stem cell; MPP = multi-potent progenitor CMP = common myeloid progenitor; CLP = 
common lymphoid progenitor; GMP = granulocyte-macrophage progenitor; MEP = megakaryocyte/erythrocyte 
progenitor; EB = erythroblast and MK = megakaryocyte. Data from Chen et al. (2014). 
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Figure 4.2– Expression of CRLF3 transcripts in the haematopoietic system. HSC = haematopoietic stem cell; MPP 
= multi-potent progenitor CMP = common myeloid progenitor; CLP = common lymphoid progenitor; GMP = 
granulocyte-macrophage progenitor; MEP = megakaryocyte/erythrocyte progenitor; EB = erythroblast and MK = 
megakaryocyte. Data from Chen et al. (2014).  
 
4.1.2 Crlf3 knockout mice 
 
An international collaborative consortium (International Mouse Phenotyping Consortium, 
www.mousephenotype.org) was established to knockout each gene in the mouse genome 
individually and phenotype any effect in the mouse progeny. As part of this consortium, the 
Wellcome Trust Sanger Institute (Hinxton, UK) developed a Crlf3 knockout mouse 
(Crlf3tm1b(KOMP)Wtsi, see section 3.1 for details). Pipeline phenotyping of 9-16 week old mice 
revealed effects limited to the blood system. Circulating magnesium levels were decreased 
(p=6.164x10-5), however both male (2.23 mg/dl) and female (2.46 mg/dl) Crlf3-/- magnesium 
levels were within the normal range of 2.20-2.67mg/dl 
(https://www.mousephenotype.org/data/); suggesting biological effects of this decrease 
would be minimal. Mean corpuscular volume (MCV), which is a measure of the average 
volume of a red blood cell, was also decreased (p=0.023 females and 1.321x10-7 males). Again 
both male (48.9 fl) and female (49.1 fl) Crlf3-/- MCV were within the normal range (48.8-50.6 
fl) suggesting a minimal biological effect. Finally, Crlf3-/- mice had thrombocytopenia with 
platelet counts decreased 30-40% compared to WT controls (p=9.969x10-11). The average 
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platelet counts for both males (960x106/ml) and females (742x106/ml) was outside of the 
normal range of 1058 – 1481 suggesting Crlf3 has a real biological influence on platelet 
numbers.  
 
Chronic thrombocytopenia generally results from either decreased platelet production or 
increased platelet destruction. Decreased platelet production is evident in patients with 
TUBB1-, TPM4- and DIAPH1-related thrombocytopenias. In the case of these particular genes, 
proplatelet formation has been shown to be impaired in vitro (Kunishima et al., 2014; Pleines 
et al., 2017; Stritt et al., 2016). In the case of TPM4, platelet lifespan was shown to be 
unaffected in Tpm4 mutated mice (Pleines et al., 2017). 
 
Increased platelet clearance is seen in FLNA-related thrombocytopenia. Begonja et al, 
demonstrated that mice with conditional inactivation of Flna in the MK lineage had 
upregulated megakaryopoiesis and thrombopoiesis, with normal proplatelet formation, 
showing platelet formation was unaffected. However, platelet clearance was rapidly increased 
in these mice mediated by macrophages (Begonja et al., 2011). 
 
However, this over simplified generalisation is not always true. In some chronic 
thrombocytopenias, both increased platelet destruction and decreased platelet production 
occur together. For example, it is likely that patients with Wilkott-Aldrich syndrome (WAS) 
experience increased destruction and decreased production of platelets. Knockout mice of 
two proteins implicated in the development of WAS, namely, profilin 1 (Pfn1-/-) and WASp 
(WASp-/-) have decreased platelet lifespans (Bender et al., 2014; Falet et al., 2009), showing 
increased platelet destruction. In the case of Pfn1-/- this platelet clearance was mediated by 
macrophages. Both Pfn1-/- and WASp-/- mice show aberrant proplatelet formation and platelet 
release into the bone marrow space (Bender et al., 2014; Sabri et al., 2006), suggesting that 
platelet production is also affected.  
 
This dual effect on platelets is also seen in patients with idiopathic or immune 
thrombocytopenic purpura (ITP). ITP can be acute, often following an infection, or chronic and 
causes a characteristic purpuric rash and increases the tendency to bleed. Platelet destruction 
is mediated by the production of IgG autoantibodies against platelet specific glycoproteins 
(usually GPIIb-IIIa and Ib-IX). Platelets bound with autoantibodies are phagocytosed by the 
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mononuclear phagocyte system primarily in the spleen but also in the liver and bone marrow. 
There is also evidence that the autoantibodies affect the production of MKs and platelets, thus 
contributing to the thrombocytopenia by decreasing platelet production (Cooper and Bussel, 
2006). 
 
4.2 Chapter hypotheses and aims 
 
We hypothesise that ablation of Crlf3 will cause isolated and maintained thrombocytopenia 
in mice. We hypothesise that the thrombocytopenia is likely caused by excessive removal of 
platelets by the spleen. Therefore, there are two main aims of this chapter, firstly, to 
determine whether ablation of Crlf3 results in long term sustained and isolated 
thrombocytopenia. The second aim is to determine the biological consequences of Crlf3 
ablation that result in thrombocytopenia. 
 
4.3 Chapter overview 
 
Firstly, this chapter will show that ablation of Crlf3 in mice results in sustained isolated 
thrombocytopenia. Secondly, we go on to show that Crlf3-/- mice have upregulated 
megakaryopoiesis and proplatelet formation both in vitro and in vivo. However, we show 
terminal maturation of preplatelets in the peripheral circulation is defective possibly due to 
increased microtubule stability. Finally, we show that rapid removal of a proportion of 




4.4.1 Confirmation of genotype 
 
We received Crlf3 heterozygous (Crlf3+/-) mice from the Wellcome Trust Sanger Institute, in 
which a LacZ-neo cassette is inserted into Crlf3 and exon 2 is excised. These mice were bred 
together to produce Crlf3-/-, Crlf3+/- and Crlf3+/+ (WT) mice. This thesis chapter will only concern 
Crlf3-/- and WT mice. Firstly, we wanted to confirm the genotype of the mice. DNA isolated 
from ear notches taken for identification were used in PCR reactions with specific primers 
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(table 3.1 and 3.12). The PCR was designed to amplify both a 281bp portion of Crlf3 that is 
only present on unaffected alleles and a 159bp that incorporates the inserted cassette and 
therefore will only be amplified if a mutated allele is present. Crlf3-/- and WT mice were easily 
identified based on the presence or absence of the 281bp and 159bp bands (fig. 4.3A). We 
then wanted to confirm the ablation of Crlf3 from the cells of interest, MKs and platelets. 
Messenger RNA from in vitro cultured MKs is almost completely ablated in Crlf3-/- mice (fig. 
4.3B). Finally, we checked for the presence of CRLF3 from in vitro cultured MKs (fig. 4.3C) and 
platelets isolated from whole blood (fig. 4.3D) by western blot. Crlf3-/- mice have minimal 
expression, or complete absence, of CRLF3 in MKs and platelets.  
 
 
Figure 4.3 – Genotyping of Crlf3-/- and WT mice. (A) Genomic DNA amplified by PCR using specific primers, 
resolved on a 1.5% agarose TBE gel to determine DNA fragment size. (B) Expression of Crlf3 relative to Gapdh 
determined by Q-PCR of WT (black) and Crlf3-/- (grey) cDNA isolated from in vitro cultured MKs. Western blot of 
in vitro cultured MK (C) and platelet (D) lysates using specific antibodies against CRLF3, β-actin and GAPDH.  
 
4.4.2 Sustained and isolated thrombocytopenia 
 
To determine the effect of Crlf3 ablation on blood cells during aging, Crlf3-/- and WT mice were 
bled from the tail vein or inferior vena cava into EDTA at young (12-20 weeks), middle 
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 (21-40 weeks) and old (>52 weeks) age time points. Full blood counts were determined using 
an automated haemocytometer. In essence, the 12-20 week time point should recapitulate 
the results of the pipeline phenotyping done by the Wellcome Trust Sanger Institute. Indeed, 
platelet counts are reduced 38.5% in males and 38.6% in females (p<0.005 in both cases) (fig. 
4.4 and table 4.1). However, MCV was unaffected in both male and female Crlf3-/- mice 
(p=0.999 for both sexes; data not shown).  
 
  
Table 4.1 – Effect of Crlf3 ablation on blood lineages at different mice ages. Full blood counts determined by an 
automated haemocytometer on EDTA anticoagulated venous blood taken from male and female young (12-20 
weeks), middle aged (21-40 weeks) and old (>52 weeks) mice. Data represents mean (SD). Unpaired 2-tailed 
Student’s t test with correction for multiple comparisons using the Holm-Sidak method. *** denotes p<0.005.  
 




Figure 4.4 – Sustained thrombocytopenia in Crlf3-/- mice. Platelet counts determined by an automated 
haemocytometer on EDTA anticoagulated venous blood taken from male (n=5-23) and female (n=5-15) young 
(12-20 weeks), middle aged (21-40 weeks) and old (>52 weeks) mice. Unpaired 2-tailed Student’s t test with 
correction for multiple comparisons using the Holm-Sidak method. *** denotes p<0.005. 
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4.4.3 Platelet production is unaffected 
 
As previously mentioned in section 4.1.2, chronic thrombocytopenia is either a result of 
increased platelet clearance, decreased platelet production or a combination of both. To 
determine if ablation of Crlf3 results in decreased platelet production, we firstly determined 
whether megakaryopoiesis and thrombopoiesis were affected in Crlf3-/- mice. 
Megakaryopoiesis was assessed by counting the number of bone marrow residing MKs in fixed 
bone samples. Unexpectedly, MK numbers are increased in Crlf3-/- mice compared to WT 
controls (MKs per high power field at 12 months of age 12.65 ± 1.03 Crlf3-/- vs 8.90 ± 2.51 WT, 
p=0.021, fig. 4.5). The main driver of megakaryopoiesis is the cytokine TPO. Therefore, we 
assessed the plasma concentration of TPO using a commercially available ELISA kit 
(experiments performed by José Guerrero, University of Cambridge, Cambridge, UK). The 
plasma TPO concentration was unaltered in Crlf3-/- mice compared to WT controls (201.3 ± 
56.1 pg/ml Crlf3-/- vs 253.3 ± 136.3 pg/ml, p=0.448; fig. 4.6), suggesting that increased 
megakaryopoiesis is not due to increased TPO levels. We then assessed whether bone marrow 
residing MK precursor cells from Crlf3-/- animals are intrinsically primed to become MKs. To 
test this, Crlf3-/- or WT bone marrow cells were cultured in culture medium supplemented with 
5ng/ml TPO for 5 days, after which the percentage of CD41 positive cells was assessed by flow 
cytometry. Interestingly, cultures from Crlf3-/- bone marrow cells produced a significantly 
larger percentage of CD41 positive cells compared to cultures from control WT bone marrow 
cells (fig. 4.7). This suggests that MK progenitor cells are intrinsically primed towards the MK 
lineage in Crlf3-/- mice.  
 
Next, we wanted to determine whether ablation of Crlf3 has an effect on MK maturation. One 
feature of MK maturation is polyploidisation. In vitro cultured MKs were fixed and stained with 
propidium iodide and assessed for ploidy level by flow cytometry. We observed no differences 
in the level of polyploidy in MKs cultured from Crlf3-/- bone marrow compared to control 
cultured WT MKs (fig. 4.8); suggesting that Crlf3 does not influence maturation of MKs. 
 
Platelets are mainly produced in the bone marrow from cytoplasmic protrusions produced by 
MKs (proplatelets). Therefore, we wanted to check whether the ability of MKs to produce 
proplatelets, and therefore platelets, was effected by ablation of Crlf3. Mature in vitro 
cultured MKs were purified by BSA gradient and seeded onto fibrinogen coated coverslips, 
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then incubated at 37oC for 3 or 5 hours to produce proplatelets. As can be seen in figure 4.9 
Crlf3-/- MKs are able to produce proplatelets that are similar in appearance to WT MKs. 
Although at 3 hours there is no difference in proplatelet formation between Crlf3-/- and WT 
MKs (373/1111 Crlf3-/- MKs imaged v 263/911 WT; p=0.290; fig. 4.9), fragmentation of 
proplatelets appears to be upregulated in Crlf3-/- MKs. Indeed, between 3 and 5 hours in WT 
MKs, proplatelet formation appears to be increasing with a trend towards increased MKs 
forming proplatelets at 5 hours (p=0.088; fig. 4.9), but the total number of MKs is relatively 
unchanged (882 total MKs imaged v 911 MKs at 3 hours). Conversely, in Crlf3-/- MKs the trend 
is towards decreased MKs forming proplatelets at 5 hours (p=0.120; fig. 4.9), probably due to 
the most mature Crlf3-/- MKs being completely fragmented by this time point, leaving only less 
mature MKs to be counted. This is evident as the total number of MKs imaged at the 5 hours 
is dramatically reduced in the Crlf3-/- samples (464 total MKs imaged v 1111 MKs at 3 hours). 
Proplatelet formation is increased in WT MKs compared to Crlf3-/- MKs at 5 hours (123/464 
Crlf3-/- MKs analysed v 459/882 WT; p=0.035; fig. 4.9) further suggesting that proplatelet 
formation is increasing from 3 to 5 hours in WT MKs but decreasing in Crlf3-/- MKs. 
 
Proplatelet formation was also studied in vivo using two-photon intravital microscopy of the 
bone marrow. MKs from Crlf3-/- mice produced proplatelets into the bone marrow sinusoids 
similarly to that of MKs from WT mice (supplementary video 1 and 2) (in vivo proplatelet 
formation experiments performed by Ayesha Baig, University of Würzburg, Würzburg, 
Germany). Taken together, these data suggest that platelet production is not impaired in Crlf3-
/- mice and decreased platelet production is not the reason for the observed 
thrombocytopenia.   
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Figure 4.5 – Megakaryopoiesis is upregulated in Crlf3-/- mice. H&E staining performed on fixed and sectioned 
mice tibias. MKs quantified blinded by manual counting for WT (black) and Crlf3-/- (grey) images (high power field 
(HPF)). Images are representative of 12 month old Crlf3-/- and WT mice and white arrow heads point to MKs. 
Scale bars are 50μm. Data represents mean ± SD (n=3-6). Unpaired 2-tailed Student’s t test with correction for 
multiple comparisons using the Holm-Sidak method. * denotes p<0.05. 




Figure 4.6 – Plasma TPO levels are unaltered in Crlf3-/- mice. Plasma thrombopoietin (TPO) concentration 
determined by ELISA for WT (black) and Crlf3-/- (grey) mice. Data represents mean ± SD (n=5-6). Unpaired 2-
tailed Student’s t test. 
 
 
Figure 4.7 –  Crlf3-/- progenitors are primed to form MKs. Flow cytometry analysis of CD41+ WT (black) and Crlf3-
/- (grey) cells after culture of bone marrow cells for 5 days in defined conditions using specific antibodies against 
CD41. Data represents mean ± SD (n= 3). Unpaired 2-tailed Student’s t test; * denotes p<0.05. 
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Figure 4.8 MK polyploidisation is unaffected by ablation of Crlf3.  In vitro cultured WT (black) and Crlf3-/- (grey) 
MKs fixed and stained with propidium iodide and analysed by flow cytometry using specific antibodies against 
CD41 to assess polyploidisation. Ploidy profiles are representative of 5 mice per genotype. Data represents mean 
± SD (n=5). Unpaired 2-tailed Student’s t test with correction for multiple comparisons using the Holm-Sidak 
method. 




Figure 4.9 Proplatelet fragmentation occurs faster in Crlf3-/- MKs. In vitro cultured MKs were seeded onto 
fibrinogen coated coverslips and incubated at 37oC for 3 or 5 hours to induce proplatelet formation. Samples 
were fixed, stained with specific antibodies against CD41 (green), a fluorescently labelled F-actin probe (red) and 
the nuclear stain DAPI (blue), and imaged by confocal microscopy. Percentage of proplatelet forming MKs was 
determined for WT and Crlf3-/- MKs as the percentage of proplatelet forming MKs compared to total number of 
MKs per image. At least 460 MKs were counted in each condition. Images are representative of 5 images taken 
for 3 mice per genotype. Scale bars are 50μm. Data represents mean ± SD (n=3). Two-way ANOVA with Tukey’s 
correction for multiple comparisons. * denotes p<0.05.  
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4.4.4 Increased platelet clearance in Crlf3-/- mice causes thrombocytopenia 
 
As decreased platelet production was not the cause of the thrombocytopenia in Crlf3-/- mice, 
we next looked at platelet clearance. First we assessed platelet survival in vivo by injecting 
biotin into the bloodstream, thus labelling all blood cells. The removal of biotin bound 
platelets over time was then determined by flow cytometry, using 24 hours post biotin 
injection as baseline biotin labelling (100%). Surprisingly, we observed no difference in platelet 
survival between Crlf3-/- and WT platelets (fig. 4.10A). This result suggests that if platelets are 
being cleared from the circulation it must happen rapidly, within the first 24 hours of release 
into the bone marrow sinusoids.   
 
We then looked at clearance by the liver, despite there being no difference in TPO levels in 
Crlf3-/- mice, as this is one of the major sites of platelet removal. Exposed terminal galactose 
residues on platelets are recognised by Ashwell-Morell receptors on liver hepatocytes and 
Kupffer cells and leads to platelet phagocytosis and production of TPO. Therefore, we assessed 
the level of terminal galactose exposure on platelets by western blot (experiments performed 
by Silvia Giannini and Karin Hoffmeister, Brigham and Women's Hospital, Boston, USA). Crlf3-
/- platelets have a slight increase in terminal galactose exposure compared to WT controls (fig. 
4.10B), suggesting platelet phagocytosis by the liver may play a role in the thrombocytopenia. 
However, this small increase is unlikely to cause a chronic 30-40% decrease in platelets counts. 
 
We then turned our attention to clearance by the spleen. Splenomegaly was observed in 2 out 
of 11 old (>52 week old) Crlf3-/- mice (fig. 4.11A), suggesting the spleen may be removing 
platelets from the circulation. To assess whether platelet removal by the spleen was 
responsible for the thrombocytopenia in Crlf3-/- mice, we splenectomised Crlf3-/- and WT mice 
(splenectomies and subsequent orbital bleeds and flow cytometry performed by Simon Stritt, 
University of Würzburg, Würzburg, Germany). As can be seen in figure 4.11B, removal of the 
spleen increases platelet counts in WT mice showing that the spleen is responsible for a 
portion of platelet removal under normal physiology. Interestingly, splenic removal in Crlf3-/- 
mice not only increased the platelet count but actually normalised it to WT values within 7 
days. This data suggests that rapid removal of a portion of newly formed platelets by the 
spleen is the cause of thrombocytopenia in Crlf3-/- mice.  




Figure 4.10 – Platelet clearance occurs within the first 24 hours of release and facilitated partly by the spleen. 
(A) WT (black) and Crlf3-/- (grey) mice injected with 1mg NHS-biotin. Blood withdrawn 24, 48, 72, 96 and 168 
hours post injection was labelled with specific antibodies against CD41, Ter119 and streptavidin and the 
percentage of streptavidin positive platelets (CD41+/Ter119-) determined by flow cytometry. Percentage of 
streptavidin positive platelets at 24 hours represents 100% biotin bound platelets (n=5). (B) Western blot of 
washed platelet lysates using specific antibodies against terminal galactose (RCA-1) and β1 integrin. (C) 
Expression of RCA-1 relative to β1 integrin determined from western blot (B) using Image Studio Lite (n=3). Data 
represents mean ± SD. (A) Two-way repeated measures (RM) ANOVA with Sidak’s correction for multiple 
comparisons; (C) Unpaired 2-tailed Student’s t test. * denotes p<0.05. 
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Figure 4.11 – Thrombocytopenia in Crlf3-/- mice is driven by splenic clearance. (A) Spleen weights of WT (black) 
and Crlf3-/- (grey) old (>52 week old) mice. Red data points show observed splenomegaly (n=11-17). (B) 
Splenectomises performed on WT (black) and Crlf3-/- (grey) mice and platelet counts determined by flow 
cytometry on venous blood (n=4-5). Data represents mean ± SD. (A) Unpaired 2-tailed Student’s t test; (B) two-
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4.4.5 Platelet clearance driven by haematopoietic compartment but not due to platelet 
activation/aggregation defects 
 
We sought to determine whether ablation of Crlf3 causes defects intrinsically to the platelets 
or extrinsically to the platelet environment. To assess this we performed bone marrow 
transplants, transplanting 5 million bone marrow cells from WT and Crlf3-/- donors to WT and 
Crlf3-/- sub-lethally irradiated recipients. Results suggest that the defect leading to splenic 
removal of platelets is isolated to the haematopoietic compartment, as WT recipients that 
receive Crlf3-/- bone marrow cells show a 59% decrease in platelet counts 3 months after 
transplantation (fig. 4.12A). In contrast, the platelet counts of Crlf3-/- mice transplanted with 
WT bone marrow cells recover to WT levels. Interestingly, restoration of platelet counts in 
Crlf3-/- mice transplanted with WT bone marrow and thrombocytopenia in WT mice 
transplanted with Crf3-/- bone marrow occurred despite incomplete chimerism (fig. 4.12B).  
 
Next, we determined whether Crlf3 ablation causes defects in the ability of platelets to 
activate and aggregate, defects that may target platelets for removal. First, we looked at the 
major platelet surface receptors by flow cytometry. Crlf3-/- platelets did not show altered 
expression of the fibrinogen receptor integrins CD41 (integrin αIIb, GPIIb) and CD61 (integrin 
β3, GPIIIa), the vWF receptor glycoproteins CD42d (GPV) and CD42a (GPIX) and the collagen 
receptor glycoproteins CD49b (integrin α2, GPIa) and GPVI, compared to WT platelets (fig. 
4.13A).  
 
Then we assessed platelet activation in response to a range of agonists in vitro by flow 
cytometry. The ability of platelets to activate was assessed by α-granule secretion (P-selectin 
surface expression) and fibrinogen binding (which requires activation of integrin αIIbβ3 
(CD41/61, GPIIb/IIIa)). Platelet activation is unaffected by removal of CRLF3, as Crlf3-/- 
platelets were able to activate similarly to WT platelets when stimulated with a range of 
agonists (fig. 4.13B).  
 
Upon activation, platelets change shape and spread which requires re-organisation of the 
cytoskeleton. We assessed the ability of Crlf3-/- platelets to spread on fibrinogen-coated 
coverslips. We observed no difference in the mean platelet area of spread platelets between 
Crlf3-/- and WT spread platelets (fig. 4.14A), suggesting Crlf3-/- platelets are able to reorganise 
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their cytoskeleton and change shape upon activation. Finally, we looked at the ability of Crlf3-
/- platelets to form stable thrombi under shear conditions in vitro, by flowing whole Crlf3-/- or 
WT blood over fibrillar collagen at arteriolar shear rates. Thrombi area was the same for Crlf3-
/- and WT blood (fig. 4.14B). These data suggest ablation of Crlf3 does not affect the primary 
haemostatic function of platelets and therefore, defects of platelet aggregation/activation are 
not responsible for platelet clearance by the spleen.  
 
 
Figure 4.12 – Defects in the haematopoietic compartment cause thrombocytopenia in Crlf3-/- mice. (A) Sub 
lethally irradiated WT (black square) and Crlf3-/- (grey circle) recipient mice transplanted with WT (black lines) or 
Crlf3-/- (grey lines) bone marrow cells. Data represents mean (n=1-2). (B) Western blot of in vitro cultured MK 
lysates using specific antibodies against CRLF3 and GAPDH. 




Figure 4.13 – platelet activation is unaffected in Crlf3-/- mice. (A) WT (black) and Crlf3-/- (grey) whole blood 
incubated with specific antibodies against CD41, CD61, CD42d, CD42a, CD49b and GPVI and assessed by flow 
cytometry, gating on platelet sized events (n=3). MFI denotes mean fluorescent intensity. (B) WT (black) and 
Crlf3-/- (grey) whole blood incubated with specific antibodies against CD41, P-Selectin and fibrinogen with or 
without addition of agonists. Percentage of CD41+ events expressing surface P-selectin (top panel) or bound to 
fibrinogen (bottom panel) was determined by flow cytometry (n=3). Data represents mean ± SD. Unpaired 2-
tailed Student’s t test with correction for multiple comparisons using the Holm-Sidak method. 
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Figure 4.14 - Crlf3-/- platelets can form stable thrombi under arteriolar shear. (A) WT (black) and Crlf3-/- (grey) 
washed platelets seeded onto fibrinogen coated coverslips and incubated for 30 mins at 37oC. Fixed samples 
stained with a fluorescently labelled F-actin probed and imaged by fluorescent microscopy. Platelet area 
determined by thresholding images on F-actin staining using ImageJ. Images representative of 5 images taken 
per mouse (n=3). Scale bars are 5µm. (B) Heparinised whole blood flowed over fibrillar collagen and imaged by 
light microscopy. Thrombus area for WT (black) and Crlf3-/- (grey) mice determined by manually measuring the 
size of each thrombi using ImageJ. Images representative of 10 images taken per mouse (n=3). Scale bars are 
50µm. Data represents mean ± SD. Unpaired 2-tailed Student’s t test. 
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4.4.6 Ineffective thrombopoiesis 
 
Rapid Romanowsky staining of blood smears made using EDTA anticoagulated blood of old 
(>52 weeks) Crlf3-/- mice revealed proplatelet like fragments (from now on termed 
preplatelets) in the peripheral circulation (fig.  4.15A). Although preplatelets are known to 
exist in the peripheral circulation of WT mice, they are not seen on blood smears when EDTA 
is used as an anticoagulant possibly due to the sphering effect of EDTA (Thon et al., 2012a); 
indeed, blood smears from old WT mice did not show preplatelets. Therefore, by observing 
preplatelets in Crlf3-/- blood smears made with blood anticoagulated using EDTA, it suggests 
there is a real difference structure and/or stability of Crlf3-/- preplatelets. To confirm the 
observed preplatelets were indeed proplatelet like fragments, Crlf3-/- blood smears were 
stained with fluorescently labelled antibodies against CD41 and vWF. The preplatelets are 
CD41 positive and have a granular staining of vWF reminiscent of proplatelets (vWF is 
packaged into immature α-granules in proplatelets) (fig. 4.15B), confirming the preplatelets 
are indeed fragments of proplatelets. Washed platelets from old Crlf3-/- mice were then fixed 
and prepared for transmission and scanning electron microscopy (TEM and SEM, respectively). 
Preplatelets with the stereotypical beads-on-a-string morphology of proplatelets were seen 
by both TEM and SEM (fig. 4.15C and D, respectively).  
 
In normal conditions, large proplatelet fragments undergo fission into smaller fragments 
which again fragment to become mature platelets. This process is facilitated by the high shear 
of the peripheral circulation. The presence of large preplatelets in the peripheral circulation 
of Crlf3-/- mice suggests a defect in the final maturation process of platelets, which we have 
termed ineffective thrombopoiesis. As removal of the spleen was able to normalise platelet 
counts in Crlf3-/- mice, we looked at the effect of splenic removal on preplatelet numbers.  To 
this end, we assessed the level of preplatelets in the peripheral circulation of young mice pre 
and post splenectomy by flow cytometry (experiments performed by Simon Stritt, University 
of Würzburg, Würzburg, Germany). Before splenectomy, preplatelets were observed in both 
WT and Crlf3-/- blood, consistent with previous observations that preplatelets exist in the 
peripheral circulation. However, Crlf3-/- mice had significantly more preplatelets in their 
peripheral circulation than WT mice (p=0.002; fig. 4.15E), suggesting the release of 
preplatelets is upregulated or fission of preplatelets to mature platelets is decreased. Post 
splenectomy, WT mice experience a small increase in platelet count (fig. 411B), which is 
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accompanied by a small increase in the number of preplatelets. WT preplatelets are able to 
mature very quickly in the peripheral circulation and therefore the removal of the spleen only 
increases the number of circulating preplatelets by a small margin (the few that would 
otherwise be cleared by the spleen). In the Crlf3-/- mice however, preplatelet counts remain 
stable or slightly decrease after splenectomy despite a large increase and normalisation of 
platelet counts. The normalisation of platelet counts without an increase in circulating 
preplatelets suggests that without the spleen, Crlf3-/- preplatelets are able to undergo fission 
and form mature platelets thus normalising platelet counts.   
 
Of note, the preplatelets recorded by flow cytometry are unlikely to be platelet 
microaggregates as events with forward/side scatter characteristics of preplatelets (i.e. larger 
than mature platelets) do not show activated GPIIb/IIIa or P-selectin surface exposure, which 
are indicative of platelet activation and needed for platelet aggregation (fig. 4.15F). 
 




Figure 4.15 – Large preplatelet are retained in the peripheral circulation of old Crlf3-/- mice. (A) Blood smear 
from EDTA anticoagulated whole blood of an old Crlf3-/- mouse. Red arrow heads point to preplatelets, black 
arrow heads point to mature round platelets. (B) Crlf3-/- blood smear stained with specific antibodies against 
CD41 (green) and vWF (red) and imaged by confocal microscopy. Washed platelets from old Crlf3-/- mice fixed 
and prepared for transmission (C) and scanning (D) electron microscopy. (E) WT (black) and Crlf3-/- (grey) mice 
were splenectomised. Heparinised venous blood incubated with specific antibodies against GPV and GPIIbIIIa. 
Percentage of preplatelets determined by flow cytometry as GPV+/GPIIbIIIa+ events with larger forward 
scatter/side scatter than mature platelets (n=4-5). (F) Heparinised venous blood incubated with specific 
antibodies against activated GPIIb/IIIa and CD62P and assessed by flow cytometry, to rule out the possibility that 
preplatelets are platelet microaggregates. Scale bars are 10μm (A), 5µm (B and D) and 500nm (C). Data 
represents mean ± SD. Two-way ANOVA with Tukey’s correction for multiple comparisons. *** denotes p<0.005. 
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4.4.7 Crlf3-/- platelets have increased microtubule stability  
 
As evidence has pointed to impaired maturation of preplatelets in the peripheral circulation, 
we looked at the major cytoskeletal proteins actin and tubulin in Crlf3-/- platelets, as these 
proteins are the major drivers of proplatelet formation. Crlf3-/- and WT washed platelets were 
fixed, permeabilised and allowed to adhere to poly-L-lysine coated coverslips in their resting 
state. Staining of resting WT platelets maintained at 37oC with fluorescent antibodies against 
α-tubulin and a fluorescently labelled F-actin probe showed a stereotypical cytoplasmic actin 
staining with a well-defined marginal microtubule coil (fig. 4.16A and B). Although many Crlf3-
/- platelets stained similarly to WT platelets, some platelets had disorganised and/or increased 
tubulin expression (fig. 4.16C and D). This abnormal tubulin staining is reminiscent of that seen 
in platelets from profilin 1 knockout mice and WAS patients (Bender et al., 2014) and patients 
with DIAPH1-related macrothrombocytopenia (Stritt et al., 2016). Profilin 1 knockout and 
DIAPH1 mutant platelets were shown to have increased microtubule stability, so we tested 
whether microtubule stability was affected in Crlf3-/- platelets. Washed platelets were 
incubated at 4oC to induce microtubule depolymerisation and then fixed, permeabilised and 
allowed to adhere to poly-L-lysine coverslips. As was expected, the majority of WT platelets 
were able to fully depolymerise their marginal microtubule coil, resulting in abolished tubulin 
staining (fig. 4.16E, F and I). However, significantly more Crlf3-/- platelets did not undergo 
microtubule depolymerisation, retaining their marginal microtubule coil (41.01% Crlf3-/- vs 
13.43% WT, p=8.4x10-5, fig. 4.16G, H and I), suggesting microtubule stability is increased in 
Crlf3-/- platelets (Platelet fixation staining and image acquisition performed by Simon Stritt, 
University of Würzburg, Würzburg, Germany).  
 
Dynamic microtubules are characterised by tyrosinated α-tubulin (Tyr-tubulin), whereas 
stable microtubules are associated with detyrosination (Glu-tubulin). The ratio between Glu- 
and Tyr-tubulin can be used as an indicator of the degree of microtubule stability (Pan et al., 
2014; Stritt et al., 2016). Surprisingly, we found no difference in the ratio of Glu-tubulin to Tyr-
tubulin expression in resting Crlf3-/- platelets compared to WT controls (fig. 4.16J and K).  




Figure 4.16 – Aberrant tubulin expression and possibly increased microtubule stability in Crlf3-/- platelets. 
Washed platelets maintained at 37oC (WT - A and B and Crlf3-/- - C and D) or stored at 4oC for 3 hours (WT - E and 
F and Crlf3-/- - G and H) adhered to poly-L-lysine coated coverslips and stained with specific antibodies against α-
tubulin (green) and a fluorescently labelled F-actin probe (red). Scale bars are 5μm. (I) Platelets with intact 
microtubule coils after incubation at 4oC were determined by manual counting of 5 images for WT (black) and 
Crlf3-/- (grey) mice (n=4). (J) Western blot of washed platelet lysates using specific antibodies against tyrosinated 
(Tyr) tubulin, detryrosinated (Glu) tubulin and GAPDH. (K) Expression of Tyr- and Glu-tubulin determined from 
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4.5 Chapter conclusions 
 
There were two main aims of this chapter, to show that the isolated thrombocytopenia in 
Crlf3-/- mice is sustained throughout life and to uncover the biological mechanisms in which 




Performing automated full blood counts on venous blood of Crlf3-/- and WT control mice at 
young (≤20 weeks), middle (21-40 weeks) and old (≥52 weeks) age time points revealed that 
Crlf3 induced thrombocytopenia is maintained throughout life. Ablation of Crlf3 effects the 
formation of platelets very specifically. The degree of thrombocytopenia varies over time, but 
there is a 25-39% decrease in platelet count in male mice and 26-42% decrease in female mice 
compared to aged matched WT controls (fig 4.4 and table 4.1). Surprisingly, the MPV is 
unchanged in Crlf3-/- mice (table 4.1). Most inherited thrombocytopenias are associated with 
increased MPV (gray platelet syndrome (Guerrero et al., 2014), Bernard-Soullier syndrome 
(Dutting et al., 2017) and Wiskott-Aldrich syndrome (Bender et al., 2014)). The normal MPV 
recorded in Crlf3-/- mice is probably due to the mechanism by which the automated 
haemocytometer defines platelets. As Crlf3-/- results in large proplatelet fragments 
(preplatelets) in the peripheral circulation (fig. 4.15A-D), MPV should be increased. However, 
these preplatelets will not be recorded as platelets by the haemocytometer and therefore the 
MPV will only be determined by mature round platelets.  
 
In our hands, no other blood lineage was affected by Crlf3 ablation despite MCV being 
recorded as significantly decreased in pipeline phenotyping done by the Wellcome Trust 
Sanger Institute.  
 
Biological consequences of Crlf3 ablation 
 
Ablation of Crlf3 appears to affect the final maturation step of platelets in the peripheral 
circulation, rather than release of platelets. Megakaryopoiesis is upregulated in Crlf3-/- mice 
(fig. 4.5) and MK maturation is unaffected in vitro (fig. 4.8). Crlf3-/- MKs are also able to produce 
proplatelets with similar morphology to WT proplatelets both in vitro (fig. 4.9) and in vivo 
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(supplementary videos 1 and 2), all data that suggests production of platelets from MKs is not 
affected. Under normal physiology, preplatelets released by proplatelet shafts into the bone 
marrow sinusoids rapidly undergo fission into mature platelets in the high shear of the 
peripheral circulation. However, Crlf3-/- mice contain large preplatelets in the peripheral 
circulation (fig. 4.15A-D), and Crlf3-/- mice have increased preplatelets in the peripheral 
circulation compared to WT control mice (fig. 4.15E), suggesting that fission of Crlf3-/- 
preplatelets is decreased. Although the exact mechanism for decreased fission of Crlf3-/- 
preplatelets has not been discovered, we were able to show that Crlf3-/- platelets have 
disorganised tubulin expression especially in the preplatelet forms (fig. 4.16A-D). The 
disorganised tubulin expression is similar to that seen in the platelets of patients with WAS 
and DIAPH1-related macrothrombocytopenia and in profilin 1 knockout mice (Bender et al., 
2014; Stritt et al., 2016). In all cases, abnormal tubulin expression confers to increased tubulin 
stability. In concordance with this, depolymerisation of the microtubules is decreased in Crlf3-
/- platelets incubated at 4oC (fig. 4.16E-I). However, we did not observe an increase in the ratio 
of detyrosinated (Glu-) tubulin to tyrosinated (Tyr-) tubulin (fig. 4.16J-K). Therefore, whether 
increased tubulin stabilisation is the cause of decreased preplatelet fission is yet to be 
resolved.  
 
The thrombocytopenia in Crlf3-/- mice can be attributed to rapid splenic removal of 
preplatelets from the circulation. Studies on platelet lifespan show the removal of platelets 
must happen within the first 24 hours of release from MKs as post 24 hours, platelet lifespan 
is comparable to WT platelets (fig. 4.10A). In splenectomised WT mice we observe a small 
increase in the platelet count (fig. 4.11B) accompanied by a small increase in the number of 
preplatelets (fig. 4.15E). WT preplatelets are known to mature very quickly in the circulation 
and therefore the removal of the spleen only increases the number of circulating preplatelets 
by a small margin (the few that would otherwise be cleared by the spleen). However, Crlf3-/- 
preplatelets mature a lot slower, which is evidenced by large preplatelets observed in the 
peripheral circulation (fig. 4.15A-D). The decrease rate of maturation of Crlf3-/- preplatelets is 
possibly due to increased tubulin stability (fig. 4.15E-I). As a consequence of the decreased 
preplatelet maturation in Crlf3-/- mice a much larger proportion of the preplatelets released 
by MKs are removed by the spleen before giving rise to mature platelets. This leads to 
thrombocytopenia. In response the bone marrow is stimulated to compensate by producing 
more MKs (as evidence in fig. 4.5). Once the spleen is removed, Crlf3-/- preplatelets are allowed 
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to mature into platelets thereby correcting the platelet count (fig. 4.11B). It is likely that the 
positive feed-back loop to the bone marrow disappears and preplatelet production from MKs 
is decreased. This is likely why we observe a slight decrease of preplatelets in the peripheral 
circulation after splenectomy in Crlf3-/- mice (fig. 4.15E), because production by the bone 
marrow has now reached a steady state comparable to that seen in the WT animals. 
 
In spite of mild thrombocytopenia and abnormal tubulin expression in platelets, Crlf3 ablation 
does not affect the ability of platelets to perform their primary haemostatic function. Crlf3-/- 
platelets express the major surface receptors required for platelet tethering, activation and 
aggregation/thrombus formation similarly to WT platelets (fig. 4.13A) and Crlf3-/- platelets 
activate appropriately in response to a range of agonists (fig. 4.13B). During the process of 
activation, platelets undergo shape change mediated by reorganisation of their cytoskeleton. 
Interestingly, despite aberrant tubulin expression and reduced cold induced microtubule 
depolymerisation, Crlf3-/- platelets are able to spread comparably to WT platelets when 
seeded onto fibrinogen (fig. 4.14A). This suggests reorganisation of tubulin and actin is 
unaffected at room temperature in Crlf3-/- platelets. In agreement with this, the size of 
thrombi produced by Crlf3-/- whole blood flowed over fibrillar collagen at arteriolar shear rates 
was similar to that of WT blood (fig. 4.14B).  






 CRLF3 as a novel therapeutic 
target for the treatment of 
essential thrombocythaemia 
  




Essential thrombocythaemia (ET) is a rare disease that results in circulating platelet counts 
above 450x109/L, caused by acquired clonal mutations mainly in JAK2, CALR or MPL. ET is a 
member of a group of diseases termed myeloproliferative neoplasms (MPN) along with 
polycythaemia vera (PV, increased red blood cells) and primary myelofibrosis (PMF, bone 
marrow fibrosis and extramedullary haematopoiesis). Treatment of ET is based on an 
individual needs and currently uses combination therapy of low dose aspirin to reduce platelet 
function and cytoreductive agents to reduce MK and platelet content. The cytoreductive 
agents have a range cardiovascular and haematological side effects and are therefore not 
suitable and/or tolerated by some patients (Cervantes, 2011; Rumi and Cazzola, 2016). An 
ideal therapy would specifically decrease platelet counts whilst having minimal side effects, 
especially those affecting the haematological and cardiovascular systems.  
 
A gain of function mutation in JAK2 (JAK2 V617F) is present in the majority of PV cases and 
approximately 50-60% of ET and PMF cases, therefore it has been studied in the most detail 
(Baxter et al., 2005; James et al., 2005; Kralovics et al., 2005; Levine et al., 2005). It is unknown 
exactly how this single point mutation can lead to different diseases, but mutant allele dose 
has been suggested as most patients with PV have clones homozygous for the JAK2 V617F 
mutation, although this is rare in ET (Scott et al., 2006). This mutation allele dose theory is 
backed up by evidence from a multitude of murine models developed to study the role of JAK2 
V617F in ET. Retroviral transduction of bone marrow with mutant JAK2 V617F containing 
vectors and subsequent transplantations leads to overexpression of mutant JAK2 relative to 
WT JAK2. Mice induced in this way show a PV phenotype with a marked increase in 
haematocrit (Lacout et al., 2006; Wernig et al., 2006). Also, transgenic mice generated using a 
human BAC containing a 5’ portion of JAK2 and retrofitted with a 3ʹ cDNA fragment containing 
the rest of JAK2 with the V617F mutation displayed varying phenotypes based on mutant JAK2 
copy number. When these transgenic mice were crossed with VavCre mice, relatively few 
transgene copies were retained and mice displayed an ET phenotype, whereas, when crossed 
with Mx1Cre mice multiple transgene copies were retained and a more PV phenotype was 
observed (Tiedt et al., 2008). 
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Despite the VavCre model described above providing a model of ET, there are some 
differences to phenotype of JAK2 V617F positive ET seen in humans. Firstly, platelet counts 
were drastically increased in VavCre mice whereas JAK2 V617F patients have mild 
thrombocythaemia, secondly splenomegaly was observed readily in VavCre mice where it is 
rare in patients and finally, haemoglobin levels where unaffected whereas they are mildly but 
significantly increased in patients (Cervantes, 2011; Tiedt et al., 2008). In 2010, Li et al 
developed an inducible (Mx1Cre) knock-in JAK2 V617F mutant heterozygous mouse (Jak2fl/+ 
Cre+). They inserted a floxed minigene together with mutant human JAK2 V617F cDNA into 
the translation start site of exon 2. Removal of the minigene by Cre-mediated recombination 
results in expression of mutant JAK2 under the control of endogenous mouse Jak2 locus. As 
such, expression levels of murine Jak2 and mutant human JAK2 are similar and there is no 
increase in total JAK2 in mutant mice. Jak2fl/+ Cre+ mice have an ET phenotype similar to that 
seen in JAK2 V617F positive patients. They have a mild thrombocythaemia, slightly increased 
haemoglobin level and splenomegaly is rarely seen. MK hyperplasia is also seen in Jak2fl/+ Cre+ 
mice and is a feature of ET (Cervantes, 2011; Li et al., 2010). Using this mouse model, it was 
shown that JAK2 V617F mutant platelets are hyper-reactive to a range of agonists, show 
increased spreading on fibrinogen and form larger thrombi under pathological shear 
conditions. This hyper-reactive state of mutant platelets may increase the chance of arterial 
and venous thrombotic events, which are the major causes of morbidity and mortality in ET 
patients (Hobbs et al., 2013). 
 
5.2 Chapter hypotheses and aims 
 
We hypothesise that CRLF3 could be a novel therapeutic target for the treatment of 
thrombocythaemia, with inhibitors against CRLF3 specifically decreasing platelet counts. 
Therefore, we aim to show a normalisation of platelet counts in ET mice crossbred with Crlf3-
/- mice. We also aim to show that the decrease of platelet counts is isolated in an ET setting.  
 
5.3 Chapter overview 
 
This chapter will show how Crlf3-/- mice were cross bred with JAK2 V617F ET mice to allow 
assessment of whether CRLF3 could be a therapeutic target for the treatment of ET. We show 
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that ablation of Crlf3 in an ET setting restores platelet counts to WT levels, the prerequisite 
for CRLF3 as a therapeutic target. We also show that other abnormalities associated with ET 




5.4.1 Breeding strategy 
 
To assess how ablation of Crlf3 affects the phenotype of ET (increased platelet counts, MK 
hyperplasia and increased platelet reactivity), we crossbred Crlf3-/- mice with knock-in JAK2 
V617F mutant mice (Jak2fl/+ Cre+) that have an ET phenotype (fig. 5.1). Pups derived from these 
mating’s were all heterozygous for Crlf3, could carry WT Jak2 alleles (Jak2+/+) or be 
heterozygous for the mutant Jak2 allele (Jakfl/+) and could carry an allele for Mx1Cre or not 
(Cre+ or Cre-, respectively). At approximately 8 weeks old, Crlf3 heterozygous Jak2fl/+ Cre+ mice 
were crossbred with Crlf3 heterozygous Jak2+/+ Cre- mice (or Jak2fl/+ Cre- mated with Jak2+/+ 
Cre+). Pups from these mating’s could have one, both or neither Crlf3 allele deleted (Crlf3+/-, 
Crlf3-/- and Crlf3+/+, respectively). As per the previous mating’s, pups could also could carry WT 
Jak2 alleles or be heterozygous for the mutant Jak2 allele and could carry an allele for Mx1Cre 
or not. Of the 12 possible genotypes, we were only interested in Crlf3+/+ Jak2+/+ Cre+, Crlf3-/- 
Jak2+/+ Cre+, Crlf3+/+ Jak2fl/+ Cre+ and Crlf3-/- Jak2fl/+ Cre+ mice (henceforth termed WT (Cre), 
Crlf3-/- (Cre), ET and ET x Crlf3-/-, respectively). All pups were injected with sterile polyinosinic-
polycytidylic acid prior to genotyping to induce the expression of the mutant Jak2 in ET and 
ET x Crlf3-/- mice and to control for any effect of interferon induction.  
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5.4.2 Ablation of Crlf3 restores platelet counts in ET mice 
 
To determine the effect of ablation of CRLF3 on the haematopoietic lineage of crossbred mice, 
full blood counts were performed on venous blood from young (0-20 week old) and old (>48 
weeks old) female mice. Only female mice were used for full blood counts, as the isolated 
thrombocytopenia seen in uncrossed Crlf3-/- mice was similar between males and females (fig. 
4.3 and table 4.1) and maintaining female animals for long periods is much more cost effective 
as female mice are able to be combined to reduce cage numbers, whereas male mice cannot. 
Platelet counts tended to be lower in Crlf3-/- (Cre) mice compared to WT (Cre) controls (686 ± 
222 x103/µl Crlf3-/- (Cre) vs 875 ± 306 x103/µl WT (Cre) in young mice and 712 ± 227 x103/µl 
Crlf3-/- (Cre) vs 1030 ± 426 x103/µl WT (Cre) in old mice, fig. 5.2 and table 5.1). As would be 
expected, ET mice have increased platelet counts compared to WT (Cre) controls. However, 
statistical significance is reached when comparing platelet counts of ET and Crlf3-/- (Cre) mice 
(p<0.005 for both young and old mice, fig. 5.2 and table 5.1), suggesting Crlf3-/- (Cre) mice have 
platelet counts lower than WT (Cre) mice and ET mice have higher platelet counts than WT 
(Cre) mice. Interestingly, ET x Crlf3-/- mice have platelet counts similar to WT (Cre) mice (879 
± 229 x103/µl ET x Crlf3-/- vs 875 ± 306 x103/µl WT (Cre) in young mice and 789 ± 294 x103/µl 
ET x Crlf3-/- vs 1030 ± 426 x103/µl WT (Cre) in old mice; p>0.999 and p=0.460 for young and 
old mice, respectively; fig. 5.2 and table 5.1) showing that ablation of Crlf3 normalises platelet 
counts in ET mice. 
 
Importantly, ablation of Crlf3 in ET mice does not lead to dysregulation of any other blood 
lineage irrespective of age (table 5.1). This confirms the isolated effect of CRLF3 on platelet 
production and suggests therapeutics that target CRLF3 may have less side effects than 
current cytoreductive agents. 


































































































































































































































Table 5.1 – Full blood counts in crossbred female mice. Full blood counts determined using an automated 
haemocytometer on EDTA anticoagulated venous blood withdrawn from young (0-20 week old; n=6-7) and old 
(>48 week old; n=5-9) female WT (Cre), Crlf3-/- (Cre), ET and ET x Crlf3-/- mice. Data represents mean (SD). Two-
way ANOVA with Tukey’s correction for multiple comparisons; ns, * and *** denote not significant, p<0.05 and 
p<0.005, respectively.  
 
5.4.3 Platelet reactivity and MK hyperplasia not increased 
 
JAK2 V617F positive ET is associated with MK hyperplasia and increased platelet reactivity as 
well as the classical increase in platelet numbers, as discussed in section 5.1. To determine 
whether ablation of Crlf3 has any effect on these other features of ET, we assessed platelet 
activation and thrombus formation in vitro and observed MK numbers in the bone marrow of 
crossbred mice.  
 
Mice tibia were fixed and sectioned and MKs counted after H&E staining. Unexpectedly, we 
observed similar numbers of bone marrow residing MKs in all genotypes (fig. 5.3). In section 
4.4.3 we showed upregulation of megakaryopoiesis in Crlf3-/- mice compared to WT controls, 
so we would have expected to see an increase in MKs in Crlf3-/- (Cre) mice compared to WT 
(Cre) controls. Also, the JAK2 V617F positive ET mice used here are known to have increased 
Plt (103/µL) MPV (fL) Hgb (g/dL) RBC (106/µL) WBC (103/µL) Age (weeks) n
875.00 (305.95) 5.62 (0.26) 14.52 (0.75) 10.52 (0.54) 10.37 (4.24) 10.21 (3.46) 6
686.29 (222.19) 5.71 (0.32) 13.63 (1.48) 9.98 (1.22) 8.90 (2.93) 9.49 (3.38) 7
1488.71 (255.17) 5.64 (0.36) 14.79 (0.94) 10.68 (0.63) 10.16 (2.27) 12.53 (4.79) 7
879.17 (228.67) 5.83 (0.53) 14.78 (1.54) 10.93 (1.27) 11.42 (2.35) 12.31 (4.24) 6
WT (Cre) vs Crlf3 -/-  (Cre) ns ns ns ns ns ns
WT (Cre) vs ET *** ns ns ns ns ns
WT (Cre) vs ET x Crlf3 -/- ns ns ns ns ns ns
Crlf3 -/- (Cre) vs ET *** ns ns ns ns ns
Crlf3 -/-  (Cre) vs ET x Crlf3 -/- ns ns ns ns ns ns
ET vs ET x Crlf3 -/- *** ns ns ns ns ns
Plt (103/µL) MPV (fL) Hgb (g/dL) RBC (106/µL) WBC (103/µL) Age (weeks) n
1030.40 (425.87) 5.46 (0.52) 13.90 (1.19) 10.24 (0.41) 12.42 (4.13) 57.86 (7.77) 5
712.43 (227.21) 5.31 (0.59) 13.54 (1.77) 9.55(1.42) 8.00 (2.06) 65.74 (8.17) 7
1445.78 (275.61) 5.30 (0.47) 13.58 (1.33) 10.23 (1.05) 9.27 (3.01) 68.06 (11.05) 9
789.29 (293.88) 5.26 (049) 14.87 (2.05) 11.04 (1.53) 9.33 (1.73) 70.84 (14.99) 7
WT (Cre) vs Crlf3 -/-  (Cre) ns ns ns ns ns ns
WT (Cre) vs ET * ns ns ns ns ns
WT (Cre) vs ET x Crlf3 -/- ns ns ns ns ns ns
Crlf3 -/- (Cre) vs ET *** ns ns ns ns ns
Crlf3 -/-  (Cre) vs ET x Crlf3 -/- ns ns ns ns ns ns
ET vs ET x Crlf3 -/- *** ns ns ns ns ns
0-20 week old mice









ET x Crlf3 -/-
Statistical 
significance
ET x Crlf3 -/-
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bone marrow residing MKs (Li et al., 2010), which was not seen by us. Although no increased 
in MK numbers was observed in ET x Crlf3-/- mice compared to ET mice, suggesting that 
inhibitors of CRLF3 may not exacerbate the MK hyperplasia associated with ET, we must take 
into consideration that the phenotype of Crlf3-/- and ET mice was not recapitulated with 
regards to MK hyperplasia.  
 
We did not expect to observe any difference in the ability of platelets to activate and form 
thrombi between Crlf3-/- (Cre) and WT (Cre) controls, as no differences were reported in 
section 4.4.5. Indeed, no difference were observed in the ability of platelets to degranulate 
and bind fibrinogen in response to a range of agonists (fig. 5.4), undergo shape change (fig. 
5.5A) or form stable thrombi under arteriolar shear conditions (fig 5.5B). 
 
However, we expected ET platelets to be hyperactive. Contrary to this, we saw no difference 
in activation of ET platelets compared to WT (Cre) platelets in response to a range of agonists 
(fig. 5.4), spreading on fibrinogen was not exacerbated (fig. 5.5A) and thrombi area was not 
increased (fig 5.5B). 
 
Finally, we wanted to observe any effect caused by ablation of Crlf3 in ET mice. Platelet 
activation was not grossly affected; ET x Crlf3-/- platelets were able to express P-selectin on 
their surface and bind fibrinogen to the same degree as WT (Cre) and ET platelets in response 
to all agonists tested, with the exception of medium concentrations of CRP where activation 
was decreased compared to WT (Cre) (fig. 5.4). Similarly, platelet spreading and thrombus 
formation under pathological shear were not affected in ET x Crlf3-/- platelets. ET x Crlf3-/- 
platelets also formed stable thrombi under shear conditions and thrombus area was not 
different to that formed by WT (Cre) or ET platelets (fig 5.5B). These data suggest that CRLF3 
does not grossly affect platelet activation and thrombus formation. However, we cannot 
interpret the effect of ablation of Crlf3 on platelet hyperactivity that is a feature of JAK2 V617F 
positive ET, as we were unable to recapitulate this platelet hyperactivity in our crossbred ET 
mice. 
 
5 – Results 2 
 122 
 
Figure 5.3 – MK hyperplasia is not exacerbated by ablation of Crlf3 in ET mice. H&E staining performed on fixed 
and sectioned mice tibias. MKs blindly quantified by manual counting for WT (Cre) (black), Crlf3-/- (Cre) (grey), ET 
(red) and ET x Crlf3-/- (green) images (n=3). Images are representative of 12 month old mice and white arrows 
point to MKs. Scale bars are 50µm. HPF is high power field. Data represents mean ± SD. One-way ANOVA with 
Tukey’s correction for multiple comparisons. 
 





Figure 5.4 – Platelet activation is not grossly affected in ET x Crlf3-/- mice. WT (black),  Crlf3-/- (grey), ET (red) and 
ET x Crlf3-/- (green) whole blood incubated with specific antibodies against CD41, P-Selectin and fibrinogen with 
or without addition of agonists. Percentage of CD41+ events expressing surface P-selectin (top panel) or bound 
to fibrinogen (bottom panel) was determined by flow cytometry. Data represents mean ± SD (n=3-4). Two-way 
ANOVA with Tukey’s correction for multiple comparisons; * denotes p<0.05. 
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Figure 5.5 – Ability of ET platelets to spread and form stable thrombi is unaltered by ablation of Crlf3.  (A) WT 
(Cre) (black), Crlf3-/- (Cre) (grey), ET (red) and ET x Crlf3-/- (green) washed platelets seeded onto fibrinogen coated 
coverslips and incubated for 30 mins at 37oC. Fixed samples stained with a fluorescently labelled F-actin probe 
and imaged by fluorescent microscopy. Platelet area determined by thresholding images on F-actin staining using 
ImageJ (n=3). (B) Heparinised whole blood flowed over fibrillar collagen and imaged by light microscopy. 
Thrombus area for 10 images for WT (Cre) (black), Crlf3-/- (Cre) (grey), ET (red) and ET x Crlf3-/- (green) mice 
determined by manually measuring the size of each thrombi using ImageJ (n=3). Data represents mean ± SD. 
One-way ANOVA with Tukey’s correction for multiple comparisons. 
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5.5 Chapter conclusions 
 
The aim of the chapter was to show that CRLF3 could be used as a novel therapeutic target 
for the treatment of ET. To this end, we cross breed Crlf3-/- mice with Jak2fl/+ Cre+ ET mice 
heterozygous for the human JAK2 V617F mutation and have a phenotype similar to that seen 
in ET patients.  Resultant pups were again crossbred to harbour ET mice with Crlf3 ablated (ET 
x Crlf3-/-), and appropriate controls (WT (Cre), Crlf3-/-(Cre) and ET mice). Importantly, ET x Crlf3-
/- platelet counts were similar to those of WT (Cre) control mice and significantly decreased 
from ET mice, suggesting removal of CRLF3 is able to normalise platelet counts in ET (fig. 5.2). 
This normalisation of platelet counts was without abnormalities in any other blood lineage 
(table 5.1), suggesting inhibitors of CRLF3 may have fewer haematological side effects than 
the cytoreductive agents currently used.  
 
Beyond an increase in platelet numbers ET is associated with MK hyperplasia (Cervantes, 
2011) and JAK2 V617F positive ET is associated with platelet hyper-reactivity (Hobbs et al, 
2013). Bone marrow MK numbers were not increased in ET x Crlf3-/- mice compare to ET 
controls (fig. 5.3), suggesting inhibiting CRLF3 should not add to the burden of MK hyperplasia 
in ET. However, we were unable to recapitulate the MK hyperplasia which is a feature of these 
ET mice and of ET patients (Li et al, 2011) or the MK hyperplasia observed in Crlf3-/- mice 
(section 4.4.3) in the crossbred ET and Crlf3-/- (Cre) mice, respectively (fig. 5.3). The reasons 
for MK hyperplasia not being observed in the crossbred mice may be due to small n numbers 
used in experiments or due to the creation of an unsettled mouse background. Crlf3-/- mice 
are on a B6Brd;B6Dnk;B6N-Tyr background, whereas JAK2 V617F ET mice are on a B6J 
background. Crossbreeding of these two backgrounds may have caused an unsettled 
background strain, since background strain is known to have a major effect on haematopoietic 
cells (peters et al, 2002). The mice used in the experiments here represent pups from 1-4 
inbred mating’s of this mixed background strain. Therefore, it may be that more inbred 
mating’s of this mixed background strain is required for the strain become settled.  
 
The major cause of morbidity and mortality in ET patients is arterial and venous thrombotic 
events. JAK2 V617F positive ET patients have higher incidences of venous thrombotic events 
than JAK2 WT ET patients (Campbell et al., 2005), this may in part be accounted for by the 
hyper-reactive state of JAK2 V617F positive platelets. Therefore, it is important that any 
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therapeutic designed to treat ET does not exacerbate the hyper-reactive state of ET 
platelets. Ablation of Crlf3 in an ET setting had little impact on the reactivity of platelets (it 
appears to decrease platelet activation at medium doses of CRP) and their ability to form 
stable thrombi (fig. 5.4 and 5.5B, respectively), suggesting that inhibitors of CRLF3 should not 
exacerbate the hyper-reactive state of platelets in JAK2 V617F positive ET. However, this 
must be put in the context that we were unable to recapitulate the hyper-reactive state of 
ET platelets in our crossbred ET mice, probably due to the reasons mentioned above.  






CRLF3 structure and function 
  




6.1.1 Protein structure  
 
Proteins are composed of a chain of amino acids, known as a polypeptide chain, produced by 
translation of RNA by ribosomes. This polypeptide chain is termed the primary structure of a 
protein and is unique for each protein. Amino acids are organic molecules that contain amine 
(-NH2) and carboxyl (COOH) groups along with a side chain that is specific to each amino acid. 
Hydrogen bonds between amide and carbonyl groups of amino acids cause regular α-helical 
and β-sheet sub structures within the protein. These highly regular sub-structures of proteins 
are termed the secondary structure. Folding of the protein into a globular three-dimensional 
structure is driven by hydrophobic forces, hiding hydrophobic amino acids from external 
water. This 3D shape of a protein is termed the tertiary structure. Finally, some proteins have 
a quaternary structure, which refers to the aggregation of multiple globular polypeptide 
chains by non-covalent bonds into a single functional unit. For example, antibodies are 
composed of 2 light chain polypeptides and 2 heavy chain polypeptides.    
 
The tertiary and quaternary 3D structure of a protein can be determined by a variety of 
different techniques. The most commonly used technique is X-ray crystallography, which is 
responsible for over 90% of solved 3D structures deposited in the Protein Data Bank 
(http://www.rcsb.org; (Berman et al., 2000)). X-ray crystallography involves exposing a crystal 
composed of purified protein of interest to a beam of X-rays, which creates a diffraction 
pattern. Computational processing of this diffraction pattern results in a 3D model of the 
protein (Smyth and Martin, 2000).  
 
Determining the 3D structure of a protein is important for drug design. Structure based drug 
design relies on the structure of the binding site/s of a protein being known. Once the binding 
site/s is determined in the protein of interest, potential small inhibitors can be identified. This 
can be done in several ways, firstly, small inhibitors from existing libraries can be screened in 
silico for their ability to fit into the binding site. Secondly, known small inhibitors can be 
optimisation for the binding site of the protein of interest; or thirdly, new inhibitor molecules 
that fit the binding site can be designed using computational programs (Anderson, 2003; 
Klebe, 2000).  
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6.1.2 Protein interactome 
 
The interactome of a protein refers to all the protein interactions that occur with a protein of 
interest within a cell. Understanding the interactome of a protein of unknown function can 
help determine its function, as proteins generally have similar functions to their interacting 
proteins (Schwikowski et al., 2000).  
 
6.2 Chapter hypotheses and aims 
 
We hypothesise that CRLF3 will contain domains that interact with other proteins and as such 
we aim to resolve the tertiary structure of CRLF3 using X-ray crystallography to discover these 
interacting domains. We also hypothesise that CRLF3 interacts with microtubules and/or 
proteins that themselves directly interact with microtubules and these CRLF3 dependent 
interactions affect microtubule stability. Therefore, we aim to uncover the interactome of 
CRLF3 in forward programmed human MKs.  
 
6.3 Chapter overview 
 
Firstly, this chapter will show how we were unable to resolve the tertiary structure of full 
length CRLF3 due to technical issues. We then show how different portions of CRLF3 were 
selected using freely available bioinformatics tools and how the portion corresponding to the 
second half of CRLF3 was produced from E. coli cells, purified, crystallised and its tertiary 
structure resolved by X-ray crystallography. We next show how we were able to attach a 
tandem affinity purification (TAP) tag to endogenous CRLF3 in human induced pluripotent 
stem cells (iPSCs). We show the interactome of CRLF3 in iPSCs as determined by mass 
spectrometry after immunoprecipitation and finally, we show that TAP-tagged iPSCs are able 










6.4.1 CRLF3 crystal structure 
 
Initially we intended to resolve the tertiary structure of full length murine CRLF3 (442 amino 
acids, longer splice variant). To do this, Crlf3 was amplified from cDNA by PCR using specific 
primers (table 3.9 and 3.12). Crlf3 was then ligated into pGEX-6P-2 vector (fig. 6.1), which 
generates glutathione-S-transferase (GST) fusion proteins when expressed in E. coli cells. Crlf3 
containing pGEX vectors were transformed into competent E. coli cells and CRLF3-GST was 
produced following the method described by Harper and Speicher (2008). GST was cleaved 
from CRLF3 with PreScission protease and CRLF3 purified by affinity chromatography. One 
litre of bacterial culture produced 0.6mg CRLF3 after GST cleavage and purification (n=1). 
Protein from 4 litres of bacterial culture was concentrated by centrifugation to ≈5mg/ml and 
used to set up crystallisation screen plates. However, despite producing enough concentrated 
CRLF3 to set up a number of crystallisation screenings using the vapour diffusion method, no 
crystals were formed (crystallisation screens performed by Giles Lewis, University of 
Cambridge, Cambridge UK).  
 




Figure 6.1 – Vector map of Crlf3 ligated into pGEX-6P-2. Crlf3 amplified from cDNA using primers shown (violet) 
ligated into BamHI and NotI restriction digested pGEX-6P-2 vector. Proteins produced from pGEX-6P-2 are fused 
to glutathione-S-transferase (GST; purple) which can be cleaved by PreScission protease at the site shown. Map 
created using SnapGene®. 
 
6.4.1.1 Design of 4 CRLF3 constructs 
 
Due to difficulties producing and crystallising the full length protein, we bioinformatically 
analysed murine CRLF3 to decide on portions of the protein that are more likely to crystallise 
(work done in collaboration with Randy Read and Richard Mifsud, University of Cambridge, 
Cambridge, UK). Figure 6.2A shows the 4 constructs that were decided upon based on a 
number of internet based tools. The first of these internet based tools, DISOPRED 
6 – Results 3 
 132 
(http://bioinf.cs.ucl.ac.uk/), predicts disorder within the primary sequence of a protein. The 
straight line (5% false positive rate (FPR)) is set as a cut off, and anything above this is predicted 
to be disordered. Disorder prediction is a valuable tool for identifying flexible regions in 
proteins that may hinder crystallisation (Bryson et al., 2005; Ward et al., 2004). As can be seen 
in figure 6.2D, the first 16 amino acids at the N-terminus are predicted to be highly disordered; 
therefore we decided to create a construct for the whole protein omitting the disordered N-
terminus (construct 1 – amino acid 17 to 442).  
 
We then used a tool that predicts the secondary structure of the protein, namely PSIPRED 
(http://bioinf.cs.ucl.ac.uk/; (Bryson et al., 2005)). As can be seen in figure 6.2B, CRLF3 is 
predicted to be composed of an α-helical section (purple cylinder) followed by a β-sheet 
section (yellow arrow). The α-helical section starts at amino acid 38; therefore we decided to 
create a construct from the start of this predicted α-helical section to the end of the protein 
(construct 2 – amino acid 38 to 442).  
 
Finally, we used HHpred (https://toolkit.tuebingen.mpg.de/;  (Alva et al., 2016)) to detect 
remote homologous proteins and predict structure (Soding et al., 2005). As can be seen in 
figure 6.2C, there are many predicted homologues of known structure for the second half of 
CRLF3, starting after the predicted α-helical section ends. However, the first half of the protein 
(amino acid 1-173) only had one predicted homologue (at the time of investigation, now 
currently has 4 predicted homologues). Based on these predictions, we decided to create a 
construct for the second half of the protein starting at amino acid 174, where the predicted 
α-helical section ends (construct 3 – amino acid 174 to 442). We have also decided to create 
a construct for the first half of the protein but still omitting the disordered N-terminus 
(construct 4 – amino acid 17-173) for completeness. 
 




Figure 6.2 – Design of 4 CRLF3 constructs based on homology and disorder. (A) 4 constructs chosen after 
bioinformatic interrogation of murine CRLF3, aligned to full length CRLF3. Construct 1 – residue 16 to end (442); 
2 – residue 38 to end; 3 – residue 174 to end and 4 – residue 16 to 173. (B) PSIPRED plot represents predicted α-
helices (pink cylinder) and β-sheets (yellow arrow) within CRLF3’s secondary structure. (C) HHpred result at time 
of interrogation. Homologous FN3 domains boxed. (D) Disorder in CRLF3 as assessed by DISOPRED. FPR is false 
positive rate. 
 
6.4.1.2 Protein production and purification 
 
After all 4 constructs were cloned in pGEX-6P-2 and transformed into E. coli cells, we produced 
protein from 1L of bacterial culture, removed GST with PreScission protease and purified by 
affinity chromatography. Only construct 3 produced significantly more protein than the full 
length protein (7.0mg construct 3 vs 0.6 construct 1, 0.7mg construct 2, 0.8mg construct 4 and 
0.6mg full length; n=1). Due to its ability to produce vast amounts of protein, we decided to 
concentrate our efforts on construct 3.  
 
We produced 13.6mg protein from 2L of bacterial culture, of which 8.2mg was retained after 
GST cleavage and purification by affinity chromatography; this was concentrated to 7.6mg/mL 
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in 1mL. The protein was further purified by ion exchange chromatography, which produced a 
large peak indicating pure protein (fig. 6.3A) that was confirmed to be CRLF3 (construct 3) by 
SDS-PAGE (fig 6.3B). The eluate collected during the large peak of ion exchange 
chromatography was again concentrated to 11.7mg/mL in 300µL. 
  
Figure 6.3 – Purification of CRLF3 construct 3 by ion exchange chromatography. (A) Protein of CRLF3 construct 
3 produced from E. coli after initial purification and concentration, purified further by ion exchange 
chromatography. (B) Eluates from ion exchange chromatography resolved by SDS-PAGE.  
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6.4.1.3 Crystallisation of construct 3 and solving of 3D structure 
 
Crystallisation was screened by the sitting drop vapour diffusion method using a variety of 
commercially available 96-well screen plates with the kind help of Yahui Yan (University of 
Cambridge, Cambridge, UK). Many conditions produced crystals of varying quality (table 6.1 
and fig. 6.4A). Crystals grown in 20% PEG 3,350, 0.2M sodium formate, pH7.0 were soaked 
with the mercury (Hg) derivative thimerosal (10mM) overnight, then cryoprotected with 25% 
ethylene glycol. The data collection was recorded at Diamond Light Source beamline I04. A 
good ‘peak’ dataset was collected with redundancy of 6.7 at the peak wavelength which was 
determined experimentally by fluorescence scanning. Diffraction data were indexed, 
integrated, and scaled to 1.86Å using Mosflm (Leslie and Powell, 2007) and Aimless (Evans, 
2011) via the xia2 (Winter, 2010) automated data processing pipeline. The Hg-single 
anomalous diffraction (SAD) phasing was solved using AutoSol-wizard (Terwilliger et al., 2009) 
which is an experimental phasing pipeline that combines Hybrid Substructure Search (HySS) 
for finding heavy-atom sites, Phaser for calculating experimental phases, and RESOLVE for 
density modification and model building. It found 14 mercury sites with the Figure of Merit 
(FOM; estimate of phase quality, ranging from 0 to 1) at 0.37 and the overall score (a 
standardised measure of how well the 3D model fits the electron density map which takes 
into account FOM, CC, Rfree and Rwork, ranging from 0-100) of 53.92 ± 7.90. The map-model 
correlation coefficient (CC; an estimate of how well the 3D model fits the electron density 
map, ranging from 0 to 1) was 0.78 after model building with Rwork at 0.28 and Rfree at 0.31 
(both measures 3D model quality, where 0 would be perfect). The structure was further 
refined to a resolution of 1.7Å using Phenix.refine (Adams et al., 2010) and by manual building 
in Coot (Emsley et al., 2010) with a native dataset collected from crystals grown in 25% PEG 
3,350, 0.2M ammonium acetate, 0.1M BIS-TRIS. This 3D structure revealed a fibronectin type 
III (FN3) domain at the N-terminus of construct 3 (fig 6.4B) that was predicted by HHpred 
(homologous proteins boxed in fig. 6.2C) and an SPRY domain at the C-terminus of construct 
3 (fig 6.4B) (X-ray diffraction data collection and creation of 3D model done by Randy Read, 
Yahui Yan and Richard Mifsud, University of Cambridge, Cambridge, UK).  
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Table 6.1 – Conditions in which CRLF3 construct 3 produced crystals 
 




Figure 6.4 – 3D structure of CRLF3 construct 3. (A) Purified CRLF3 construct 3 protein was mixed with 
contents of well H10 of JCSG-plus by Molecular Dimensions and crystals allowed to form following the 
vapour diffusion method. (B) Crystals underwent X-ray diffraction and 3D structure solved by 
experimental phasing. Domains are labelled. FN3 is fibronectin type 3. Molecular graphics prepared 
using PyMOL. 
 
6.4.2 Adding a Tandem Affinity Purification (TAP) tag to endogenous CRLF3 in human iPSCs 
 
To add the TAP tag, consisting of an N-terminal calmodulin binding domain and C-terminal 3x 
FLAG tag repeat separated by a TEV cleavage site, to endogenous CRLF3 we used the 
CRISPR/Cas9 method Ran et al. (2013). Cas9 nuclease was guided by specific single-guided (sg) 
RNA’s in a green fluorescent protein (GFP) expressing plasmid to introduce a double stranded 
break (DSB) in DNA close to the CRLF3 stop codon (fig. 6.5A). A donor vector was then 
introduced to initiate homology directed repair (HDR) to add the TAP tag to the 3’ end of CRLF3 
before the stop codon (fig 6.5B). 
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Figure 6.5 – Schematic diagram of adding a TAP-tag to CRLF3 by CRISPR/Cas9. (A) Cas9 nuclease (black  
outline) is targeted to CRLF3 exon 8 close its stop codon (red box) by an sgRNA consisting of a 20-nt guide 
sequence (CRISPR, purple) and a scaffold (light blue). The guide sequence pairs with the DNA target (purple bar 
on top strand), directly upstream of a 5ʹ-NGG protospacer adjacent motif (PAM; dark blue). Cas9 mediates a 
double strand break (DSB) ~3 bp upstream of the PAM (green triangles). (B) The DSB caused by Cas9 close to 
CRLF3’s stop codon (red) in addition to the supplied donor vector leads to homology directed repair (HDR) and  
precise gene editing. The TAP tag (blue) is added directly before the stop codon of CRLF3, guided by 5’ and 3’ 
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 Originally, we intended to use the iPSC line FFDK1 as it was being cultured in-house and it was 
known to forward programme to MKs. The donor vector for HDR, was created by cloning of 
1kb 3’ and 5’ CRLF3 homology arms and TAP tag into linearized pBS KS vector by Gibson 
assembly (fig. 6.6). The donor vector was inserted into XL-10 Gold ultra-competent E. coli and 
vector DNA was extracted from liquid cultures using a commercially available kit. Sequencing 
of the donor vector using the M13F and M13R primers (table 3.12 and fig. 6.6) revealed 
multiple mutations in the 5’ homology arm, with 3 mutations occurring in exons and one 
leading to an amino acid substitution (proline to leucine at amino acid 435). As we intended 
to tag wildtype CRLF3, as recorded at the National Centre for Biotechnology Information 
(https://www.ncbi.nlm.nih.gov/), we screened other in-house iPSC lines for mutations in 
CRLF3. To this end, CRLF3 cDNA from iPSC lines BobC and Qolg was amplified by PCR using 
specific primers (table 3.11 and 3.12), cloned into TOPO vector by TOPO TA cloning and 
transformed into E. coli cells. Sequencing of DNA after extraction from liquid cultures revealed 
a 4bp deletion at amino acid 41 in BobC leading to a frameshift. However, no mutations were 
seen in Qolg CRLF3, therefore we continued with this line, creating a donor vector as above 
by Gibson assembly. The donor vector was confirmed to be correct by sequencing using M13F 
and M13R primers and restriction digestions. Restriction sites for EcoRI are found in the 5’ and 
3’ homology arms (fig. 6.6) and digestion resulted in 4195bp and 869bp fragments as expected 
(fig. 6.7). Whereas, restrictions sites for XmnI are found in TAP tag and ampicillin resistance 
region of pBS KS (fig. 6.6) and digestion resulted in 3154bp and 1910bp fragments as expected 
(fig. 6.7). 
 
Qolg TAP-tag donor vector and sgRNA/Cas9-GFP plasmid were inserted into Qolg iPSCs, in a 
single cell solution, by electroporation and then cells seeded onto vitronectin coated plates. 
Electroporated cells were maintained for 2 days then sorted by fluorescent-activated cell 
sorting (FACS) based on expression of GFP. Individual GFP-positive cells were sorted to 
individual wells of laminin coated 96 well plates (FACS sorting performed by staff of NIHR 
Cambridge BRC Cell Phenotyping Hub, University of Cambridge, Cambridge UK). Of the 96 GFP 
positive cells sorted, thirteen survived and formed colonies, which were expanded and gDNA 
isolated. PCR amplification of gDNA using specific primers (table 3.12 and fig. 6.6) revealed 
that only 6 of the 13 clones had the TAP tag-inserted onto CRLF3 (fig. 6.8A). Protein expression 
of CRLF3-TAP in the positive clones was confirmed by western blot (fig. 6.8B) and flow 
cytometry (fig. 6.8C) using specific antibodies against the TAP tag.   
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Figure 6.6 – Vector map of TAP-tag donor vector. 3’ and 5’ CRLF3 homology arms (green and yellow, respectively) 
and TAP-tag (blue) cloned into linearised pBS KS vector by Gibson assembly. Homology arms and TAP-tag were 
amplified and pBS KS vector was linearised by PCR using the primers shown (light purple). Correct assembly of 
donor vectors was confirmed by sequencing using the M13F abd M13R primers (light purple) and by restriction 
digestion with EcoRI and XmnI (black). Map created using SnapGene®. 
 
 




Figure 6.7 – Confirmation of TAP-tag donor vector by restriction digestion. Undigested donor vector DNA or 
DNA digested with XmnI or EcoRI resolved on a 1.5% agarose TBE gel supplemented with DNA SafeView. 
 
Figure 6.8 – Confirmation of CRLF3-TAP in iPSCs. (A) gDNA isolated from FACS sorted iPSC clones amplified by 
PCR with primers located in the TAP-tag and 3’ homology arm (table 3.12 and fig. 6.6) and resolved on a 1.5% 
agarose TBE gel supplemented with DNA SafeView. (B) Western blot of TAP-tagged and untagged iPSCs using 
specific antibodies against FLAG and GAPDH. (C) Fixed and permeabilised TAP-tagged (green and blue) and 
untagged (grey) iPSCs stained with FITC conjugated antibody against FLAG and assessed by flow cytometry.  
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6.4.2.1 CRLF3’s interactome in iPSCs 
 
To determine the as yet unknown interactome of CRLF3, TAP-tagged and untagged WT iPSCs 
were lysed and CRLF3 and proteins bound to CRLF3 were immunoprecipitated with antibodies 
specific for the TAP tag. Mass spectrometry of the immunoprecipitated proteins revealed 18 
proteins that were present in the TAP-tagged samples but not untagged samples (table 6.2) 
(Mass spectrometry performed by Renata Feret, Marco Chiapello and Mike Deery, Cambridge 
Centre for Proteomics, University of Cambridge, Cambridge, UK). CRLF3 was present in all TAP-
tagged samples, but not untagged-samples, confirming CRLF3 was correctly tagged with the 
TAP-tag. Interestingly, four of these proteins (highlighted blue) are known to form 
desmosomes along with other proteins. Desmosomes are cell-to-cell adhesion molecules that 
bind cytoskeletal keratin filaments. Although numerous keratin isoforms were seen in both 
the TAP-tagged and untagged samples, 5 isoforms were only seen in the tagged samples 
(highlighted green).   
 
 





 UniProt ID PROTEIN





P02533  Keratin, type I cytoskeletal 14
P08779  Keratin, type I cytoskeletal 16
P13647  Keratin, type II cytoskeletal 5
P02538  Keratin, type II cytoskeletal 6A
Q8N1N4  Keratin, type II cytoskeletal 78
A0A087WVD4  Arsenite methyltransferase 
Q9NRM1  Enamelin
Q86YZ3  Hornerin
Q5T749  Keratinocyte proline-rich protein
H3BPJ9  NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10
A0A0A0MRQ5  Peroxiredoxin-1
Q7KZ85  Transcription elongation factor SPT6
O95625  Zinc finger and BTB domain-containing protein 11
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6.4.2.2 Forward programming of tagged iPSCs  
 
Finally, we wanted to forward programme TAP-tagged iPSCs into MKs to allow determination 
of CRLF3’s interactome in MKs and visualisation of CRLF3 within MKs and during proplatelet 
formation. TAP-tagged iPSCs were forward programmed using the method developed by 
Moreau et al. (2016). We confirmed the presence of the TAP-tag in forward programmed TAP-
tagged MKs by western blot (fig. 6.9A). The shift in size of the CRLF3 band in TAP-tagged MKs 
seen in figure 6.9B, results in a band with the same molecular weight as TAP-tagged MKs when 
blotted with antibodies against the TAP-tag; confirming that CRLF3 had been tagged with the 
TAP-tag. Based on immunoprecipitation experiments for mass spectrometry using forward 
programmed MKs performed previously by colleagues (unpublished data), large numbers of 
MKs (≈ 50 million) are needed for each sample. At the time of writing, we have not been able 
to produce this large quantity of MKs to perform immunoprecipitation and mass spectrometry 
assays, therefore the interactome of CRLF3 in MKs remains unknown.   
 
Forward programmed MKs from TAP-tagged and untagged control iPSCs were seeded onto 
fibrinogen and allowed to form proplatelets. Samples were then fixed and stained with the 
nuclear stain DAPI and specific antibodies against the TAP-tag (anti-FLAG) to determine CRLF3 
localisation during proplatelet formation. However, due to significant background staining 
with the anti-FLAG antibody in untagged forward programmed MKs, it was impossible to 
determine where CRLF3 was localised (fig. 6.10). 
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Figure 6.9 – Confirmation of CRLF3-TAP in forward programmed MKs. Western blot of TAP-tagged and untagged 
forward programmed MKs using specific antibodies against FLAG and GAPDH (A) and CRLF3 and GAPDH (B). 
 
 
Figure 6.10 – High unspecific staining in proplatelet forming forward programmed MKs. Proplatelet forming 
untagged (left) and TAP-tagged (right) forward programmed MKs stained with antibodies against the TAP-tag 
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6.5 Chapter conclusions 
 
The first aim of this chapter was to uncover the tertiary structure of CRLF3. We were unable 
to crystallise protein from full length CRLF3, therefore we were unable to determine the 3D 
structure of full length CRLF3. Using bioinformatic tools we chose 4 constructs covering 
different regions of the full length protein that were predicted to crystallise more readily. We 
concentrated our efforts on construct 3, which covers the predicted beta sheet region of 
CRLF3 (fig. 6.1), as it was produced in large quantities by E.coli cells compared to all other 
constructs. We were able to crystallise protein of CRLF3 construct 3 and its 3D structure was 
resolved at a resolution of 1.7Å by Hg-SAD and manual refinement. The 3D structure revealed 
both a FN3 domain at the N-terminus and a SPRY domain at the C-terminus of construct 3 (fig 
6.4B). The FN3 domain was initially predicted by HHpred (homologous proteins boxed in fig. 
6.2C). 
 
The second aim of the chapter was to discover the interactome of CRLF3 in MKs. To this end, 
we were able to tag endogenous CRLF3 with a TAP tag using CRISPR/Cas9 technology in human 
iPSCs (fig. 6.7-8). We were able to forward programme TAP-tagged iPSCs into MKs using the 
method of Moreau et al. (2016). However, due to the vast number of MKs needed to perform 
immunoprecipitation and mass spectrometry assays, we were unable to perform these 
experiments and therefore the interactome of CRLF3 remains unknown in MKs. We did 
however, perform immunoprecipitation and mass spectrometry assays on tagged and 
untagged iPSCs, which revealed 18 proteins in the tagged samples that were not present in 
the untagged samples (table 6.2). Interestingly, many of these are associated with 
desmosomes, which are involved in resisting shear forces.  
 
Finally, we tried to discover the localisation of CRLF3 in MKs during proplatelet formation using 
fluorescent microscopy with antibodies against the TAP-tag (anti-FLAG). However, due to 
significant background staining caused by the anti-FLAG antibody in untagged forward 
programmed MKs (fig. 6.10), we were unable to determine CRLF3’s localisation.  
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7.1 Ablation of Crlf3 causes isolated chronic thrombocytopenia 
 
In the first section of this thesis we showed that Crlf3 knockout mice (Crlf3-/-) developed by 
the Wellcome Trust Sanger Institute as part of an international consortium have a chronic and 
isolated thrombocytopenic phenotype (fig. 4.4 and table 4.1). There are currently over 20 
known genes in which mutations lead to an inherited thrombocytopenias, CRLF3 is not one of 
these genes. CRLF3 is 93% homologous between human and mice, suggesting both gene and 
protein are highly regulated. In keeping with this, predicted loss of function mutations in 
CRLF3 are extremely rare, with only 31 mutations predicted to lead to a loss of function 
observed in 121,408 alleles genotyped as part of the Exome Aggregation Consortium (ExAC) 
(Lek et al., 2016). Furthermore, no individual out of 70,344 whose genome was sequenced in 
two studies were shown to have homozygous mutations in CRLF3 (60,704 individuals in ExAC 
(Lek et al., 2016) and 9640 individuals as part of the BRIDGE Bleeding, thrombotic and Platelet 
Disorders (BPD) project (Westbury et al., 2015)) and no individual was shown to carry 
compound heterozygous mutations in the BPD study. It is also likely that mutations in CRLF3 
would cause an autosomal recessive disorder as heterozygous mice (Crlf3+/-) are unaffected 
and individuals with heterozygous mutations in CRLF3 did not have any platelet defects in the 
BPD study. These factors may be responsible for why CRLF3-related thrombocytopenias have 
not been observed in the human population. 
 
We showed that despite the thrombocytopenia, Crlf3-/- platelets were still able to fulfil their 
primary haemostatic function. No incidence of bleeding was reported in Crlf3-/- mice and Crlf3-
/- platelets: express the major surface receptors required for thrombus formation similarly to 
WT platelets (fig. 4.13A), are able to activate appropriately in response to a range of agonists 
(fig. 4.13B) and produce thrombi at arteriolar shear rates, similar to WT platelets (fig 4.14B).  
 
We went on to show that the ablation of Crlf3 causes preplatelets to be retained in the 
peripheral circulation (fig. 4.15A-D), suggesting terminal maturation of platelets is defective 
in Crlf3-/- mice. Under normal physiology, large preplatelets are released from proplatelet 
shafts into bone marrow sinusoids (Junt et al., 2007; Zhang et al., 2012). These preplatelets 
then rapidly undergo fission into mature discoid platelets by twisting of microtubules driven 
by the shear stress of the peripheral circulation (Thon et al., 2012a; Thon et al., 2010). Why a 
proportion of preplatelets are unable to mature into discoid platelets in Crlf3-/- mice in still not 
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fully understood. However, we have shown that microtubules are disorganised in Crlf3-/- 
platelets, especially in the preplatelet forms (fig. 4.16A-D). Disorganised microtubules is a 
feature of platelets from patients with WAS (Bender et al., 2014) and DIAPH1-related 
macrothrombocytopenia (Stritt et al., 2016) and profilin 1 knockout mice (Bender et al., 2014). 
In all cases, abnormal microtubule organisation is associated with increased tubulin stability. 
In agreement with this, depolymerisation of the microtubules is decreased in Crlf3-/- platelets 
incubated at 4oC (fig. 4.16E-I). Also, post splenectomy there is a trend towards increased 
preplatelets in the peripheral circulation of Crlf3-/- mice compared to WT control mice (fig. 
4.15E), suggesting that Crlf3-/- preplatelets survive longer in the peripheral circulation and may 
indicate increased stiffness of microtubules. However, increased tubulin stability is associated 
with increased levels of detyrosinated (Glu-) tubulin (Pan et al., 2014; Stritt et al., 2016), 
something that was not seen in Crlf3-/- platelets (fig. 4.16J-K). Therefore, more experimental 
data is needed to fully understand whether Crlf3 ablation causes increased microtubule 
stability and whether this increased stability is the cause of decreased fission of Crlf3-/- 
preplatelets.  
 
As the disorganised expression of tubulin is similar between Crlf3-/- platelets and that seen in 
patients with WAS and DIAPH1 mutations and profilin 1 knockout mice, it would be of interest 
to determine whether CRLF3 interacts with WAS, DIAPH1 or profilin1. If CRLF3 was found to 
interact with any of these proteins, it would help shed light on the function of CRLF3 in MKs 
and platelet genesis. 
 
Myosin IIA has also been implicated in the fission of preplatelets. It is thought that the high 
shear force of the peripheral circulation causes dephosphorylation and activation of myosin 
IIA, which permits fission of preplatelets into mature discoid platelets. Patients with mutations 
in the gene that encodes myosin IIA, MYH9, have macrothrombocytopenia as a result of 
increased phosphorylation and inactivation of myosin IIA (Chen et al., 2013b; Spinler et al., 
2015). However, very large preplatelets in the peripheral circulation, as seen in Crlf3-/- mice 
(fig. 4.15A-D), have not been recorded in patients with MYH9 mutations (Chen et al., 2013b) 
or conditional Myh9 knockout mice (Eckly et al., 2009), suggesting fission of large preplatelets 
to smaller preplatelets still occurs. Interestingly, proplatelet formation is up-regulated in in 
vitro cultured MKs from conditional Myh9 knockout mice (Eckly et al., 2009), a feature that 
we observed in in vitro cultured Crlf3-/- MKs (fig. 4.9); although the opposite was seen in MKs 
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cultured from patients with MYH9 mutations (Chen et al., 2013b). As phosphorylation of 
myosin IIA is implicated in the fission of platelets, it would be interesting to determine 
whether ablation of Crlf3 has an effect on the level of phosphorylation of myosin IIA.  
 
The thrombocytopenia seen in Crlf3-/- mice is a consequence of increased platelet clearance 
rather than decreased platelet production. We showed that megakaryopoiesis is upregulated 
in Crlf3-/- mice (fig. 4.5), maturation of Crlf3-/- MKs, as assessed by polyploidy, is unaffected in 
vitro (fig. 4.8) and proplatelet formation occurs quicker in Crlf3-/- MKs in vitro (fig. 4.9); all data 
that suggests platelet production from MKs is not decreased. Increased preplatelet clearance 
was confirmed in Crlf3-/- mice by performing splenectomies on young mice. Splenectomised 
Crlf3-/- mice showed restoration of platelet counts to WT levels within 7 days (fig. 4.11B), 
irrefutably linking the thrombocytopenia to splenic clearance. It is likely that rapid removal of 
preplatelets by the spleen is causing the thrombocytopenia in Crlf3-/- mice. Despite having the 
same percentage of circulating preplatelets before splenectomy, there was a trend towards 
increased circulating preplatelets in Crlf3-/- mice compared to WT controls post splenectomy 
(fig. 4.15E). This suggests that if the preplatelets are not rapidly removed by the spleen, they 
can eventually undergo fission into mature platelets.  
 
7.2 CRLF3 as a novel therapeutic for the treatment of thrombocythaemia 
 
Thrombocythaemia which occurs secondary to many conditions such as infection, cancer and 
inflammation. However, thrombocytopenia may also be genetically inherited and this is 
termed ET. ET is a rare inherited disease caused by mutations mainly in JAK2, MPL and CALR 
that results in a chronic increase in platelet counts (Cervantes, 2011). The major complications 
of ET are arterial and venous thrombotic events; therefore the focus of therapeutic treatment 
is primarily to prevent thrombotic events without increasing the risk of bleeding (Dombi et al., 
2017). Patients at high risk of thrombotic or bleeding events are treated with low dose aspirin 
and cytoreductive agents. The cytoreductive agents are not MK and platelet specific and 
therefore are associated with a range of haematological side effects (Cervantes, 2011). 
 
In the next section of this thesis we crossbred Crlf3-/- mice with JAK2 V617F knock in mice that 
have an ET phenotype (fig. 5.1), to determine whether CRLF3 may be a potential therapeutic 
target for the treatment of ET (and for the treatment of other thrombocythaemias). 
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Importantly, ablation of Crlf3 in the setting of ET restored platelet counts to WT values (fig. 
5.2 and table 5.1), suggesting therapeutics against CRLF3 could normalise platelet counts in 
ET patients. Interestingly, ablation of Crlf3 in ET mice had no effect on any other blood lineage 
(table 5.1), suggesting therapeutics against CRLF3 may have less haematological side effects 
than the cytoreductive agents currently in use.  
 
Beyond an increase in platelet numbers, ET also causes MK hyperplasia in the bone marrow 
(Cervantes, 2011). In our ET mice with Crlf3 ablated (ET x Crlf3-/-), we showed no increase in 
MK hyperplasia compared to WT (Cre) controls (fig. 5.3). However, this result must be put in 
the context that we did not observe MK hyperplasia in ET mice. One possibility for why MK 
hyperplasia was not observed in the ET mice may be due to an unsettled background strain 
created by cross breeding of Crlf3-/- mice with ET mice. Crlf3-/- animals are on a 
B6Brd;B6Dnk;B6N-Tyr background, whereas JAK2 V617F ET mice are on a B6J background. 
Mixing these two backgrounds may have caused an unsettled background, since background 
strain is known to have a major effect on haematopoietic cells (Peters et al., 2002). The 
crossbred mice used in these experiments represent pups from 1-4 inbred mating’s of this 
mixed background strain. It may be that multiple more inbred mating’s are required for the 
mixed background strain to become settled. Another possibility is that the numbers of animals 
used for each experiment was too small to determine significant differences. Therefore, 
whether ablation of CRLF3 effects MK numbers in an ET setting is yet to be determined. 
Repeating the quantification from bone marrow sections on mice crossbred at least 10 times 
should show any effect.  
 
JAK2 V617F positive ET is also associated with platelet hyper-reactivity (Hobbs et al., 2013) 
and this hyper-reactivity may explain why JAK2 V617F positive ET patients have higher 
incidences of venous thrombotic events than JAK2 WT ET patients (Campbell et al., 2005). 
Similarly to MK hyperplasia, we show that ET x Crlf3-/- platelets are not hyper-reactive (fig. 
5.4), but this is in the context that we failed to show the hyper-reactive nature of ET platelets.   
 
7.3 Structure, function and localisation of CRLF3 
 
In the final section of this thesis, we aimed to determine the tertiary structure of CRLF3, shed 
light on its function by determining its interactome and determine the localisation of CRLF3 in 
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MKs. We tried to determine the 3D structure of full length CRLF3 by X–ray crystallography, 
however due to technical difficulties in producing and crystallising full length CRLF3, we 
designed 4 partial constructs based on homology and disorder using freely available 
bioinformatic tools (fig. 6.2). Of these 4 constructs, only construct 3 which covers the 
predicted β-sheet region of the protein was able to be produced in greater quantities than the 
full length protein. After purification and concentration we were able to crystallise CRLF3 
construct 3 protein in a range of conditions using the sitting drop vapour diffusion method 
(table 6.1 and fig 6.4A). The 3D structure was determined by Hg-SAD then further refined to a 
resolution of 1.7 Å (fig. 6.4B). The 3D structure uncovered a fibronectin type III (FN3) domain 
at the N-terminus and a SPRY domain at the C-terminus of construct 3 (fig 6.4B).  FN3 is 
composed of 90-100 amino acids with a well-defined β-sandwich structure with seven β-
strands. The FN3 domain is very common and expected to occur in approximately 2% of all 
animal proteins. Known proteins containing FN3 domains are all involved in molecular 
recognition and include cytokine receptors (e.g. erythropoietin receptor and interleukin 6 
receptor), cell adhesion molecules (e.g. fibronectin and collagen XII) and protein kinases and 
phosphatases (e.g. insulin receptor and CD45 antigen) (Bork and Doolittle, 1992; Koide et al., 
1998). The SPRY domain was first identified in a Dictyostelium discoidueum kinase splA and 
mammalian calcium-release channels ryanodine receptors and is a subgroup of the B30.2 
domain, which contains a SPRY domain preceded by a shorter PRY domain. Approximately 150 
human proteins contain B30.2 (PRY-SPRY) or SPRY only domains and experimental data 
suggest these SPRY containing domains facilitates protein interactions (Woo et al., 2006). For 
example, Zhai et al, showed that the B30.2 domain was responsible for the interaction 
between TRIM7 and glycogenin (Zhai et al., 2004). This suggests that CRLF3 recognises another 
protein/s in MKs/platelets and interaction of CRLF3 with this protein/s allows proper fission 
of preplatelets in the peripheral circulation. However, it may be that FN3 and SPRY are not the 
only binding domains of CRLF3, therefore it would be of interest to uncover the 3D structure 
of the full length protein. This could be done using the full length protein or by determining 
the 3D structure of the unknown α-helical portion of CRLF3 and joining the two portions 
computationally. 
 
Determining the interactome of a protein of unknown function can help determine its 
function, as proteins generally have similar functions to their interacting proteins 
(Schwikowski et al., 2000). Therefore to help shed light on the function of CRLF3, we aimed to 
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uncover its interactome. We tagged endogenous CRLF3 with a tandem affinity purification 
(TAP) tag, consisting of an N-terminal calmodulin binding domain and C-terminal 3x FLAG tag 
repeat separated by a TEV cleavage site, by CRISPR/Cas9 in human iPSCs (fig. 6.8). We 
intended to determine CRLF3’s interactome in MKs. To produce TAP-tagged MKs, we forward 
programme TAP-tagged iPSCs into MKs using the method of Moreau et al. (2016); however, 
we have been so far unable to produce enough MKs to perform immunoprecipitation and 
mass spectrometry assays. Therefore, we performed immunoprecipitation and mass 
spectrometry experiments on TAP-tagged and untagged control iPSCs. Results revealed 18 
proteins that were present in the TAP-tagged samples but not untagged samples (table 6.2). 
Interestingly, four of these proteins are known to form desmosomes along with other 
proteins. Desmosomes are cell-to-cell adhesion molecules are important for resisting shear 
forces (Garrod and Chidgey, 2008). Although desmosomes are not known to exist in platelets 
or preplatelets, unsurprisingly as platelets are not in physically contact in their resting state, 
it is interesting that platelet maturation is driven by shear forces. It may be possible that CRLF3 
is involved in resisting shear forces in many cell types. In platelets it is possible that binding of 
CRLF3 to unknown protein/s is important for permitting shear forces to drive cytoplasmic 
rearrangement and/or myosin IIA dephosphorylation and therefore fission into mature 
platelets.  
 
CRLF3 has has been shown to interact with proteins of the DOCK and LRCH family (Couzens et 
al., 2013), however no DOCK or LRCH family proteins were shown to interact with CRLF3 by us 
(table 6.2). These conflicting results in CRLF3’s interactome may be due to the differing cell 
type used in the immunoprecipitation experiments. It may be that CRLF3 interacts with 
different proteins in different cell types. This would explain why, despite CRLF3 being 
ubiquitously expressed in the haematopoietic system (fig. 4.1), Crlf3-/- mice have a platelet 
isolated phenotype. Therefore, it is important to uncover the interactome of CRLF3 in MKs or 
platelets.  
 
CRLF3 is known to be localised in the cytoplasm in human cell lines (Yang et al., 2009). 
However, as Crlf3-/- mice have an isolated platelet phenotype it would be interesting to 
determine the localisation of CRLF3 in MKs, especially during proplatelet formation. As 
commercially available antibodies against CRLF3 are not specific enough to perform 
immunohistochemistry, we intended to determine the localisation of CRLF3 in TAP-tagged 
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CRLF3. However, we have shown that proplatelet forming forward programmed MKs have 
high autofluorescence (fig. 6.10), therefore we were unable to determine the localisation of 
CRLF3. It would be of interest to optimise the fixation and staining protocol to decrease the 
autofluorescence in forward programmed MKs, to allow the localisation of CRLF3 to be 
determined. 
 
7.4 Towards a therapeutic against CRLF3 
 
Many steps would need to be taken before a therapeutic against CRLF3 could be trailed in 
humans. Firstly, it would be important to determine whether a therapeutic against CRLF3 
would be tolerated. Apart from thrombocytopenia, Crlf3-/- mice are otherwise unaffected, 
however these mice have not had CRLF3 since embryogenesis. Inhibition of CRLF3 in animals 
that have had working CRLF3 could have drastically different effects and this is currently 
unknown. It would be interesting to create an inducible Crlf3 knockout mouse, as ablation of 
Crlf3 post gestation would mimic treatment with an inhibitor of CRLF3.  
 
Secondly, the binding site/s of CRLF3 would need to be determined. To do this, the 3D 
structure of CRLF3 would need to be resolved as mentioned above. Once the binding site/s 
are known, existing small inhibitors can be screened in silico and optimised or new inhibitors 
can be designed computationally. Thirdly, the interactome and downstream pathways of 
CRLF3 would need to be determined, as this would allow high throughput screening of the 
potential inhibitors in cell lines. Knowledge of the downstream pathways of CRLF3 would allow 
for determination of whether the inhibitor was able prevent CRLF3 having an effect on its 
downstream interacting proteins and would show any off target effects of the inhibitor. Once 
highly selective inhibitors have been identifies in high throughput screenings, these molecules 
would need to be tested in animal models to determine whether they could lower platelet 
counts and to assess any off target effects.   
 
7.5 Final Remarks 
 
Current treatments of high risk ET patients relies on cytoreductive agents and despite being 
effective at decreasing platelet counts, these cytoreductive agents have a range of 
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haematological side effects. An ideal therapy would decrease platelet counts to normal values 
with minimal side effects. We have shown that CRLF3 has a role specific to controlling platelet 
numbers in mice. Crlf3-/- mice have a chronic and isolated thrombocytopenic phenotype 
caused by rapid removal of large preplatelets from the peripheral circulation. It appears that 
CRLF3 affects the fission of preplatelets into mature platelets in the peripheral circulation, 
potentially due to affecting tubulin stability.  
 
We have shown the rational for continued research of CRLF3 as a therapeutic target for the 
treatment of ET, ET mice with Crlf3 ablated show restoration of platelet counts to WT 
numbers. Also, ablation of CRLF3 does not seem to add to other burdens of ET, such as MK 
hyperplasia and platelet hyper-reactivity. Despite these initial positive results suggesting 
CRLF3 could be a novel therapeutic target for the treatment of ET, much work needs to be 
done to confirm pharmacological inhibition of CRLF3 would be a more effective treatment of 
ET than current cytoreductive therapies.  
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